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Atrial fibrillation (AF) is an emerging global epidemic. Incidence and prevalence of the 
condition continues to rise, and AF related health care utilisation has become costly and 
burdensome. Furthermore, quality of life in AF is akin to those with other chronic 
cardiovascular conditions such as heart failure. The literature review in Chapter 1 of this 
thesis explores current research in AF and explores the opportunities that exist for 
improving outcomes in this condition. Chapter 2 explores national trends in 
hospitalisations due to AF in Australia and compares this to two other common 
cardiovascular conditions, heart failure (HF) and myocardial infarction (MI). This 
demonstrates that hospitalisations due to AF have grown at a significantly greater rate 
than that of HF and MI and are now the most common cause for cardiovascular 
hospitalisation in Australia. The rising incidence of AF has led to a search for new risk 
factors for the condition in addition to exploring appropriate targets and thresholds for 
existing risk factors. In Chapter 3, the association between alcohol and AF is examined 
with a view towards determining a lower threshold at which risk of developing the 
condition is increased. Results of this study demonstrate that up to one standard drink per 
day does not confer an increase in risk, with gender differences apparent at moderate 
levels of intake. 
Chapter 4 is concerned with exploring the current literature in relation to the use 
of the integrated care approach in AF and its impact on clinically relevant outcomes. This 
synthesis of the current literature shows that this approach is associated with 
improvements in several clinically relevant outcomes including reductions in all-cause 




management of AF is reviewed in a cohort of symptomatic individuals who have 
presented to the emergency department due to AF with a view towards determining 
factors predictive of re-presentation. As hospitalisations remain the most expensive 
component of AF care, this is particularly relevant in the search for modifiable factors 
that may present an opportunity for intervention. Of interest, the use of a non-standardised 
personalised AF action plan for management of future episodes was associated with a 
significant increase in risk of both AF related emergency department presentations and 
hospitalisations. In Chapter 6, the impact of a brief nurse led educational intervention, 
which incorporates lifestyle and behavioural goal setting, in AF is evaluated. The brief 
approach used in this study did not impact on health-related quality of life or 
cardiovascular risk factor status in a contemporary cohort of individuals with AF at short 
term follow up. Finally, in Chapter 7, a new target for improving outcomes in this 
condition is examined, with a review of the current literature concerning polypharmacy 
and clinically relevant health outcomes in the AF population. This has demonstrated 
association with several important outcomes including increased all-cause mortality, 
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Chapter 1: Literature Review 
1.1 EPIDEMIOLOGY OF ATRIAL FIBRILLATION 
Atrial fibrillation (AF) is a growing global epidemic. The lifetime risk of developing this 
condition is one in four in adults over the age of 40.1 Progressive increases in the 
incidence and prevalence of AF have been demonstrated over recent decades and show 
no sign of abating.2 Over 50 years of follow up in the Framingham study cohort, an 
increased incidence of AF from 3.7 to 13.4 cases per 1000 person years in men and 2.8 
to 8.6 cases per 1000 person years in women was demonstrated.3 Over the same period 
of time, a quadrupling of AF prevalence was observed ranging from 20.4 to 96.2 cases 
and 13.7 to 49.4 cases per 1000 person years in males and females respectively.3 In the 
Manitoba study, the incidence of AF rose sharply with age from 0.5 per 1000 person 
years in those younger than 50 to 9.7 per 1000 person years after the age of 70.4 It is 
expected that by the year 2050, 15.9 million individuals in the United States of America 
(USA) will be living with this condition, underscoring the importance of strategies to 
prevent the onset of AF.5 Furthermore, in part due to large populations and rising levels 
of modifiable cardiovascular risk factors, absolute numbers of individual living with AF 
in the Asia Pacific region is expected to far exceed that of North America in coming 
decades, with significant implications for this region.6 
AF is associated with numerous complications, including increased risks of 
thromboembolic complications such as ischaemic stroke and heart failure (HF), and 
growing health care burden with hospitalisations due to the condition now outnumbering 
those for HF in Australia.7  The last two decades alone have witnessed an almost doubling 




onset of the condition, and improve outcomes in the prevalent AF population have 
become an urgent global healthcare need.  
 
1.2 HOSPITALISATION TRENDS FOR ATRIAL FIBRILLATION  
Health care resource utilisation remains one of the greatest challenges borne out of the 
growing AF epidemic. Hospitalisations comprise the largest component of this with 
numerous countries demonstrating significant increases over recent decades. In the 
United States of America (US) between 2000-2010 an overall 23% increase in 
hospitalisations due to AF was observed with an associated 1787 United States Dollars 
(USD) per hospital admission increase over the same time period.8 More recent data has 
supported a continuing upwards trend in the elderly population in the US with adjusted 
rates of hospitalisations for AF increasing at a rate of 1% per year from 1999-2013, but 
with an associated reduction in readmission rates and inpatient mortality over the same 
time period.9 Contemporary data from the Nationwide Emergency Department Sample 
in the US demonstrated a 30.7% increase in Emergency Department presentations from 
2007-2014.10 Despite a reduction in rates of admission from the emergency department 
from 70% to 62% , there was still a significant 16% increase in hospitalisations over this 
time period driven by the large increase in emergency department presentations over this 
time.10 In Europe, similar trends with rising hospitalisation rates have been demonstrated 





1.2.1  AF hospitalisations in the Asia Pacific region 
Comparatively little is known about AF related hospitalisations in the Asia Pacific region. 
Recent data has suggested that in part due to larger populations and growing rates of 
modifiable cardiovascular risk factors, absolute numbers of individuals with AF in this 
region will be significantly greater than that of North America and Europe, with 
important implications for health care resource utilisation.6 In the southwest of China, a 
20 fold increase in AF has been observed in conjunction with a 13 fold increase in stroke 
in individuals with AF between 2001 and 2012.14 Additionally, stroke rates in individuals 
with AF demonstrated significantly greater increases compared to those without the 
condition (6.4% vs 2.8% for AF vs no AF; Odds Ratio [OR] 2.28; 95% CI 1.81-3.08; 
p<0.01).14 A contemporary nationwide Korean study demonstrated a 420% increase in 
hospitalisations associated with AF over the ten year period between 2006-2015 with the 
majority of admissions occurring in individuals over 70 years of age.15 An increase in the 
complexity of individuals with AF was also demonstrated in this study with significant 
increases in CHA2DS2-VASc (Congestive Heart Failure, Hypertension, Age >75 years 
[doubled], Diabetes, Prior Stroke or Thromboembolism [doubled], Vascular disease, Age 
65-74, sex category[female]) and HAS BLED (Hypertension, Abnormal renal or liver 
function, Prior stroke, Prior major bleeding, Labile international normalised ratio [INR], 
Elderly, Drugs or Alcohol) scores, in addition to a two fold increase in peripheral arterial 
disease and a 1.7 fold increase in chronic kidney disease.15 There was, however, an 
associated reduction in inpatient mortality, which is consistent with recent US data.9 The  
CHA2DS2-VASc score is used to predict risk of stroke in individuals with AF with higher 
numerical values denoting a higher stroke risk and resultant need for therapy with oral 




of oral anticoagulant therapy and to identify individuals in which modifiable factors can 
be managed to reduce this risk.17 
In Australia, in line with global data, the incidence and prevalence of AF is 
expected to continue rising with significant ongoing implications for health care resource 
utilisation. It is projected that by the year 2034, an approximate doubling of the number 
of Australians over the age of 55 living with AF will be observed.18 Previous Australian 
data demonstrated that AF related hospitalisations significantly outnumbered those for 
HF over the 15-year period between 1993-2007, although there were larger absolute 
numbers of hospitalisations due to MI.7 In Western Australia, age and sex standardised 
data demonstrated the largest rise in incident AF hospitalisations (as a principal 
diagnosis) in the 35-64 year old age group over the sixteen-year period between 1995 and 
201019, with this representing significant health care resource implications as it is likely 
that these individuals will present to hospital on multiple occasions, thereby contributing 
to growing prevalent hospital admission rates. Indeed, this study also examined prevalent 
hospital admission rates and found similar, albeit greater, trends in increased 
hospitalisations for AF, and again demonstrated the greatest rise in the youngest age 
group of 35-64 years.19  
 
1.2.2 Economic costs of AF 
The cost of AF to healthcare systems worldwide is significant with hospitalisations the 
main driver of this. In Canada, hospital costs attributable to AF in 2010 were 815 million 
Canadian dollars, of which 710 million was due to the direct cost of hospitalisations.20 In 
the United Kingdom (UK), 50% of AF related healthcare expenditure is due to 




rose by more than 53% from 244 million pounds sterling to 459 million pounds.21 In the 
US, similar upwards trends have also been demonstrated with an absolute national 
increase in hospitalisation costs due to AF of 1.31 billion USD from 2001-2010.8  The 
highest increase in cost was observed in the 50-64 year old age group, with a significantly 
greater rise observed in males.8 Reasons for this are unclear but may be related to a greater 
prevalence of AF in males compared to females, and may also be due to a greater 
likelihood of receiving invasive therapy for AF such as electrical cardioversion and 
ablation.22 The additional cost of AF as a comorbid diagnosis is also significant, with 
estimates that this added an incremental 1.95 billion USD annually to the cost of inpatient 
hospitalisations in 2001.23 In this study, the overall cost of treatment for AF including 
hospitalisations, as a principal and secondary diagnosis, outpatient management and 
prescriptions was 6.65 billion USD.23 It is likely that this number has exponentially grown 
over the last decade due to the rising incidence of AF, growing numbers of 
hospitalisations due to the condition and expanding indications for costly invasive 
procedures such as AF ablation.  
In Australia, the total economic cost of AF was estimated at 1.25 billion Australian 
dollars (AUD) in 2010.24 This takes in to account costs associated with AF related 
hospitalisations and its two major complications (stroke and heart failure), disability and 
residential aged care costs and costs due to lost productivity. Indeed, the combined cost 
of the two major complications of AF, stroke and heart failure, account for 35% of this 
expenditure and underscores the importance of efforts directed at risk mitigation. 
Hospitalisations due to AF itself accounted for 13% of all expenditure. It is likely that 
these costs have significantly grown in recent times, owing to the growing incidence and 




1.2.3 Quality of life in AF 
Health related quality of life in paroxysmal AF has been demonstrated to be consistent 
with, or worse than, those with other forms of cardiovascular disease including ischaemic 
heart disease and heart failure.25 Furthermore, it has been demonstrated that little 
correlation exists between traditional markers of disease severity, such as left ventricular 
ejection fraction, New York Heart Association (NYHA) class, left atrial dimension, AF 
frequency and duration, and health related quality of life.25 In asthma and other chronic 
cardiovascular conditions, patient beliefs about their condition and treatment and 
strategies to manage symptoms are closely correlated with quality of life, depression and 
perceived disability.26-28 Depression and/or anxiety is common in individuals with AF 
and is positively associated with greater AF symptom burden, impaired health related 
quality of life and AF recurrence. Furthermore, it has been demonstrated that individuals 
with persistent AF demonstrate a greater severity of depression than those with 
paroxysmal AF.29  
Given the association between AF, poor quality of life and depression, factors 
associated with this are key to reducing the burden of this condition. From a qualitative 
study of interviews conducted with 30 individuals with AF undertaking three different 
treatment modalities (cardioversion, AF ablation and AV node ablation) several themes, 
which may contribute to poorer quality of life, emerged.30 These themes were the 
unpredictable nature of AF episodes and symptoms; strategies for dealing with AF 
symptoms and treatment concerns and expectations. The ‘vicious cycle’ of AF was 
expressed by a number of participants with one reporting that they felt individuals who 
experienced a myocardial infarction were ‘better off’ as they attended cardiac 
rehabilitation classes and were able to return to normal life.30 Concerns about side effects 




the condition or therapy used to treat symptoms. The efficacy of invasive treatments such 
as AF ablation and AV node ablation was expressed by several participants, with many 
describing this as a ‘last resort’ as they were unable to tolerate living with the 
unpredictability and symptom burden of their condition.  
A large registry of 10,087 individuals with AF demonstrated that higher symptom 
burden (European Heart Rhythm Association [EHRA] class ≥ 2 vs class 1) and poorer 
quality of life (highest quartile of the Atrial Fibrillation Effect on Quality of Life 
Questionnaire (AFEQT) were both significantly associated with a higher risk of all cause 
hospitalisation (Hazard ratio [HR] 1.23, 95% CI 1.15-1.31; p<0.001 and HR 1.49, 95% 
CI 1.2-1.84; p≤0.001 respectively).31 It is possible that improved knowledge and 
enhanced chronic condition management, including control of symptoms, could lead to 
better patient outcomes, including improved quality of life, and reduced health care 
burden in this population.  
 
1.3 MODIFIABLE RISK FACTORS FOR INCIDENT AF 
1.3.1 Background 
Temporal adverse trends in modifiable cardiovascular risk factors have been 
demonstrated in recent times. Indeed it has been speculated that the observed reduction 
in the rate of decline of mortality rates for cardiovascular disease (CVD) and stroke in 
the US observed since 2011 is partially driven by rising modifiable cardiovascular risk 
factors.32 A cross sectional study of more than 5000 participants from four US 
communities with 25 years of follow up demonstrated unfavourable recent trends in 
modifiable cardiovascular risk factors.33 Over this time period mean body mass index 




observed although rates of smoking decreased from 30.4% to 17.1% over follow up. 
Whilst an initial reduction in total cholesterol and low density lipoprotein C (LDL-C) was 
observed over the first ten years of follow up, this was largely reversed in years 20-25 
which demonstrated an upwards trend in levels with the exception of the cohort of black 
women enrolled in this study.33 Obesity was significantly associated with elevation in 
LDL-C compared to individuals of normal weight. Similar patterns have also been 
demonstrated in other studies including the Mississippi Behavioural Risk Factor 
Surveillance System study which reported trends in self-reported cardiovascular risk 
factors in 11,978 participants.34 Over 9 years of follow up, significant increases in rates 
of elevated cholesterol levels, diabetes and hypertension were observed across the entire 
cohort with racial differences noted between black and white participants.34 Rates of 
diabetes were significantly increased across the black cohort with a decrease in the 
prevalence of smoking in whites that was not observed in the black population.34 Gender 
differences are also apparent with the Global Burden of Disease Study from 2013 
demonstrating that for women in high income countries, an elevated BMI contributed the 
largest attributable risk to death and disability adjusted life years (DALYs), whilst for 
men systolic blood pressure and use of tobacco contributed the largest risk.35  
Indeed, similar trends have also been demonstrated in the Asia Pacific region with 
a decrease in smoking rates from 79% in 1980 to 45% of the population in 2007 at which 
point it has stagnated.36 A BMI of ≥25kg/m2 also increased from 29% to 34% in the over 
30 year old population. Hypercholestrolaemia has also increased in prevalence in the 
Korean population between 1998 and 2011, although rates of hypertension have 
improved, largely driven by improved management of the condition in those with a prior 
diagnosis.36 Rates of modifiable cardiovascular risk factors have also grown in China, 




study of 16,371 suburban residents of China, 83.5%, 47.2% and 17.5% of participants 
had 1, 2 or ≥3 modifiable cardiovascular risk factors respectively, highlighting the 
importance of primary prevention strategies to manage risk. 
 
1.3.2 Established risk factors for incident AF 
Numerous established risk factors have been identified for incident AF. These are largely 
derived from large epidemiological studies which have consistently identified numerous 
factors associated with AF development. Several AF risk factors are non-modifiable and 
include ageing, gender and genetics.38,39 Indeed, the incidence of AF has shown a steep 
increase associated with advancing age with European data demonstrating a rate of 1.1 
per 1000 person years for the 50-59 year old age group rising to 20.7 per 1000 person 
years in the 80-84 year old age bracket.40 North American data has demonstrated a 
quadrupling of the age adjusted incidence rate for AF from 3.7 to 13.37 per 1000 person 
years over the 50 year period up to 1998.3 Additionally, both incidence and prevalence 
rates for AF are higher in males compared to females.2 However, the observed increase 
in incidence of AF in recent decades cannot be accounted for by ageing populations alone. 
Numerous potentially preventable or modifiable conditions are also associated with 
the development of AF and include coronary artery disease, heart failure and chronic 
kidney disease.39 In recent years, the contribution of modifiable risk factors for AF has 
gained momentum as an appreciation of their role not only in the development of AF, but 
also progression of the condition, has been explored. Conditions such as hypertension, 
overweight and obesity, diabetes and smoking are established factors associated with AF 
development.41 Recently, newer factors including obstructive sleep apnoea (OSA), 




study from the Atherosclerosis Risk in Communities (ARIC) study, has demonstrated 
that numerous modifiable cardiovascular risk factors are evident in individuals more than 
15 years prior to AF diagnosis and highlights potential opportunities to intervene to 
prevent onset of the condition.46  The importance of modifiable risk factors in the 
development of AF has recently been highlighted with evidence from the Framingham 
cohort demonstrating a significantly lower lifetime risk of AF development in those with 
optimal control of five modifiable risk factors (not smoking, low alcohol intake, normal 
BMI, normal blood pressure and no prior history of MI or HF) with a one in five risk 
compared to a one in three risk in individuals with at least one elevated risk factor.47 The 
cumulative risk of multiple cardiovascular risk factors has also been demonstrated in the 
ARIC study, with each component of the metabolic syndrome (elevated blood pressure, 
elevated waist circumference, low high density lipoprotein cholesterol, impaired fasting 
glucose and elevated triglycerides)  independently conferring an increase in risk of AF 
development.48 Collectively all five components was associated with a more than 
fourfold increase in risk of AF development compared to those without these risk factors 
(HR 4.40, 95% CI 3.25-5.94).48 A particular focus on modifiable risk factors for AF is of 
significant importance due to potential for intervention at a primary prevention level to 
curtail this growing epidemic. Each of the major modifiable risk factors for incident AF 
will be discussed below. 
 
1.3.3 Hypertension 
Due to a high prevalence in the general population, hypertension is the largest population 
attributable risk factor for AF.49 Hypertension is known to heighten the risk of AF 




development is also increased even at levels considered pre-hypertensive (systolic blood 
pressure of 130-139mmHg), with a 28% increase in risk observed (HR 1.28; 95% CI 
1.00-1.63) in 34,221 females participating in the Women’s Health Study.53 This increased 
risk was also observed in the Multi-Ethnic Study of Atherosclerosis Study in which 
sustained pre hypertension, over a median follow up of 5.3 years, was associated with an 
increased risk of incident AF in 5,311 individuals (HR 1.8, 95% CI 1.004-3.2).54 Over 
long term follow up of 35 years, pre-hypertension, as reflected by a systolic BP of 128-
138mmHg, was also associated with an increased risk of incident AF in 2014 Norwegian 
males (HR 1.6, 95% CI 1.15-2.21).55  
Furthermore, a longer duration of hypertension and treatment received for the 
condition were independently associated with development of incident AF in the 
Framingham Heart Study when time updated variables over a 15 year period were 
considered.56 A baseline diagnosis of hypertension with an increase of systolic BP over 
time conferred an almost two fold increase in risk of incident AF (HR 1.95, 95% CI 1.08-
3.49; p=0.03), whilst even an initial diagnosis with hypertension and a decrease in BP 
over time was associated with a more than two fold increase in risk (HR 2.05, 95% CI 
1.24-3.37; p+0.005).56 Mechanistically, the substrate for AF development due to 
hypertension is thought to involve both structural and electrical remodelling with 
numerous contributing factors such as atrial dilatation, interstitial fibrosis, inflammation 
and conduction disturbances.57,58 Whilst numerous studies have described the association 
between hypertension and AF, the optimal target at a primary prevention level to reduce 






A strong association between obesity and AF has consistently been demonstrated.3,52,59,60 
A 29% increase in risk of AF development has been demonstrated with each 5 unit 
increase in body mass index (BMI) in a recent meta-analysis of cohort studies.61 
Furthermore, heightened risk of AF occurrence has been demonstrated in post-operative 
and post-ablation populations with incremental increases in BMI, with each 5 unit 
increase conferring a 10% and 13% risk increase respectively.61 A possible mechanism 
mediating the association between obesity and AF is increased left atrial pressures and 
volume and a shortening of the effective refractory period.62 A sheep model has 
demonstrated structural and electrical remodelling in the setting of obesity including 
conduction slowing, conduction heterogeneity, increased left atrial size and interstitial 
fibrosis, resulting in an increased propensity for AF, in addition to more sustained 
episodes.63  
 
1.3.5 Obstructive sleep apnoea 
Obstructive sleep apnoea (OSA) confers a greater than two fold increase in the risk of 
incident AF.64,65 The prevalence of OSA in individuals with AF ranges from 40-50%, 
although some have suggested it could be much higher.42,66 In individuals with known 
AF, OSA is associated with worse outcomes including a greater risk of anti-arrhythmic 
drug therapy (AAD) failure, higher rates of AF recurrence post cardioversion and catheter 
ablation and a threefold increase in risk of ischaemic stroke.67-69 
Mechanistically, the link between OSA and AF is complex and multifaceted. It 
encompasses both structural and electrical remodelling including atrial enlargement, 




acute and chronic mechanisms are postulated to contribute to the increased risk of AF 
observed in OSA including endothelial dysfunction, atrial fibrosis, acute respiratory 
obstructive episodes, sympatho-vagal imbalance and inflammation.42,71 Treatment with 
continuous positive airway pressure (CPAP) has been shown to enhance the likelihood 
of freedom from AF post catheter ablation,72 although it has not been shown to reduce 




Diabetes is associated with a significant increase in risk of incident AF.39,52 A meta-
analysis of studies that adjusted for other AF risk factors demonstrated a 24% increase in 
risk (RR 1.24, 95% CI 1.06-1.44).74 Mechanistically the link between diabetes and AF 
has been postulated to be due to numerous factors including autonomic dysfunction, 
electrical and structural remodelling and inflammation.75 Animal studies have 
demonstrated a greater propensity for AF in diabetic animals compared to controls, with 
higher levels of atrial fibrosis and conduction delay observed in the diabetic state.76 
Furthermore, the duration of diabetes is also an important factor with a case control study 
demonstrating a 3% increase in risk of incident AF for each additional year of treated 
diabetes.77 Poor glycaemic control, as demonstrated by higher glycosylated haemoglobin 
(HbA1c) levels, was associated with incremental increases in risk of AF development.77 
 
1.3.7 Physical activity 
The association between physical activity and AF is somewhat complicated by a potential 




based sample each increase in metabolic equivalent achieved during exercise testing was 
associated with a 7% lower risk of incident AF, with a greater magnitude of effect 
observed in obese compared to non-obese individuals.79 There may be an upper threshold 
of exercise at which risk of AF is increased with a reduction in risk observed at moderate 
intensity levels of exercise, but not high intensity levels in a population based study of 
5446 individuals ≥65 years of age over 47,280 person years of follow up.80  Exercise 
training has numerous benefits which may in part account for the observed reduction in 
AF risk. These include improved management of conditions such as hypertension and 
diabetes,81 weight loss,82 and improved cardiac structure and function.83   
 
1.3.8 Dyslipidaemia 
The association between dyslipidaemia and incident AF is yet to be firmly established. 
Unlike numerous other cardiovascular conditions at which elevated low density 
lipoprotein (LDL) levels are strongly correlated with outcomes, an inverse association 
between LDL and AF has been described.51,84,85 HDL appears to confer a protective effect 
with higher levels associated with a reduction in risk of AF86 and lower levels associated 
with an increased risk of AF.87,88 
 
1.3.9 Smoking 
Conflicting data exists as to the impact of smoking on the risk of incident AF. Whilst 
numerous epidemiological studies have not demonstrated any association with AF, 39,51,59 
others have described an association with risk estimate increases ranging from 32% to 
200%.4,89,90 This may be due to variations across studies in numbers of cigarettes smoked 




analysis found a 23% increase in risk of AF attributable to current smoking.91 The link 
between smoking and AF could be multifactorial and attributed to inflammation, atrial 
fibrosis and oxidative stress,92 although an exact mechanism in the setting of AF is yet to 
be determined. In established AF, current cigarette smoking has been associated with 
numerous adverse events including increased all-cause mortality (Relative risk [RR] 
1.82, 95% CI: 1.33–2.49; p=0.0002), cardiovascular death  (RR 1.54, 95% CI 1.31–1.81; 
P<0.00001) and major bleeding (RR 1.93, 95% CI 1.08–3.47; P=0.03).93 However, no 
impact on risk of stroke or thromboembolism was observed in this meta-analysis.93 
Cigarette smoking is also a known contributor to atherogenesis, endothelial dysfunction 
and promotion of a heightened prothrombotic state all of which are unfavourable in the 
setting of AF.94 
 
1.3.10 Alcohol 
Little uncertainty exists over the association between high levels of alcohol intake and 
incident AF. Numerous epidemiological studies have described this association, although 
the level at which risk is increased has not been well characterised. In the Framingham 
cohort study, alcohol intake of greater than 3 standard drinks (SD) per day was associated 
with a heightened risk,95 whilst in other higher risk populations increases in risk were 
observed even at lower levels of intake.96 Other studies have described gender differences 
with moderate to high levels of alcohol intake associated with risk of incident AF in males 
but not females.97-99 Two meta analyses have demonstrated a small but significant 
increase of approximately 8% at alcohol intake of 1 SD per day, but due to methodology 





There are numerous plausible mechanisms linking chronic alcohol intake to AF 
development. Originally thought to be related to binge drinking only, due to the 
observation of increased atrial arrhythmias during holiday seasons (‘holiday heart’ 
syndrome),102 more recent observations have come to appreciate the role of chronic 
consumption in risk of AF development. Numerous proarrhythmic electrical changes 
associated with alcohol intake including a shortening of the effective refractory period, 
increased sympathetic activation, a reduction in vagal tone modulation and alterations in 
atrial current densities, may all contribute to a heightened AF risk.103-105 The dose of 
alcohol consumed may be an important factor with a study of 75 individuals undertaking 
ablation for AF demonstrating a significant increase in low voltage zones and conduction 
slowing in the atria of those consuming moderate levels of intake (mean 14.3±4.2 drinks 
per week), compared to mild drinkers (4.4±2.3 drinks per week).106 It is also plausible 
that the observed increase in risk is partially mediated through other cardiovascular risk 
factors, such as hypertension and obesity, which chronic alcohol intake, particularly at 
higher levels of intake, is associated with.107,108 
 
1.3.11 Emerging risk factors for AF 
Several studies have described an association between epicardial and pericardial fat and 
incident AF. Epicardial fat has been defined as the layer of fat between the myocardium 
and visceral pericardium and has been linked to both prevalence and severity of AF. In a 
study of 273 individuals of which 76 were in sinus rhythm, with 126 and 71 with 
paroxysmal and persistent AF respectively, greater pericardial fat volumes were observed 
in those with AF compared to those in sinus rhythm, even after adjustment for traditional 




epicardial fat compared to those with paroxysmal AF.109 In the Framingham study cohort, 
of 3,217 individuals who underwent computed tomography scanning, the 54 individuals 
with AF were found to  have significantly greater pericardial fat volumes compared to 
those without, in a multivariate adjusted model.110 The same association did not hold true 
for either intrathoracic or visceral abdominal fat and suggests that the fat layer 
surrounding the heart may have significant implications for AF risk. In another study of 
110 individuals undertaking first time ablation for AF and 20 controls individuals, 
pericardial fat was associated with presence and severity of AF, in addition to being 
predictive of AF recurrence after ablation.111  
Mechanistically, the link between pericardial fat and AF is potentially attributable 
to numerous factors. The autonomic system is likely to play a key role. Ganglionated 
plexi are located within the epicardial fat pad and can stimulate both the sympathetic and 
the parasympathetic nervous system, with this intrinsic cardiac nerve activity known to 
precede the onset of AF in animal models.112 Unique gene expression found in human 
atrial pericardial fat tissue, but not in ventricular or coronary pericardial fat samples in 
another study, suggested that genes associated with oxidative phosphorylation, cardiac 
muscle contraction and calcium signalling pathways could also play a part in arrhythmia 
development.113 Recently, a cardiac magnetic resonance imaging study demonstrated 
electro-anatomical remodelling including conduction slowing, low voltage areas and 
greater fractionation of electrograms in areas adjacent to pericardial fat depots.114  
Aortic stiffness has also been identified as another potential risk factor for AF 
development. In a study of 68 individuals without other significant comorbidity, referred 
for catheter ablation for AF, measures of aortic stiffness were correlated with AF 




not well defined but may be a marker of pre hypertension, which has been independently 
associated with an increased risk of developing the condition.53 
 
1.3.12 Treatment for AF 
The four pillars of treatment for AF include the use of rate control, rhythm control, oral 
anticoagulation to reduce stroke risk and cardiovascular risk factor management. Each of 
these factors will be discussed below. 
 
1.3.13 Rate and rhythm control 
Preference for treatment of AF with a rate or rhythm control approach is dependent upon 
many factors. These include the presence or absence of left ventricular (LV) dysfunction, 
left atrial size, the presence of symptoms and their degree of severity, atrial size and 
ability to achieve adequate rate control with medication alone.115 Patient preference is 
also an important factor to consider in choice of treatment approach. Contemporary trials 
of a rate control strategy compared to rhythm control are somewhat lacking, although 
earlier studies have suggested no mortality benefit with the use of a pharmacological 
rhythm control approach.116,117 In the Atrial Fibrillation Follow Up Investigation of 
Rhythm Management (AFFIRM) study, 4060  ‘high risk’ individuals with AF (over the 
age of 65 or with multiple concomitant risk factors) were randomised to a 
pharmacological rate or rhythm control strategy.116 Pharmacological treatment in each 
arm was left to the discretion of the treating physician. After five years, there was no 
difference in mortality between these two treatment strategies (21.3% vs 23.8% for rate 
vs rhythm control respectively; HR 1.15, 95% CI 0.99-1.34, p=0.08). All cause 




rhythm control arm compared to a rate control strategy (73% vs 80.1% for rate vs rhythm 
control respectively, p<0.001).116 Further evidence in support of this was demonstrated 
in the Rate Control vs Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) 
study.117 In this study, 522 individuals were randomised to an aggressive rhythm control 
strategy, which included the use of serial cardioversions and pharmacological treatment, 
or a rate control strategy. Despite a greater likelihood of sinus rhythm in the rhythm 
control strategy (39% vs 10% for rhythm vs rate control respectively), the rate control 
strategy was non inferior to rhythm control in the primary composite outcome of 
cardiovascular death, heart failure, thromboembolism, bleeding, pacemaker implantation, 
and severe adverse effects of drugs (22.6% vs 17.2% for rhythm vs rate control 
respectively; absolute difference -5.4, 90% CI -11.0 to 0.4). No significant difference in 
any of the individual components of the composite end point was demonstrated.117 
Whilst the use of AAD are associated with significantly lower risk of AF recurrence 
compared to placebo, there is no evidence of any other benefit including a reduction in 
stroke risk or mortality.115 Their use in long term management in AF should take in to 
consideration patient preferences in addition to other factors such as age, symptoms 
severity, degree of physical activity and left ventricular (LV) dysfunction. Any use of 
long term AAD requires close monitoring due to potential for harm. 
 
1.3.14 The evolving role of AF ablation 
In recent years, the role of catheter ablation has played a growing role in the management 
of AF. In the US, ablation for AF increased 10-fold from 2,644 procedures in 2000 to 
21,345 in 2013, with AF the fastest growing indication for ablation therapy of all cardiac 




growing at a rate of 30.9% per year (adjusted for population estimates) over the ten year 
period up to 2010.119 This is in stark contrast to other commonly used cardiovascular 
procedures, such as percutaneous coronary intervention (PCI), which demonstrated a 5% 
annual growth, adjusted for population estimates, over the same time period.119 However, 
whilst AF ablation is a widely used procedure that has demonstrated exponential growth 
over recent decades, the impact of this procedure on recurrent hospitalisations for AF is 
unknown. Indeed, whilst this procedure has demonstrated superiority in terms of freedom 
from AF compared to other treatments such as AAD therapy,120,121 long term attrition 
rates are significant.122,123 Furthermore, few studies have examined the impact of this 
procedure on clinical outcomes such as hospitalisations and mortality.  
 Trials of catheter ablation to date have not suggested any mortality benefit except 
in individuals with concomitant heart failure.124 Recently, results of the Catheter Ablation 
versus Anti-Arrhythmic Drug therapy for Atrial Fibrillation (CABANA ) study have 
provided further insights in to the role of this procedure for AF.125 The intention to treat 
analyses did not demonstrate any difference in the primary composite endpoint of death, 
disabling stroke, major bleeding or cardiac arrest after a median 4 years of follow up in 
2204 individuals between individuals who underwent ablation compared to those who 
were pharmacologically managed (HR 0.86, 95% CI 0.65-1.15; p = 0.30). However, there 
was a high rate of crossover (27.5% from pharmacological management to ablation) and 
9.2% randomised to ablation did not receive this therapy. All-cause mortality did not 
differ between groups, although there was less death or cardiovascular hospitalisation 
(HR 0.83, 95% CI 0.74-0.93; p = 0.001) and fewer AF recurrences (HR 0.52 95% CI 
0.45-0.60; p <0 .001) in the ablation group compared to those allocated to medical 
therapy.125 In a secondary analysis of this study undertaken according to treatment 




the primary end point of this study at final follow up (HR 0.67, 95% CI 0.50-0.89; 
p=0.006). All-cause mortality (HR 0.60, 95% CI 0.42-0.86; p=0.005) and death or 
cardiovascular hospitalisations were all significantly reduced in the ablation arm 
compared to pharmacological therapy (HR 0.83, 95% CI 0.74-0.94; p=0.002).125 Disease 
specific quality of life in this study, as assessed by the AFEQT, demonstrated greater 
improvement in the ablation arm compared to medical therapy at 12 month follow up 
(adjusted difference 5.3 points, 95% CI 3.7-6.9; p < .001) with a difference of ≥5 points 
deemed a ‘clinically important difference’.126 This difference persisted at five year follow 
up with a mean 3.4 point difference in favour of ablation (95% CI 2.1-4.8, p<0.001). 
Reduced symptom burden, as assessed by Mayo AF Specific Symptom Inventory 
(MAFSI), was also demonstrated in the ablation arm compared to medical therapy 
(adjusted difference, -1.5 points, 95% CI, -2.0 to -1.1; p < 0.001) with a pre-determined 
clinically important difference of ≤-1.5 at 12 months.126 This effect was still evident at 
five year follow up with a mean adjusted difference of -1.1 (95% CI -1.5 to -0.8; 
p<0.001). AF frequency was also significantly reduced at both 12 month and five year 
follow up.126  
In select populations ablation has demonstrated a more definitive benefit. The 
Catheter Ablation for Atrial Fibrillation in Heart Failure (CASTLE-AF) trial 
demonstrated a reduction in the primary composite endpoint of all-cause mortality and 
hospitalisation for worsening heart failure in a cohort of 336 individuals with either 
paroxysmal or persistent AF and heart failure, after a median follow up of 37.8 months 
(28.5% vs. 44.6%; HR 0.62, 95% CI 0.43 to 0.87; p=0.007).124 A large retrospective 
analysis of 5238 individuals undertaking first time ablation for AF demonstrated a 
reduction in cardiovascular (arrhythmic and non arrhythmic) hospitalisations in the 12 




procedure, a 56% reduction in arrhythmia related hospitalisations was observed, in 
addition to a 43% reduction in hospitalisations for heart failure. No impact on non 
cardiovascular hospitalisations was observed.127 Current evidence would support the use 
of this procedure in symptomatic individuals (unless heart failure is present) who are 
intolerant or decline the use of AAD therapy, or who have poor quality of life as a result 
of their condition. 
 
1.3.15 Anticoagulation 
An essential component of AF management is the reduction of stroke risk with the use of 
oral anticoagulant therapy in those in which this is necessitated based on level of risk. In 
the majority of international guidelines, this risk is calculated based on the CHA2DS2-
VASc score with scores of two or more in males and three or more in females the 
recommendation for treatment with oral anticoagulant therapy unless contraindicated.128 
Consideration should also be given to anticoagulation initiation in males with a 
CHA2DS2-VASc score of one and females with a CHA2DS2-VASc score of two. The 
recently published Australian AF guidelines have suggested a ‘sexless’ score due to the 
lack of significance of female gender in isolation on stroke risk in AF.115 Therefore, a 
CHA2DS2-Va score of 2 or more is the threshold for recommendation of anticoagulant 
therapy in these guidelines. However, wide variation in stroke risk at the same CHA2DS2-
VASc score across cohort studies has been demonstrated.129 In a systematic review of 34 
studies at a CHA2DS2-VASc score of two, stroke risk was reported as below 1% per year 
in 27% of studies, 1-2% in 40% of studies and greater than 2% in 33% of studies.129 
Furthermore, the dynamic nature of the CHA2DS2-VASc score has recently been 




for regular reassessment.130 In this database of 31,039 low risk individuals with AF, 13%  
experienced an ischaemic stroke over a mean follow up of 5.5 years. In almost 90% of 
individuals who experienced a stroke, there was a change in their CHA2DS2-VASc score 
over follow up which may have necessitated institution of oral anticoagulation (OAC) to 
reduce stroke risk with potential to significantly reduce the likelihood of this devastating 
complication. 
Numerous studies have demonstrated that OAC treatment to reduce stroke risk is 
often poorly managed with both over and underuse of appropriate therapy in AF 
populations. Data from large registries has confirmed that OAC is frequently 
inappropriately overused in those at low risk of stroke with 47% of individuals in the 
Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD) registry 
and 57% in the Outcomes Registry for the Better Informed Treatment of Atrial 
Fibrillation (ORBIT AF) treated with oral anticoagulant therapy despite a CHA2DS2-
VASc score of 0.131 Whilst the appropriate use of oral anticoagulant therapy in those in 
which it is recommended, i.e. with a CHA2DS2-VASc score ≥2, demonstrated 
improvement over time, it still remains suboptimal. In the GARFIELD registry, 
appropriate treatment occurred in 69% of participants and in the ORBIT AF registry this 
was 87% with evidence of significant regional variability. Across countries in 
GARFIELD this ranged from 31%-93% and across various states in the USA this ranged 
from 66%-100%.131  
In Australia high rates of inappropriate use of oral anticoagulation therapy have 
also been demonstrated. In a study examining the use of OAC in Indigenous and non-
Indigenous Australians with AF, 76.3% of the Indigenous cohort and 71.3% of the non-
Indigenous cohort with a CHA2DS2-VASc≥2 were not prescribed this therapy. Overuse 




under and overuse in Indigenous compared to non-Indigenous Australians (p=0.045 and 
p<0.001 respectively).132 The provision of appropriate anticoagulation has also 
demonstrated to be of greater likelihood for those attending specialist care provided by 
an electrophysiologist, compared to that delivered in the emergency department.133 
 
1.3.16 Cardiovascular risk factors in established AF 
Cardiovascular risk factor management, in addition to rate control, rhythm control and 
anticoagulation, has emerged as the ‘fourth pillar’ of AF management and is considered 
an essential component of holistic management of the condition. Numerous 
cardiovascular risk factors have demonstrated an association with both AF burden and 
progression of the disease. In Olmsted County, Minnesota a longitudinal cohort study of 
3,248 individuals with paroxysmal AF were followed for a median of 5.1 years.134 Both 
obesity (BMI 30-34.9kg/m2) and severe obesity (BMI >35kg/m2) were associated with 
progression to permanent AF (HR 1.54, 95% CI 1.2-2.0, p=0.0004 and HR 1.87, 95% CI 
1.4-2.5, p<0.0001 respectively).134 The Euro Heart Survey examined predictors of 
progression to permanent AF in 1,219 individuals with paroxysmal AF.135 In this study 
independent predictors included heart failure, age, chronic obstructive pulmonary 
disease, previous transient ischaemic attack or stroke and hypertension.135 Those who 
progressed to more permanent forms of the arrhythmia also had a greater likelihood of 
admissions for any cardiovascular reason (71% vs 50%; p<0.001), were more likely to 
undertake electrical cardioversion (26% vs 13%; p<0.001) and more likely to experience 
an ischaemic stroke (5% vs 1%; p=0.005).135 In another study of 1385 individuals 
presenting with paroxysmal AF with relatively short term follow up (approximately 6 




escalating BMI levels [HR 1.26 (95% CI: 0.92-1.72); 1.35 (95% CI 0.96-1.91); 1.50 (95% 
CI 0.97-2.33); and 1.79 (1.13-2.84) for overweight, obese 1, obese 2 and obese 3 
respectively].136 Other modifiable cardiovascular risk factors such as diabetes and 
hypertension were not independently associated with progression in this short term follow 
up study.136 However, a Korean study from a large national database demonstrated that a 
blood pressure of greater than 130/80mmHg was associated with a greater risk of major 
cardiovascular events with an incremental increase in risk observed in those with poorly 
controlled BP, defined as ≥140/90mmHg.137 An increased risk was also observed in those 
with intensively controlled BP of ≤120/80mmHg.137 Furthermore, in a community based 
cohort of individuals with AF, the progression to more permanent forms of the arrhythmia 
has been associated with a greater risk of adverse effects including a combination of 
mortality and all cause hospital admissions (HR 2.89, 95% CI 1.28-6.55; p=0.011).138  
 
1.3.17 Risk factor management in AF 
Over recent years, the role of cardiovascular risk factor modification in AF has asserted 
itself as a key component of gold standard management of this condition. This has 
become evident through its inclusion in numerous recent international 
guidelines.115,128,139 Several studies have demonstrated the efficacy of this approach, 
although multi-centre randomised controlled evidence in this area is lacking.  
The first study to address the concept of targeting cardiovascular risk factor 
management (RFM) in AF was a randomised controlled trial (RCT) which enrolled 150 
overweight or obese individuals with AF.140 The intervention group attended a physician 
led cardiovascular RFM clinic at three monthly intervals for a total of 15 months follow 




both of which were significantly less in the intervention group compared to control. This 
was corroborated by 7-day Holter monitoring which demonstrated a reduction in number 
of AF episodes and total duration of AF in the intervention group.  In the Aggressive Risk 
Factor Reduction study for Atrial Fibrillation cohort study (ARREST AF cohort study), 
a comprehensive risk factor management (RFM) program in overweight individuals 
(BMI≥27kg/m2 with paroxysmal or persistent AF who had been referred for AF ablation, 
resulted in significantly greater arrhythmia free survival in those who participated in the 
program compared to those who declined (HR, for likelihood of sinus rhythm at final 
follow up for RFM vs control, 4.8; 95% CI 2.04-11.4; p<0.001).141 This RFM program 
had several unique factors which may attribute to its success. Firstly, the program targeted 
numerous risk factors simultaneously. Weight loss was targeted with a resultant BMI aim 
of ≤27kg/m2, or a reduction of at least 10% of initial body weight, in all participants. 
Physical activity was recommended, beginning at 150 minutes per week, with increases 
of up to 250 minutes per week. Other risk factors were concomitantly managed including 
lipid profile and blood pressure, with the addition of pharmacotherapy to lifestyle 
measures as necessary to achieve pre-defined targets. Obstructive sleep apnoea and 
diabetes was screened for and treated in all eligible individuals. Smoking cessation and 
reduction of alcohol intake were also aggressively targeted. This clinic was delivered by 
a single provider, which ensured care standardisation, and had regular follow up at 3-6 
monthly intervals with more frequent visits scheduled as required. All participants were 
encouraged to maintain a lifestyle journal, which was a record of all food and drink 
intake, exercise undertaken and thrice daily home blood pressure measurements, and was 
reviewed at each visit to assist in meeting risk factor targets.  
The results of this intervention were further affirmed in longer term follow up as 




atrial fibrillation cohort’ (LEGACY) study.142 In this study, 355 individuals with 
paroxysmal or persistent AF participated in a multifactorial risk factor management 
program with a mean follow up of approximately 4 years. In this observational cohort 
study, participants were divided in to three groups according to the degree of weight loss 
achieved at final follow up (≥10% weight loss, 3-9% weight loss or <3% weight loss or 
weight gain). Freedom from any atrial arrhythmia at final follow up was significantly 
greater in those who achieved >10% weight loss compared to those who achieved the 
smallest amount of weight loss or gained weight (HR 5.9; 95% CI 3.4-10.3, p<0.001).142 
Structural remodelling including a significantly greater reduction in left atrial size and 
interventricular septal thickness was also demonstrated in the group achieving the 
greatest degree of weight loss compared to those who attained smaller degrees of weight 
loss or gained weight. Furthermore, post hoc analysis of this study has demonstrated that 
weight loss, as part of an overall cardiovascular risk factor management program, is 
effective in reducing the likelihood of progression to more permanent forms of AF.143 
The cost effectiveness of this approach has also been demonstrated with this risk factor 
management program demonstrating an incremental cost effectiveness ratio of $62,653 
per quality adjusted life year gained.144 These studies underscore the importance of 
targeting cardiovascular risk factors as a rhythm control strategy in the overweight and 
obese AF population.  
However, in those with more advanced forms of the arrhythmia, weight loss has 
not demonstrated the same degree of effectiveness as a rhythm control strategy. In a study 
of 90 individuals with longstanding persistent AF, despite substantial weight loss in those 
participating in a dietician led weight loss program (median reduction of -24.9kg, 
Interquartile Range [IQR] -19.1 to -56.7kgs; p<0.001) with no significant difference 




difference in AF burden was demonstrated as evidenced by 7 day Holter monitoring or 
AFSS questionnaire post catheter ablation for AF.145 It is possible that a more advanced 
substrate for AF is evident in these individuals, accounting for the lack of observed effect. 
Despite the lack of observed impact on AF burden, the weight loss group did demonstrate 
improved physical and mental component summary scores of the SF-36 (8.4±3; p=0.013 
and 12.8±8.2; p<0.02 for physical and mental component summary scores respectively), 
with no significant difference observed in those who declined this program (2.4 ± 14.3; 
p=0.43 and 3.1 ± 9.6; p=0.53 for physical and mental component summary scores 
respectively).145 
Other studies have also demonstrated enhanced outcomes with the use of 
cardiovascular risk factor management. In the post ablation field, the role of cardiac 
rehabilitation in paroxysmal and persistent AF has demonstrated enhanced outcomes with 
a statistically significant increase in peak V02 in the intervention group compared to 
controls.146 In this study of 210 individuals, who were enrolled prior to undertaking 
catheter ablation, the intervention included 12 weeks of thrice weekly exercise sessions 
and four educational sessions delivered by a nurse which commenced one month 
following catheter ablation for AF. The education sessions focussed on both information 
and education about AF, in addition to dealing with physical and psychological symptoms 
associated with the condition and the ablation procedure. After four months of follow up, 
the primary endpoint of peak V02 was significantly greater in the intervention group, with 
no significant impact on quality of life as assessed by the Short form 36 (SF-36) 
questionnaire. This is in keeping with other studies in AF management which also 
demonstrated no significant impact on quality of life.147 In the post ablation study, there 
was no significant difference in serious adverse events between groups, although an 




The concept of targeting cardiovascular risk factors as a rhythm control strategy 
was further endorsed with the recently published ‘Routine vs Aggressive risk factor 
driven upstream rhythm Control for prevention of Early atrial fibrillation in heart failure 
(RACE 3)’ trial.148 This study enrolled 245 individuals, with early persistent AF (>7 days 
but <6 months with ≤1 prior cardioversion) and early HF (preserved or reduced ejection 
fraction, duration < 1 year), who were randomised to control or an intervention which 
consisted of four pharmacological and lifestyle components: 1. Mineralocorticoid 
receptor antagonists (MRAs); 2. Statins; 3. Angiotensin converting enzyme (ACE-I) or 
Angiotensin Receptor Blockers (ARBs); 4. Cardiac Rehabilitation. Six weekly visits 
occurred for the duration of the study to the HF/arrhythmia nurse to specifically address 
any AF or HF related symptoms or issues in the intervention group. Results of this study 
demonstrate greater utilisation of MRAs and statins in the intervention group compared 
to control. At 1 year, maintenance of sinus rhythm, delineated by 7 day Holter monitoring, 
was significantly greater in the intervention group compared to controls (75% vs 63% for 
intervention vs control respectively; OR 1.765; 95% CI 1.021–3.051; p=0.042).148 This 
intervention had no impact on AF symptom burden, as determined by the EHRA class. 
At one year follow up, significant differences were observed between the intervention 
and control groups with respect to several cardiovascular risk factors including systolic 
blood pressure, diastolic blood pressure, BMI, weight, total cholesterol and LDL 
cholesterol. However, a number of these results, particularly blood pressure and lipid 
profile, could be attributed to pharmacologic measures which were utilised more 
frequently in the intervention group (as per protocol). However, other risk factors such 
as BMI and weight, whilst achieving statistically significant results are unlikely to 
represent significant clinical difference (e.g. there was a mean increase of 0.12 kg/m2 in 




follow up). This is likely reflective of the counselling in which participants in the 
intervention group received. Dietary counselling by dieticians was only provided in those 
with a BMI ≥ 30kg/m2. All participants were allowed up to 2 standard alcoholic drinks 
per day and there were no predefined targets for BP, lipids, BMI or waist circumference.  
Treatment of isolated risk factors in AF has not resulted in enhanced outcomes 
compared to usual care populations. Aggressive management of blood pressure, via pre-
defined protocols, in a symptomatic AF population undertaking catheter ablation did not 
result in significantly different likelihood of atrial arrhythmia recurrence after a six month 
follow up period, despite significantly improved blood pressure control.149 This is likely 
due to management of one isolated risk factor without consideration of other factors, such 
as the metabolic syndrome150 and obstructive sleep apnoea,151 which are known 
contributors to AF recurrence post ablation. However, in those with resistant 
hypertension and paroxysmal or persistent AF treated by catheter ablation, renal 
denervation in addition to pulmonary vein isolation enhanced the likelihood of freedom 
from AF, as determined by implantable cardiac monitoring (HR 0.40, 95% CI: 0.21‐0.80) 
and significantly reduced blood pressure (mean between group systolic blood pressure 
difference of -8mmHg, 95% CI -12 to -3mmHg) in a combined analysis of two studies 
enrolling 37 and 39 individuals in the intervention and control group respectively.152  
Importantly, the AF substrate in those with resistant hypertension is likely to be of a more 
advanced nature and require a different treatment approach to that of the wider AF 
population. This underscores the importance of services directed at comprehensive and 
holistic AF care, considering each individual’s differing profile, as most likely to result 





1.4 HOSPITALISATIONS IN AF – OPPORTUNITIES TO REDUCE HEALTH 
CARE BURDEN 
1.4.1 Hospital readmissions in the AF population 
Given the growing burden of hospitalisations due to AF, insights in to potentially 
modifiable factors associated with these is of great interest due to their ability to stem the 
growing epidemic of health care resource utilisation due to AF. Whilst the growing 
incidence of AF is a significant contributor to the increasing burden of hospitalisations,2,5 
other factors have also been identified. Rates of hospital readmission in individuals with 
AF are significant. A US sample of 6439 individuals demonstrated an 18% readmission 
rate within 30 days in those hospitalised primarily for AF.153 In this cohort more than 
10% of readmissions were due to AF, with other complications of the condition such as 
heart failure and cerebrovascular disease accounting for 7.1% and 6% of readmissions 
respectively.153 Another study of 3498 individuals found similarly high readmission rates 
which approached 40% for all causes at 12 months following an initial presentation with 
AF or atrial flutter.154 For cardiovascular re-hospitalisation, AF or atrial flutter was the 
most dominant cause accounting for 47.5% of all readmissions, with congestive heart 
failure the primary diagnosis for readmission in 9.9% of all cases, coronary artery disease 
in 7.4% and stroke/TIA in 6.2%.154 Follow up admissions for AF or atrial flutter as a 
primary diagnosis were significantly longer, and associated with higher cost.154  
 
1.4.2 Factors associated with repeat hospitalisations 
A large dataset from the Nationwide Inpatient Sample in the US which examined almost 
193,000 hospital admissions due to AF between January 1, 2009 and 31 December, 2010 




65.155 The highest rate of hospitalisations occurred in individuals over 85 years of age in 
this dataset, which is in keeping with Australian data demonstrating higher rates of 
hospitalisations for AF in older age groups.156 Interestingly, this US study demonstrated 
different rates of associated comorbidities in younger vs older patients hospitalised for 
AF (<65 years of age vs ≥65 years of age). Whilst hypertension and diabetes were the 
two most common comorbidities in each age demographic, there were higher rates of 
associated obesity and alcohol abuse in the younger age group, with more chronic kidney 
disease evident in the older population.155 This raises the question of potentially 
modifiable factors amenable to intervention, particularly in younger age groups due to 
the modifiable nature of these risk factors including obesity and alcohol intake, to reduce 
the burden of hospitalisations. Significant geographical variations have been 
demonstrated too, although reasons for this are unclear.10,155 This is potentially related to 
co-morbid conditions, patient acuity or variations in practice across hospitals, some of 
which may be amenable to intervention.  
A Canadian based study of 2068 community dwelling, anticoagulated individuals 
with AF examined factors associated with all cause hospitalisations in the cohort of 879 
individuals who were admitted to hospital during a median follow up time of 2.7 years. 
In this study, 66% of all hospitalisations were due to non-cardiac causes. A multivariate 
adjusted model demonstrated that advanced age, heart failure and the presence of vascular 
disease were all predictive of hospitalisation in this cohort.157 However, in a similar 
cohort of 9484 community dwelling individuals with AF in the USA, cardiovascular 
causes were found to be the dominant cause of hospitalisations, accounting for 49%  of 
all hospitalisations during the one year follow up period.158 In this study, 31% of all 
participants experienced at least one hospitalisations during follow up, with more than 




hospitalisation tended to be older, were more likely to be female and were more likely to 
have co-existent cardiovascular conditions including coronary artery disease, 
hypertension, cerebrovascular disease and peripheral vascular disease.158 A higher 
CHADS2 (Congestive Heart Failure, Hypertension, Age ≥ 75 years, Diabetes and Prior 
Stroke or TIA [doubled]) score and worse AF symptom severity, as determined by the 
EHRA class category, were also associated with hospitalisations. The CHADS2 and 
CHA2DS2-VASC scores were also found to be predictive of first cardiovascular 
hospitalisation in another large retrospective cohort study of 377,808 individuals with 
AF. A threefold increase in risk of cardiovascular hospitalisation was observed in those 
with a CHA2DS2-VASc score of 9 compared to those with a score of 0 with a 2.3-2.7-
fold increase in those with a CHADS2 score of 6.
159 
In Olmsted County, Minnesota, a case control observational study of 1430 
individuals with AF, demonstrated significantly higher rates of hospitalisations in the AF 
group compared to controls (58.8 vs 26.4 per 100 person years for AF vs control group) 
over a mean follow up of 6.3 years.160 Numerous factors were associated with 
hospitalisations during follow up with the highest risk associated with heart failure and 
chronic kidney disease. Other factors related to admission included coronary artery 
disease, stroke, cancer, ever smokers, heart failure, chronic obstructive pulmonary 
disease and depression.160 Hospitalisation and death due to cardiovascular causes 
occurred more frequently in the AF cohort compared to controls. Similar predictive 
factors for admission to hospital were also demonstrated in another US based study of 
ED presentations with advanced age (≥75 years), heart failure, diabetes, hypertension, 
chronic kidney disease, chronic obstructive pulmonary disease and income.10 In this 
study, significantly greater rates of admission were observed in metropolitan hospitals 




1.4.3 Strategies to reduce AF related hospitalisations 
Significant geographical variation in management of AF in the emergency department 
has been demonstrated. In a survey of Canadian, American and Australasian emergency 
department physicians the use of rate control as an initial strategy varied from 43.1% in 
the United Kingdom (UK) to 94% in the USA.161 The use of cardioversion in the 
emergency department also varied significantly ranging from 25.9% in the USA to 65.9% 
in Canada.161 Even within countries significant variation in practices have been 
demonstrated. A review of eight academic centres in Ottawa, Canada demonstrated large 
variations in the use of strategies for the acute management of AF.162 Potentially 
modifiable predictors of the use of electrical cardioversion included the prior use of 
electrical cardioversion and hospital site with odds ratios varying between 0.38 to 3.05.162 
Significant variation in rates of admission after successful cardioversion were also 
demonstrated with this occurring in only 27.2% of cases in the United Kingdom 
compared to 84.6% in Canada. This is clearly supportive of the concept that factors 
beyond that of clinical need play a part in contemporary AF care and is reflective of the 
lack of evidence based clinical guidance and lack of agreement in this area as 
demonstrated in current AF guidelines.163 Importantly, this represents a potential avenue 
to curtail the growing health care burden due to AF.   
In hospital strategies, such as the use of emergency department protocols, have been 
tested in numerous studies to standardise care and reduce unnecessary hospital 
admissions for AF. In a pilot ‘before and after’ study in the USA, an emergency 
department protocol which included early referral (generally next day appointment) to an 
AF clinic resulted in a dramatic reduction in rates of admission to hospital. In the pre-
intervention period, rates of admission to hospital were 43% compared to 19% in the post 




included a review of appropriate use of rate control and stroke preventative therapies, risk 
factor assessment and modification, patient education and facilitating communication 
between the emergency department and primary care practitioners. The number of AF 
clinic visits in this study is not reported on. Length of hospital admission did not 
significantly differ between the pre and post intervention period in this study and, 
surprisingly, a comparison of rates of re-presentation to hospital for AF in the pre and 
post study period was not reported on. Similarly, another US based study of an emergency 
department management protocol for AF also resulted in significantly fewer admissions 
(80% vs 16%, p<0.01); a significantly lower length of stay for inpatient hospital 
admission (mean length of stay 32 vs 85 hours; p=0.002) and a longer length of stay for 
emergency department presentations in the intervention group compared to control (mean 
8 vs 16 hours; p<0.001)165. There was also a greater likelihood of restoration of sinus 
rhythm in the intervention group compared to control. The AF pathway in this study 
differed significantly from the prior study with greater collaboration between emergency 
department physicians and specialist EP cardiologists and was also without onwards 
referral to a specialist AF clinic or indeed any structured follow up care.165 This may in 
part account for the lack of observed difference in rates of re-presentation to hospital for 
AF in the pre and post intervention study periods. Another US based study of an AF 
emergency department protocol followed by one clinic visit in a specialised AF clinic run 
by Nurse Practitioner’s or Physician’s Assistants under the oversight of 
electrophysiologists, resulted in a significant improvement in AF related quality of life, 
as assessed by the AFEQT questionnaire, at 90 days of follow up.166 Over the 90 day 
follow up period, there were 15 repeat emergency department visits in 100 individuals 
and four hospitalisations. There was no control group or assessment of the pre-




1.4.4 Management of AF in the Emergency Department 
The early use of cardioversion has been evaluated in several studies to assess the impact 
of this strategy on early discharge from the emergency department. An emergency 
department protocol for AF management in Ottawa, Canada which involved the initial 
use of intravenous procainamide followed by early electrical cardioversion if restoration 
of sinus rhythm did not occur, resulted in 93.3% of the 660 enrolled patients reverting to 
sinus rhythm prior to discharge.167 AF recurrence rate within 7 days was 8.6% with no 
control group for comparison purposes. There was no structured onwards referral 
pathway in this study. A medical record review of 289 visits in 168 low risk patients who 
had presented to emergency department with a primary diagnosis of AF in Ottawa, 
Canada demonstrated that 97% of patients were discharged directly from the emergency 
department with an average length of stay of five hours.168 Electrical cardioversion was 
utilised in 28% (this was following failure of chemical cardioversion in 89% of 
individuals in this group) with success in 89%, with chemical cardioversion attempted in 
62% with a 50% success rate. Short term follow up, which was limited to events at the 
treating hospital only, demonstrated a low risk of major adverse events with one patient 
requiring admission following administration of diltiazem which resulted in bradycardia 
and atrioventricular (AV) block.168 In another US based study of 388 electrical 
cardioversion procedures undertaken at 4 emergency departments, restoration of sinus 
rhythm occurred in 86% of cases.169 In the 7 day follow up of this study 39 patients 
returned to the emergency department, of which 25 were for repeat episodes of AF. 
Again, this study was undertaken by medical record review. Similarly, another study 
undertaken by medical record review of 30 participants treated with electrical 
cardioversion compared to a control group who were treated with a rate control strategy 




successful in 97% of cases. Six individuals who underwent electrical cardioversion were 
admitted to hospital however, the mean length of stay was significantly lower in those 
undertaking electrical cardioversion compared to a rate control strategy (22.8 hours vs 
55.6 hours; p<0.001).170 Hospital charges associated with each of these strategies was 
also examined in this study with electrical cardioversion significantly cheaper than that 
of a rate control approach (1598 USD vs 4271 USD; p=0.001). Recently, a strategy of 
delayed cardioversion in individuals presenting to emergency with an AF duration of <36 
hours was demonstrated to be non inferior to a strategy of early pharmacological and/or 
electrical cardioversion in a randomised controlled trial.171 In this study of 433 
individuals, there was no difference in observed rates of sinus rhythm as recorded on 
ECG at four weeks post emergency department presentation. Furthermore, adverse events 
did not significantly differ between groups including transient ischaemic attack, 
ischaemic stroke, acute coronary syndrome and unstable angina.171 There was no 
evidence of between group differences in recurrent ED visits due to AF, nor in time to 
first recurrent episode or any documented ECG evidence of AF recurrence during study 
follow up. However, a recently published study demonstrated that in 150 individuals with 
persistent AF, a strategy of presenting to the emergency department within 36 hours of 
symptom onset for electrical cardioversion was superior to usual care (cardiologist 
appointment followed by elective outpatient cardioversion) in reduced symptom burden 
at 12 months (EHRA score ≥2 in 44% vs 72%; p<0.005 for emergency department 
cardioversion vs usual care respectively) and in longer time to next AF recurrence 
(295 ± 15 vs 245 ± 15 days; p = 0.001 for emergency department cardioversion vs usual 
care respectively).172 Whilst observational studies have demonstrated low risk of 
complications with the use of electrical cardioversion in low risk individuals,173 the 




undertaken to date have been limited due to generally small numbers and short term 
follow up. There is a lack of both prospective and randomised data to guide clinicians in 
this area. Additionally, the lack of structured follow up in each of these studies is perhaps 
accountable for the high rate of return visits to the emergency department for repeat AF 
episodes. 
 
1.5 OPPORTUNITIES TO IMPROVE OUTCOMES IN THE AF 
POPULATION 
1.5.1 Exercise based interventions in AF 
Other studies have focussed on the impact of physical activity, as an isolated intervention, 
on outcomes in the AF population. A RCT of 51 individuals with paroxysmal or persistent 
AF evaluated the impact of thrice weekly aerobic interval training on AF burden, 
symptoms, quality of life, cardiac function and lipid profile. After short term follow up 
(four weeks) mean AF burden, as assessed by an implantable loop recorder, increased in 
the control group (from 10.4% to 14.6%) and decreased in the intervention group (from 
8.1% to 4.8%; p=0.001 for difference between groups).174 Peak VO2 was also 
significantly increased in the intervention group compared to control, left ventricular 
ejection fraction significantly improved, there was a significant decrease in total 
cholesterol, LDL cholesterol and triglycerides in the intervention group compared to 
control. At short term follow up, weight and BMI were also significantly decreased in the 
intervention group compared to control subjects. There was no statistically significant 
difference in cardioversions or hospital admissions between groups, although the study 




SF-36, which was improved in the intervention group, there was no impact on overall 
quality of life with this intervention. 
In those with permanent AF, a small scale study of 49 individuals randomised to 
a 12 week aerobic exercise intervention or control, demonstrated a significant 
improvement in exercise capacity (as determined by cycle ergometer testing) and six 
minute walk test distances in the intervention group compared to the control group (both 
p=0.001).175 Furthermore, at final follow up (immediately post cessation of the 12 week 
intervention), greater improvements in the Minnesota Living with Heart Failure 
(MLWHF) Questionnaire was observed in the intervention group, in addition to an 
improvement in the physical functioning, general health and vitality domains of the SF-
36. However, between group differences for either questionnaire were not significant at 
follow up.175  Whilst resting heart rate was reduced in the intervention group, surprisingly 
this intervention did not impact on blood pressure. Similarly, another small study with 
short term follow up in individuals with chronic AF demonstrated improvements in four 
of the subscale domains of the SF-36 questionnaire (physical functioning, bodily pain, 
vitality and role emotional) as well as the physical component summary score (49±6 pre-
program compared to 52±6 post program; p<0.05).176 Symptom burden, as assessed by 
the generic arrhythmia Symptoms and Severity Checklist, also demonstrated 
improvements in symptoms of tiredness/lethargy and a reduction in severity of shortness 
of breath, following the exercise training sessions. Interestingly, this study, despite its 
randomised nature, did not report on between group differences. The control group also 
undertook the intervention on completion of the initial follow up period and aggregate 
results of both groups are presented. 
Overall, whilst numerous studies have described benefits attached to exercise 




of clinically relevant outcomes and short term follow up periods. As part of a 
comprehensive risk factor management program, exercise demonstrated incremental 
benefit to that of weight loss in 308 individuals with non-permanent AF.177 In this study, 
individuals who lost ≥10% of their body weight over follow up and gained ≥2 metabolic 
equivalents (METs) on standard exercise testing, had a 75.6% likelihood of freedom from 
AF, as delineated by 7 day Holter monitoring, compared to a 44.8% likelihood in those 
who lost ≥10% of body weight but gained <2 METs in fitness over follow up (p<0.001). 
Further reduction in likelihood of AF freedom were evident in those who lost <10% of 
their body weight over follow up regardless of gain in METs.177 Whilst there are clear 
benefits to regular exercise in relation to overall cardiovascular health, further larger scale 
studies are required to elucidate the optimal mode and intensity of exercise programs to 
enhance patient outcomes. 
 
1.5.2 Polypharmacy and adverse outcomes 
Polypharmacy represents a potential novel risk factor which may offer opportunity to 
improve outcomes in the AF population. Numerous adverse outcomes have been 
demonstrated with polypharmacy in a broad range of other conditions. An observational 
study of older men (65-83 years) in Western Australia demonstrated an increased 
statistically significant risk of numerous adverse outcomes including all cause death (OR 
1.04, 95% CI 1.00-1.07, p=0.046), all cause hospitalisation (OR 1.04, 95% CI 1.03-1.06, 
p<0.001) and cardiovascular events (OR 1.09, 95% CI 1.06-1.12, p<0.001) with 
increasing numbers of prescribed medicines.178 In a large prospective observational 
registry (n=46,946) of adults with type 2 diabetes, the prescription of four or more 




95% CI 1.04-1.43 for 4-5 medications, HR 1.33; 95% CI 1.12-1.58 for 6-7 medications 
and HR 1.59; 95% CI 1.34-1.89 medications; p values not reported).179 In another study 
of older men (>70 years of age), each one numerical increase in prescription of 
medication conferred an increased risk of disability (OR 1.08; 95% CI 1.00-1.15; p-0.04), 
falls (OR 1.07; 95% CI 1.03-1.12; p=0.002) and mortality (OR 1.09; 95% CI 1.04-1.15; 
p=0.0009).180 
 
1.5.3 Polypharmacy and AF 
Few studies have examined the impact of polypharmacy on outcomes in the AF 
population. Two of the direct oral anticoagulants (DOAC) studies have examined the 
impact of polypharmacy in AF as post hoc analyses and found this to be independently 
associated with numerous adverse outcomes.181,182 Other studies have described on 
impact on quality of life, however a systematic search and synthesis of this literature to 
date has not been undertaken.  
 
1.5.4 Mobile health technology in AF 
Few interventions have examined the use of mobile health technology in AF. In China a 
cluster RCT, involving two hospitals, of a mobile health application demonstrated 
enhanced patient reported outcomes in the intervention group compared to usual care.183 
The application was designed to integrate clinical risk scores, such as the CHA2DS2-
VASc and HAS-BLED scores, with patient test results, which would allow the 
application to make a recommendation concerning appropriate anti-thrombotic therapy. 
There was a patient education component to the software which covered areas such as 




medications, use of left atrial appendage occlusion devices, and treatment of AF with 
concomitant conditions such as ischaemic heart disease, pulmonary embolism and deep 
vein thrombosis. The application also had capability for individuals to maintain a record 
of parameters such as their heart rate and blood pressure. After a mean follow up of 95 
days, the intervention arm demonstrated an improvement in AF related knowledge, as 
assessed by a validated AF Knowledge Questionnaire, compared to baseline measures. 
There was also a demonstrable improvement in several quality of life parameters 
(EuroQol questionnaire) although no effect on anxiety and/or depression was observed. 
Self-reported medication adherence, as assessed by a 3 item Adherence Estimator tool, 
was also improved in the mobile health application group compared to usual care. 
Although it is reported that there was a health care provider component to this application, 
this was not further explored and the interplay between the patient application and the 
health care provider is unclear. No objective outcomes were reported in this study.  
 Recently, in conjunction with release of disease specific guidelines, the European 
Society of Cardiology has released two mobile health applications specifically related to 
AF.184 The applications were developed to both ensure patient involvement in their care, 
and support health professionals in decisions concerning care delivery. The first is an 
application specifically for patients and includes educational material in addition to acting 
as an electronic health record and forum for individuals to keep electronic records of AF 
episodes with an in-built symptom diary. The second application is for health care 
professionals and acts as a facilitator to ensure that AF care is guideline adherent. 
Treatment algorithms, based on current guidelines, are integrated in to the application 
and it is also capable of maintaining a list of all consenting individuals using the patient 




facilitated through the applications. At this stage, there has not been a prospective study 
evaluating these applications. 
 
1.6 INTEGRATED CARE FOR ATRIAL FIBRILLATION 
The growing burden of AF demands a new paradigm in care delivery for this condition. 
As prevalence continues to increase, hospitalisations related to the condition outnumber 
those of other common cardiovascular conditions such as HF and MI, and poor quality 
of life is evident in this population, urgent action is needed to comprehensively develop 
strategies to improve outcomes in the AF population. Alternative models of care delivery 
have demonstrated improved outcomes in the setting of numerous chronic cardiovascular 
conditions including HF and across the spectrum of ischaemic heart disease.185,186 
However, significant heterogeneity in models utilised has evolved for chronic 
cardiovascular condition management, with group programs such as cardiac 
rehabilitation used more frequently for ischaemic heart disease, and more intense and 
individualised models used in the HF population. This is perhaps due to the perceived 
‘severity’ of the condition and may account for some of the observed differences in 
outcomes. This has led to uncertainty concerning optimal methods and components of 
care delivery in these populations. This situation is compounded by the frequent co-
existence of these conditions in any given individual. In AF, there is a pressing need to 
develop and evaluate alternative models of care delivery to address the growing health 





1.6.1 Heart failure management: the role of ambulatory care 
A commonly applied model in the outpatient heart failure setting is nurse led with support 
from a range of health care professionals. In the heart failure population, a recently 
updated Cochrane meta-analysis reviewed three different models of care in the outpatient 
setting.187 A case management approach, typically involving close monitoring of the 
patient following admission to hospital, was undertaken in  28 of the 47 studies identified. 
This was generally undertaken by a nurse and usually involves home visits and/or 
telephone calls with reporting and referral to other members of the healthcare team. There 
were seven clinic based models identified, which involved care delivery in a specialist 
outpatient clinic run either by a cardiologist or specialist nurse. A multidisciplinary model 
was evaluated in nine studies with this defined as holistic care delivered by numerous 
professions with a view towards ensuring a smooth transition from health care facility to 
home.185,187 Three studies were unable to be categorised as any particular type of 
intervention. 
All-cause mortality was significantly reduced in both the case management (RR 
0.78, 95% CI 0.68 to 0.90) and multidisciplinary approaches (RR 0.67, 95% CI 0.54 to 
0.83) based on 26 and eight studies respectively. There was no evidence that a clinic-
based approach impacted on this outcome. Case management and multidisciplinary 
interventions reduced all cause readmissions (RR 0.92, 95% CI 0.83 to 1.01 and RR 0.85, 
95% CI 0.71 to 1.01 respectively), with no impact of clinic based RCTs on this outcome. 
The case management approach was associated with reduced heart failure readmissions 
(RR 0.64, 95% CI 0.53 to 0.78), as was multidisciplinary interventions (RR 0.68, 95% 
CI 0.50 to 0.92). Many outcomes in this meta-analysis were hampered by low to moderate 
quality evidence, giving rise to concern about the validity of results obtained. 




adequately undertaken. Based on the evidence to date either case management or 
multidisciplinary models of care appear to be most effective in relation to improved 
patient outcomes and reduced health care burden. In 30 of the 47 studies included in this 
meta-analysis, nurses were responsible for delivery of the intervention, often within the 
construct of a multidisciplinary team. Subgroup analysis of the case management 
approach by provider of the intervention (specialist nurse, nurse/community nurse, 
pharmacist or multidisciplinary care provision) did not demonstrate any significant 
impact of any one provider on all-cause mortality. However, the use of a specialist nurse 
in this model was associated with a significant reduction in both all cause (RR 0.85, 95% 
CI 0.73 to 0.99) and heart failure specific hospital readmissions (RR 0.58, 95% CI 0.47 
to 0.70) with no evidence of statistically significant impact from other providers.187 
Whilst nurse led models, often within the construct of a multidisciplinary team, have been 
the most widely studied models to date, it is possible that significant benefit may also be 
demonstrated by other health care providers or team constructs, however further research 
in this area is required. 
Despite the relatively large number of studies exploring alternative models of care 
delivery for heart failure, only one study utilising a case management model has been 
undertaken in the Australian health care setting. This single centre study enrolled 200 
participants admitted to hospital for heart failure, with usual care comprising standard 
cardiologist and primary care provider visits, contact with cardiac rehabilitation 
programs, dieticians and social workers as per standard treatment pathways.188 The 
intervention of this study comprised one home visit delivered by a specialist nurse 7 to 
14 days post discharge from hospital. An extensive home and physical assessment were 
undertaken at this visit, with the nurse providing information and education to empower 




cardiologist and general practitioner and, when it was deemed appropriate, a flexible 
diuretic regime was devised for patients and their families to self-manage. Repeat home 
visits only occurred if two or more unplanned hospital admissions for heart failure 
occurred over follow up. After six months of follow up, this intervention resulted in a 
significant 40% reduction in the composite endpoint of out of hospital death and 
unplanned hospital readmissions in favour of the intervention group. Further exploration 
of components of this composite endpoint demonstrates no significant difference between 
groups for all-cause mortality (18 vs 28 deaths in intervention vs usual care respectively; 
p=0.098) but significantly less hospital readmissions in favour of the intervention group 
(68 vs 118 events for intervention vs usual care respectively; p=0.031). Beyond six 
months, this effect was no longer evident with similar readmissions across both groups.188 
 
1.6.2 Ischaemic heart disease: the role of secondary prevention clinics and cardiac 
rehabilitation 
In the ischaemic heart disease population, greater heterogeneity in outcomes has been 
demonstrated. Whilst the use of individualised approaches to care management in these 
populations has demonstrated significant benefit, with nurse led outpatient clinics 
participating in a cluster randomised controlled study of 19 general practices in Scotland 
demonstrating superior outcomes with reductions in all cause and cardiovascular 
mortality at four-year follow up,189 at longer term follow up of 10 years this benefit was 
no longer evident.190 A cluster randomised controlled trial of 1316 participants from 20 
primary care practices in England evaluated the impact of nurse delivered intervention 
which included patient assessment, medication up titration and management and liaison 




deemed necessary.191 This study demonstrated an improvement in those meeting target 
blood pressure and lipid levels in the nurse intervention group compared to usual care 
(OR 1.61, 95% CI 1.22-2.13, p=0.0113 and OR 1.58, 95% CI 1.05-2.37, p=0.0314 for 
blood pressure and total cholesterol respectively). Greater prescription of lipid lowering 
and beta blocker therapy in the intervention group was also demonstrated with no impact 
on Aspirin prescription or ACE inhibitors. Significant improvement in systolic BP, 
diastolic BP and total cholesterol values were also demonstrated with no impact on BMI. 
Conversely, another primary care cluster randomised controlled study of 597 individuals 
post admission to hospital for myocardial infarction or angina, demonstrated no impact 
on objectively measured cardiovascular risk factors at 12 months (blood pressure, 
cholesterol, BMI) with the use of a cardiac liaison nurse which aimed to ensure structured 
follow in general practices.192    
Few studies have examined outcomes at long term follow up, so it is possible that 
attrition in benefit is observed over time. Two studies examining follow up beyond 12 
months failed to demonstrate any sustained benefit from nurse delivered interventions 
focussing on modification of risk factors.190,193 This is likely to be multifactorial and 
encompass both provider and patient factors including a reduction in intensity of follow 
up and consequent lack of accountability in addition to patient factors such as motivation 
and commitment to ongoing self-monitoring and lifestyle change. A systematic review 
of seven randomised controlled trials demonstrated significant heterogeneity in 
methodology, care delivery structure and outcomes measured, resulting in difficulty 
assessing the impact of nurse led care in this ischaemic heart disease population.194 Whilst 
it was concluded that the use of such clinics was not associated with any harm, evidence 




The use of group based cardiac rehabilitation (CR) programs is an established 
paradigm in the management of a broad range of chronic cardiovascular conditions 
including stable angina, acute coronary syndromes, post percutaneous coronary 
intervention (PCI) and following cardiac surgery. This is evidenced by the highest level 
of recommendation in numerous national and international guidelines195,196, with a class 
II recommendation in the most recent European acute coronary syndrome guidelines.197 
Furthermore, a dose dependent increase in benefit has been demonstrated with a US based 
study demonstrating significantly improved outcomes in 30,161 Medicare beneficiaries 
attending 36 sessions of cardiac rehabilitation compared to those attending one, 12 or 24 
sessions.198 Compared to those attending one session, attendance at 36 sessions was 
associated with a 47% reduction in all cause death (HR 0.53, 95% CI 0.48 to 0.59) and a 
31% reduction in risk of MI (HR 0.69, 95% CI 0.58 to 0.81) with dose dependent 
decreases observed in those attending less sessions.198   
Despite heterogeneity in the structure of group based programs, the most recently 
published systematic review and meta-analysis of 14,486 participants from 63 RCTs 
demonstrated that the use of CR was associated with significant reductions in 
cardiovascular mortality, all-cause hospital admissions and improved quality of life.199 
However, no impact on all-cause mortality, MI or the use of revascularisation was 
demonstrated.199 Important differences in outcomes were observed by subgroup analysis. 
Higher exercise dose was associated with a significant reduction in cardiovascular 
mortality (RR 0.75, 95% CI 0.65-0.86), which was not evident at lower exercise doses 
(RR 0.47, 95% CI 0.19-1.15). Similar to the ischaemic heart disease clinic models of 
care, interventions recording outcomes at longer than 12 months duration did not 
demonstrate any significant impact on any outcome with reductions in myocardial 




0.62 to 0.84) and all cause hospitalisation (RR 0.63, 95% CI 0.46 to 0.88) which was 
observed in those recording outcomes at ≤ 12 months.199  Importantly, no impact on any 
outcome was observed in studies undertaken in Australasia, although this is somewhat 
hampered by the small number of studies involved (five out of 63 included studies). 
Unanswered questions remain about the optimal method of delivery for cardiac 
rehabilitation programs including exercise dose, the added benefit of comprehensive 
programs including education, the optimal duration of program delivery and follow up 
regime. Additionally, the optimal mix of health care providers involved in service 
delivery is yet to be fully delineated. 
A contemporary analysis of cardiac rehabilitation trials published between 2010 
and 2015 confirmed a statistically significant overall reduction in cardiovascular 
mortality, in addition to reductions in MI and cerebrovascular events.200 Interestingly, 
sub group analyses of these contemporary studies revealed a significant reduction in all-
cause mortality in programs managing six or more cardiovascular risk factors, compared 
to those who managed less, as well as in programs who had the ability to prescribe and 
up-titrate cardioprotective medications, which was not evident in those who did not have 
this capacity.200 It is plausible that the intensity of the intervention delivered is a key 
component in delivering enhanced patient outcomes in this population. 
However, brief interventions have also demonstrated enhanced patient outcomes in 
the ischaemic heart disease population. In a single centre study of 710 individuals with 
documented coronary heart disease (prior MI or angiographically proven disease), semi 
personalised text messages delivered four times per week over 24 weeks resulted in an 
improved cardiovascular risk factor status. The text messages were targeted according to 
each individual’s baseline risk factor profile and were designed to encourage participants 




health care professionals and participants. This resulted in a small but significant 
improvement in the primary outcome of LDL cholesterol (mean difference -5mg/dL, 95% 
CI -9 to 0; p=0.04) at 6 months, in addition to more marked improvements in other 
cardiovascular risk factors including systolic blood pressure, physical activity levels, 
numbers of current smokers and BMI.201  
 
1.6.3 Integrated care 
Integrated care is an approach to health care delivery which was borne out of the Chronic 
Care Model developed by Wagner and colleagues202, with recognition that standard 
medical care is often inadequate in meeting the needs of those with chronic conditions. 
This approach takes in to account the needs, values and preferences of patients in addition 
to care delivery based on the best available evidence. The original Chronic Care Model 
identified five effective interventions to improve outcomes in those with chronic illness. 
These included:  
1. The use of evidence-based care;  
2. Reorganisation of systems of practice and providers;  
3. Assistance in patient self-management strategies;  
4. Increased availability of expert care;  
5. Increased access to clinical information.202  
Translation of this model into clinical practice further identified six areas deemed critical 
to the successful application of the Chronic Care Model.203 These key areas include: 
Health Care Organisation which involves leadership and organisational support for the 




change to current practice management. Community resources was also identified as a 
key area with accessibility to care not readily available at the primary organisation. Self-
management support involves a shift from more paternalistic health consultations to 
encounters that empower individuals to self-monitor and manage their condition. 
Communication with patients is a critical component of this and ensures that individuals 
play an active role in their care decisions.  Redesigned health systems allow for support 
for promotion of behaviour change and self-management support, assessment of response 
to therapy and protocol driven care delivery. Decision support systems allow for delivery 
of evidence based guidelines and should be integrated into standardised care pathways 
and, finally, clinical information systems support the delivery of this model of care, 
usually through the support of software systems.203  
The integrated care model is based on this concept although a consistent definition 
and care delivery structure has yet to be fully delineated. A study reviewing the evidence 
for integrated health systems yielded 175 definitions of the concept and little consistency 
in methods of evaluation.204 Indeed, at a relatively early stage of this concept, the 
inconsistency in definition and application of this approach was widely recognised.205 
Therefore implementation and evaluation of integrated care delivery is fraught with 
numerous challenges. To address these challenges, a definition of integrated patient care 
has been proposed by a Harvard based research group, as opposed to health service 
delivery organisational integration, to allow for greater standardisation and ability to 
evaluate this concept. This has been proposed as: “patient care that is coordinated across 
professionals, facilities, and support systems; continuous over time and between visits; 
tailored to the patients’ needs and preferences; and based on shared responsibility 




constructs has been proposed for implementation and evaluation of this concept. These 
include:  
1. Co-ordination within the care team;  
2. Co-ordination across care teams;  
3. Co-ordination between care teams and community resources;  
4. Familiarity with the patient over time;  
5. Continuous proactive and responsive action between visits;  
6. Patient-centred; and  
7. Shared responsibility for care.206  
Application of this framework would support greater consistency and evaluation of 
integrated care delivery from both a research and clinical perspective. As this has not 
been successfully undertaken to date, this has led to inherent difficulties in 
implementation and evaluation of the integrated care concept.  
 
1.6.4 Integrated care for chronic condition management 
Despite these challenges, numerous studies have demonstrated enhanced patient 
outcomes with the use of an integrated care approach. A meta review of twenty seven 
systematic reviews examined the impact of integrated health care delivery on outcomes 
in a number of chronic diseases including heart failure, diabetes, chronic obstructive 
pulmonary disease and asthma.207 Whilst there was inconsistency in definitions and 
outcomes in the use of this approach, most studies demonstrated benefit with evidence of 
reduced hospital admissions and readmissions, improved adherence to guideline 




not possible.207 One of the largest evaluations of an integrated care concept to date is that 
of the Intermountain Health Service in Utah, USA. This study evaluated the use of 
integrated team-based care at 27 primary care practices, and compared outcomes to 
individuals attending 75 primary care practices using a traditional practice management 
approach.208 Key elements of the team based care approach included care co-ordination 
for chronic diseases through the use of standardised protocols, patient involvement and 
engagement in care planning, involvement of family and community and clearly defined 
roles and expectations for all team members, supported by an accessible electronic patient 
record for each individual. Over a four year period, the use of team based integrated care 
was associated with reduction in hospital admissions (IRR 0.89, 95% CI 0.85-0.94, 
p<0.001), reduced emergency department visits (IRR 0.77, 95% CI 0.74-0.80, p<0.001) 
and reduced primary care physician visits (IRR 0.93, IRR 0.92-0.94, p<0.001).208 
Payments received by health care professionals and organisations for those in team based 
care were also significantly lower than that of traditional practice management, and 
highlights the lack of a structured funding model for the use of this approach.  
 
1.6.5 Integrated care in AF 
Comparatively little evidence exists concerning alternative models of care delivery in the 
AF population. In recent times, recognition of AF as a chronic cardiovascular condition 
has led to the development of several studies examining the impact of care co-ordination 
on outcomes in the AF population.  A widely used approach in studies thus far is the use 
of an integrated care model. The first of these studies utilised an integrated care approach 
in a single centre RCT in the Netherlands. This study enrolled 712 individuals with newly 




management.209 Those in the intervention group attended a nurse led, physician supported 
outpatient clinic which included a number of key elements. These were: 1. Delivery of 
protocol driven care; 2. Guideline adherent care according to the most recent European 
guidelines for AF 3. The use of a software support system to ensure standardisation of 
care, and 4. Patient involvement in all decisions concerning care. Patients in usual care 
received care by a cardiologist in the outpatient setting. Over a mean follow up of 22 
months, this intervention resulted in a significant reduction in the primary endpoint, a 
composite of cardiovascular hospitalisations and mortality, in those attending the 
integrated care clinic (OR 0.65, 95% CI 0.45-0.93, p=0.017).209 This intervention was 
also cost effective with a gain of 0.009 quality adjusted life years and a saving of 1109 
euros (approximately $1,753 Australian dollars) per patient,210 but did not significantly 
impact on quality of life as assessed by the SF-36.210  
Another study examined the impact of home-based care co-ordination in AF in a 
multi-centre RCT at three centres in Australia. For this study, individuals who had been 
hospitalised primarily due to AF were eligible, with the intervention including a home 
based educational visit 7-14 days after enrolment, written patient education, protocol 
driven diagnostic testing and recommendation concerning guideline adherent treatment 
to the treating general practitioner (GP) and cardiologist.211 This intervention did not 
result in a reduction of the primary endpoint of all-cause mortality and hospitalisations in 
the intervention group compared to control (HR 0.97, 95% CI 0.76-1.23; p=0.851). It did, 
however, result in proportionately more days alive and out of hospital in the intervention 
group compared to control.  
Finally, the use of an integrated care approach was used in a Canadian multi-centre 
study, which applied this model to a population of individuals presenting to three 




after study comprised an educational telephone call 2-3 days post discharge, a group-
based education session, individual review of each case by a physician and nurse with 
diagnostic testing, and a detailed letter to the treating physician concerning treatment 
recommendations. Following this, care was returned to the treating physician. In a 
propensity matched analysis, this intervention resulted in a reduction in the composite 
primary endpoint of death, cardiovascular hospitalisation and AF related ED visits (OR 
0.71, 95% CI 0.59-1.00, p=0.049).212 This reduction was largely driven by reduced AF 
related ED visits. 
Whilst variability in methodology and outcomes for each of these studies is evident, 
they have made significant advances in our understanding of improving outcomes in AF 
through alternative models of care delivery. However, significant uncertainty exists as to 
optimal methods and models of care delivery.  
 
1.6.6 Shared decision making in AF 
An essential component of the integrated care approach for chronic condition 
management is the use of a shared decision-making process. This process moves away 
from paternalistic models of care, where the patient is instructed by the health care 
professional on treatment recommendations, and instead moves toward a shared process 
in which treatment options are discussed in the context of patient values and preferences. 
This process involves discussion between the patient and clinician with the clinician 
discussing treatment options, benefits and risks and the patient expressing their values 
and preferences in relation to these options.213 Ideally this process should also include 
family members or significant others, and may require discussion within a 




In AF, the choice of stroke prevention therapy presents an important opportunity 
to utilise a shared decision-making process with the aim to improve adherence to the 
treatment regimen. In this context, the use of a shared decision making process would 
involve discussion concerning risk of stroke based on risk assessment scores such as the 
CHA2DS2-VASc score, risk of bleeding according to scores such as the HAS-BLED 
score, discussion of patient preferences for treatment, agreement on a treatment regime 
and regular follow up to assess the impact of this decision.214 The use of shared decision 
making by a multidisciplinary team as part of an integrated care approach has been 
highlighted in numerous recent international AF guidelines.115,215 
Several studies have evaluated the use of decision support aids to facilitate this 
process in AF with mixed results. Most of these studies relate to use of OAC for stroke 
prevention. The largest study in which this was evaluated involved examining the 
outcomes of five decision support tools recommended by current AF guidelines at that 
time, in 15,129 newly diagnosed AF patients.216 Concordance with recommendations 
from three of these tools resulted in a significant reduction in the risk of any adverse AF 
events, which included a composite of any thromboembolic or major bleeding event, with 
the use of three of these tools, but after adjustment for potential confounders this benefit 
was no longer evident. Similarly, a Canadian cluster randomised controlled study of 434 
non-valvular AF patients from 102 community-based practices examined the impact of 
an educational booklet and audiotape, which was tailored to each individual’s stroke risk, 
on appropriate use of OAC. Despite a small improvement in the absolute use of OAC at 
3 months follow up (12% increase), this benefit was not evident at 12 months.217 Another 
RCT of participants in the Stroke Prevention in AF (SPAF III) study cohort examined the 
impact of a decision aid which encompassed an educational booklet, a worksheet and an 




were more able to quantify their stroke and bleeding risks and were more likely to reach 
a decision concerning their treatment, there was no significant impact on adherence to 
treatment at 6 months.218 Clinical outcomes were not reported in this study. Another RCT 
which examined the impact of an educational intervention, which encompassed a small 
group session facilitated by a DVD, an educational booklet and a self-monitoring diary, 
resulted in a greater amount of time spent in the therapeutic range (TTR) for the 
intervention group in 97 patients with AF taking warfarin.219 There were no significant 
differences between groups in quality of life, anxiety and depression, knowledge scores 
or illness perceptions as determined by questionnaires.219 Although not a prespecified 
endpoint of this study, adverse events occurred less frequently in the intervention group 
compared to control (one event compared to seven events in intervention and usual care 
respectively).   
In Australia, a cluster randomised controlled study examined the impact of a 
computerised decision assist tool on the prescription of antithrombotic therapy by 48 
General Practitioner’s in New South Wales on moderate to high risk individuals with AF 
(CHA2DS2-VASc score ≥1).
220 Use of this tool resulted in a small but statistically 
significant improvement in the prescription of OAC from 89.3% to 92.2% (p=0.02). 
When the tool recommended a change in therapy, this occurred in 64% of cases with 
reasons for disagreement including GPs considering the treatment inappropriate, patient 
declined therapy or cardiologist had recommended alternative therapy.220  
 
1.6.7 The role of education in AF 
Education forms an important component of providing holistic chronic condition 




in AF populations. A RCT of a brief nurse delivered educational intervention for 
individuals with AF presenting to the ED, demonstrated a reduced rate of adverse events 
in the intervention group compared to control. In this study of 240 individuals, the 
intervention consisted of standardised advice regarding AF including: a basic explanation 
of the arrhythmia, condition and treatment related complications, medication adherence, 
attending appointments for treatment follow up, signs and symptoms of future episodes 
including how to monitor the pulse to assist with arrhythmia recognition.221 Outcomes 
evaluated include AF related complications such as stroke, heart failure and any 
bradycardia requiring treatment, in addition to other non-specific outcomes including 
ventricular tachycardia, any arrhythmia causing haemodynamic instability and any 
haemorrhage in anticoagulated individuals. At 12 months, there were significantly less 
cumulative adverse events in the intervention group (31.9% vs 48.4%; p=0.005). 
However, there was no statistically significant difference between ED presentations or 
hospitalisations between the groups. Heart failure was the most commonly observed 
complication and occurred less frequently in the intervention group (16.6% vs 26.6%; 
OR 0.55, 95% CI 0.28-0.99; p=0.04 for intervention vs control respectively). The 
significant result observed in the primary cumulative endpoint was largely driven by a 
reduction in heart failure in the intervention group, with no other significant differences 
evident between groups for any other outcome. 
In a post ablation cohort, a nurse led educational intervention, delivered at five 
different timepoints, resulted in a significant improvement in quality of life and AF 
symptom burden in a RCT.222 The education was delivered in hospital, both pre and post 
procedure, and followed pre-defined topics which spanned basic information concerning 
their condition, causes and risk factors, typical AF symptoms and when help should be 




this, three telephone calls were received by participants in the intervention arm lasting 5-
10 minutes with a focus on symptoms, queries concerning medications and lifestyle 
management. No further contact was permissible with the nurse after three months post 
AF ablation. At six months, statistically significant improvements in numerous symptoms 
including palpitations, tiredness, difficulty sleeping, headache, trouble concentrating, and 
light-headedness/dizziness were evident in the nurse led educational group. Furthermore, 
the physical functioning and vitality domains of the SF-36 were also significantly 
improved in the intervention arm.222 At six months, there was no difference in either all 
cause or AF related hospitalisations. There was no reporting of between group differences 
for objective AF burden or cardiovascular risk factor outcomes. 
 
1.7  CONCLUSIONS 
The burgeoning AF population and poor outcomes observed in this population deserves 
urgent attention. As incidence and prevalence levels of this condition continue to rise, 
opportunities abound to improve patient outcomes and reduce associated health care 
burden. This ranges from enhanced management of risk factors to prevent onset of the 
condition to improved management of those with established AF. Optimal components 
of service delivery to achieve this are yet to be fully delineated, with further research in 





Chapter 2: National Trends in 
Hospitalisations due to Atrial 
Fibrillation in Australia 
2.1 INTRODUCTION 
2.1.1 Background 
Atrial fibrillation (AF) poses a major global healthcare burden. In contrast to many other 
chronic cardiovascular conditions, the incidence and prevalence of AF has dramatically 
risen over the last two decades and is expected to continue rising at an exponential 
rate.2,5,223 AF confers a significant increase in risk of all-cause mortality, with this risk 
evident even in low risk individuals with few comorbidities.224,225 A significant 
component of the healthcare system burden associated with AF is due to hospitalisations, 
related not only to the condition itself but also due to complications such as syncope, 
stroke and heart failure (HF).153  
 
2.1.2 AF hospitalisation trends in the USA and Europe 
Although AF hospitalisations are a significant global issue, most published data has 
emerged from North America and Europe. Previous US data demonstrated a 2-3 fold 
increase in AF hospitalisations over the 14 year period to 1999226 with more recent data 
demonstrating that AF admissions increased by 23% over the decade from 2000-2010, 
with greatest absolute increases observed in the age groups of 35-49 year olds and over 
80 years olds.8 In this same cohort, gender differences were apparent with greater absolute 




recently, a study of over 65 year old Medicaid eligible individuals in the US over the 
fourteen year period until 2013 demonstrated that AF related hospitalisations increased 
by 0.85% per annum, with greatest increases observed in those of more advanced age 
(2.22% per annum in those aged over 85).9 Once again, gender differences were notable 
with greater rates of increase observed in females at 1.2%, compared to males at 0.35% 
per annum.  Similar hospitalisation trends have also been demonstrated in Europe across 
numerous countries. In France, over a three year follow up period between 2005 and 2008 
a 26% increase in hospitalised individuals with a diagnosis of AF was demonstrated.13 In 
Scotland, a threefold increase in hospitalisations with AF as a principal diagnosis was 
demonstrated in the ten year period leading up to 1996.11 The Danish Hospital Discharge 
Registry also demonstrated a 60% increase in hospitalisations due to AF over the thirteen 
year period leading up to 1994.12 
 
2.1.3 AF hospitalisations in the Asia Pacific region 
Comparatively little data exists on AF epidemiology and hospitalisations from the Asia 
Pacific region. Recent data has projected rates of AF in this region to be far greater than 
that of the USA and Europe, in part due to larger populations and the growing rates of 
associated cardiometabolic risk factors.6 Other studies have confirmed trends for AF 
hospitalisations in western countries are also occurring in Asian countries. A 420% 
relative increase in AF hospitalisations from 2006-2015 in Korea has been demonstrated 
(with AF listed as any diagnosis).15 Previous Australian data on AF hospitalisations over 
the fifteen-year period between 1993 and 2007 demonstrated a greater relative increase 
of 203% for AF hospitalisations compared to 79% for MI and 17% for HF,7 but it is 





2.1.4 Economic cost of atrial fibrillation 
In addition to the individual and societal burden, the economic cost associated with AF is 
significant, the largest component of which is related to hospitalisations. In the United 
Kingdom, hospitalisations accounted for approximately 50% of AF-related healthcare 
expenditure.21 The cost of AF-related admissions has also demonstrated an upwards trend 
in the US, rising by an average total of USD 1,787 per admission over a 14-year period.9  
Recently, the management of AF has continued to evolve considerably to include 
advances such as the routine use of catheter ablation techniques, non-vitamin K antagonist 
anticoagulants, and aggressive cardiovascular risk factor management.128,227 The potential 
impact of these advances on hospitalisation rates, length of stay and cost remains 
uncertain.  
In the present study, we sought to characterise contemporary national trends in 
hospitalisations due to AF in Australia. We determined the number, rate and length of 
stay for AF hospitalisations compared to two other common cardiovascular conditions, 
MI and HF. We also quantified associated healthcare costs and examined changes in AF-
related procedures over a two-decade period in Australia.  
 
2.2 METHODS 
2.2.1 Hospitalisation Data 
Data on AF, MI and HF hospitalisations were extracted from the National Hospital 
Morbidity Database, which is maintained by the Australian Institute of Health and 
Welfare (AIHW). For the years 1993-1997, data were coded according to the 
International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-




410 for MI. From 1998-2013, data were coded according to the International Statistical 
Classification of Diseases and Related Health Problems, Tenth Revision, Australian 
Modification (ICD-10-AM) with AF and atrial flutter coded as I48, HF as I50, and MI as 
I21. Coding by principal diagnosis only was utilised for each condition. Data were 
acquired on the overall number and average length of stay of hospitalisations for each 
condition according to year, and further subdivided according to age and gender 
categories.  
 
2.2.2 Procedural Data 
Procedural data were obtained from two sources: the National Hospital Morbidity 
Database from the AIHW, and Medicare Item Reports maintained by the Department of 
Human Services. AIHW data are reflective of procedures undertaken in all public and 
private hospitals, whereas Medicare data are based upon procedures billed for by 
physicians and other health care providers utilising the Medicare Benefits Schedule at 
private hospitals across Australia. AIHW procedural data for AF ablation were available 
from 2000-2013. Data were also acquired for analyses comparing the rate of increase of 
AF ablation and other ablation procedures.  
Medicare data for AF ablation were available from 1995-2013. As with data from 
AIHW, Medicare data were also collected for analyses comparing the rate of increase of 
AF ablation and other ablation procedures. Medicare data for electrical cardioversion 
were available from 1993-2013. 
Ethics approval for use of the AIHW database is not required as this data is 





2.2.3 Statistical Analysis 
Time trends in the aggregate annual number of hospitalisations due to AF, MI and HF 
were assessed using negative binomial regression models. All models were age and 
gender adjusted and included an offset term for the logarithm of the estimated midyear 
Australian population, which was obtained from the Australian Bureau of Statistics. The 
same approach was used in the analysis of procedural data with changes in rates for each 
procedure over the period examined as raw data, and then as a proportion of total 
cardiovascular procedures, and finally adjusted for population estimates. Likelihood ratio 
(LR) tests were used to compare between nested negative binomial models in which 
interactions between predictor variables (age, gender, and year) were included and then 
excluded. A linear regression model was used to examine changes in length of stay for 
each condition over the study period, with an F-test used to assess the interaction between 
condition and year. Cost weights for relevant Australian Refined-Diagnostic Related 
Groups (AR-DRGs) were derived from the National Hospital Cost Data Collection 
Database (NHCDC) from 1997-2009, and from the Independent Hospital Pricing 
Authority (IHPA) for the years 2011-2013. Cost weights for the year 2010 are not 
available and were unable to be acquired. Annual average cost weights per AF, MI, and 
HF inpatient episode were estimated as the sum of the product of the cost weights for the 
relevant AR-DRGs for each condition and their proportion of the total inpatient episodes 
for each condition. The NHCDC and IHPA reported inpatient data from an incomplete 
sample of Australian hospitals and so the estimated annual average cost weights were 
multiplied by the total number of inpatient episodes for each condition, which were 
reported by the AIHW to obtain a total yearly cost for each condition (the AIHW did not 
report episodes by AR-DRG). All analyses were undertaken using Stata version 14.1, and 





2.3.1 AF, MI and HF Hospitalisations 
National AF hospitalisations increased by 295% over the 21-year period from 1993 to 
2013, reaching an annual total of 61 424 admissions at the end of the study period. In 
comparison, MI and HF hospitalisations only increased by 73% and 39%, reaching an 
annual total of 54 116 and 53 643 hospitalisations, respectively (p<0.001; Figure 1 and 
Table 1). These effects persisted after adjustment for population estimates. The annual 
increase in AF hospitalisations was 5.2% (incidence rate ratio [IRR] 1.052; 95% CI 1.046-
1.059; p<0.001), compared to a 2.2% increase per annum for MI (IRR 1.022; 95% CI 
1.017-1.027; p<0.001) and negligible annual change for HF hospitalisations (IRR 1.000; 
95% CI 0.997-1.002; p=0.78). As a percentage of all hospitalisations across Australia, 
there was a relative increase in AF hospitalisations of 87%, from 0.34% in 1993 to 0.63% 
in 2013 (Figure 2). The incidence rate per 10,000 of the population increased by 199% 
for AF from 8.8 to 26.3 admissions, compared to a 5% increase for HF from 21.9 to 23.0 
admissions, and 31% for MI from 17.7 to 23.2 admissions, per 10,000 population (Table 
1). 
 
2.3.2 Age and gender subgroup analyses 
All age categories demonstrated a significant rise in AF hospitalisations relative to the 
youngest age group (Figure 3). The associated rise was relatively homogenous for all age 
groups at 3.8-4% annually, until the over 80 age category which demonstrated a steeper 
rise at 4.8% per annum (p=0.008). Males and females showed similar relative increases 




2.3.3 Length of stay and total bed days used 
Whilst length of stay significantly decreased over the time studied across all three 
conditions, the observed decline in length of stay for AF hospitalisations was significantly 
less (decrease of 0.05 days per year; 95% CI 0.03-0.08; p<0.001) than that for HF 
(decrease of 0.12 days; 95% CI 0.10-0.15; p<0.001) and MI (decrease of 0.14 days; 95% 
CI 0.12-0.17; p<0.001; both p<0.001 compared to AF; Table 1). However, due to the 
increasing number of hospitalisations, there was still a significant annual increase in total 
bed days attributable to AF (estimated annual increase of 5,440 days; 95% CI 4,986- 
5,894; Table 1).  
 
2.3.4 Hospitalisation costs 
The total cost of AF hospitalisations demonstrated a 479% relative increase from 
$50,927,140 Australian dollars (AUD) in 1997 to $295,003,937 AUD in 2013. 
Comparatively, the cost of hospitalisations for MI and HF increased by only 210% for 
both conditions over the study period (Figure 4). The cost per admission increased by 
137% for AF hospitalisations from $2,029 to $4,803 AUD, compared to an increase of 
90% in cost per admission for MI, and a 141% increase for HF. 
 
2.3.5 Procedural trends 
The use of AF ablation rose steeply over the two decades studied with data from both the 
AIHW and MBS broadly consistent and demonstrating a 26% annual increase (IRR 1.26, 
95% CI 1.22-1.30 for AIHW, p<0.001). Procedural numbers rose from 59 in 2000 to 1 
743 AF ablations in 2013. All age and gender groups demonstrated a significant rise in 




although to a lesser degree than in the main analyses (IRR 1.09, 95% CI 1.07-1.13, 
p<0.001). AF ablation represented a small percentage of all cardiovascular procedures 
undertaken in Australia at 0.01% in 2000, increasing to 0.32% in 2013. As a proportion 
of all AF hospitalisations, AF ablation represented 0.01% in 2000, increasing to 2.80% 
in 2013. The rate of increase of AF ablation was greater in males than females (IRR 1.69, 
95% CI 1.28-2.24: p<0.001). Gender subgroup analysis showed that the use of AF 
ablation has increased annually by 28% in males (IRR 1.28, 95% CI 1.22-1.34, p<0.001) 
and 23% in females (IRR 1.23, 95% CI 1.18-1.28, p<0.001).  
Electrical cardioversion increased significantly over the study period with a 10% 
annual increase (IRR 1.10; 95% CI 1.09-1.10, p<0.001). This rose from a total of 1,340 
procedures in 1993 to 9,724 in 2013. As a proportion of all cardiovascular procedures, 
this is represented by a 7% annual increase (IRR 1.07; 95% CI 1.05-1.09, p<0.001). 
 
2.4 DISCUSSION 
Hospitalisation data and the associated costs have important implications for the 
rationalisation and optimisation of service delivery. In this study, using a National 
prospective dataset the following new information is demonstrated: 
• Hospitalisations due to AF continue to progressively grow over this 21-year 
period and have almost doubled since the beginning of this century; 
• AF surpassed HF in 2008, MI in 2011 and is now the most common cause for 
hospitalisation amongst these three conditions; 
• All age and gender categories have demonstrated a significant increase with the 




• A significant increase in the use of AF ablation that is unlikely to account for 
the increase in AF hospitalisation rates; 
• A modest increase in the use of cardioversion; 
• A significant rise in the cost of AF hospitalisations, with little difference in 
length of stay over the time period studied. 
AF hospitalisations have demonstrated a progressive increase such that AF is currently 
the most common cause of cardiovascular hospitalisation in Australia. Furthermore, the 
associated cost of AF hospitalisations has more than quadrupled over the 21-year study 
period from 1993 to 2013. Whilst AF-related procedures have significantly increased, 
they are unlikely to account alone for the observed rise in hospitalisations.  
 
2.4.1 Reasons underpinning the growth in AF hospitalisations 
The growing trend in hospitalisations due to AF is likely to be multifactorial and 
encompass both modifiable and non-modifiable components. The ageing population is 
in-part responsible for the growth in total number of AF hospitalisations. However, an 
11.3% increase in the age-standardised hospitalisation rate for AF from 2003 to 2011 
demonstrates the growing burden of this condition independent of the impact of the 
ageing population. These trends are in stark contrast to other cardiovascular conditions, 
such as coronary heart disease, which has demonstrated a 32% reduction over the same 
time period.228 In line with this rising prevalence rate is recent data suggesting a growing 
rate for incident AF hospitalisations, particularly in younger age groups (35-64 year 
olds).19 It is likely that these individuals will make frequent hospital presentations, 
thereby contributing to continuing growth in prevalent hospital admission rates. 




hypertension, coronary artery disease, obesity and diabetes.39,50,52,61   In line with data 
from the USA demonstrating suboptimal cardiovascular risk factor profiles in the 
majority of the population,229 the prevalence of cardiovascular risk factors remains high 
in Australia; 1 in 3 are hypertensive, 2 in 3 are overweight or obese, and over half are 
physically inactive.230 In the USA, a slowing of the rate of decline in cardiovascular 
mortality has been speculated to be in-part attributable to the epidemic rates of obesity 
and its associated complications such as diabetes.231 It is likely that rising AF incidence 
and associated hospitalisations may be partially driven by the rise in these modifiable 
cardiovascular risk factors. Efforts directed at these are likely to slow or even reverse the 
ongoing growth in health care burden both related to AF and other cardiometabolic 
conditions.  
 
2.4.2 Opportunities to reduce AF hospitalisations 
Previous data have demonstrated that the greatest burden of AF hospitalisations lies in 
prevalent (recurrent) admissions.19 Directed management strategies aimed at addressing 
individuals known to have AF could therefore have the greatest potential benefit in 
preventing re-hospitalisation in these individuals. Although our data are unable to 
discriminate between incident and prevalent AF admissions, a substantial proportion is 
likely to be attributable to prevalent admissions. The present study thus suggests that 
efforts to reduce these recurrent hospitalisations are thus an urgent priority. Although 
there are minimal data pertaining to alternative models of care delivery in the AF 
population, early results have been promising, with some studies demonstrating a 





2.4.3 AF hospitalisations in Australia compared to other populations 
Notably, the continued rise in AF hospitalisations in Australia appears to be exceeding 
that of other comparable countries. For example, a recent USA study examining trends in 
AF related hospitalisations demonstrated an absolute 23% increase in hospitalisations 
from 2000-2010.8 In our study, there was an absolute increase of 68% over the same time. 
Although other countries such as Scotland and Denmark have also reported significant 
increases in AF hospitalisations, published data are from earlier time periods.11,12 Whilst 
the global burden of hospitalisations due to AF is clearly increasing, the rate of increase 
in Australia appears to be comparatively higher, presenting a major public health issue 
that demands further investigation. Furthermore, our data suggests that the increase in AF 
hospitalisations spans all age and gender strata, in contrast to comparable recent data 
emerging from the USA, which demonstrates significant heterogeneity across various age 
and gender groups.8,9 Reasons for these differences are unclear, but support the concept 
that factors underpinning this growing trend in hospitalisations extend beyond an ageing 
population. 
 
2.4.4 Procedural trends and their impact on AF hospitalisations 
Whilst the use of AF ablation has grown considerably over this two-decade period, it does 
not appear to be the major driver of the increase in AF hospitalisations. Our results show 
a 21% annual increase in the number of AF ablation procedures, which far exceeds that 
of ablation used for other purposes. Whilst AF ablation has evolved as an effective 
therapy for rhythm control in those with drug-refractory AF, with favourable outcomes 
over pharmacological rate control, recurrence rates over longer term follow up are 




the ‘fourth pillar’ of AF care in addition to rate and rhythm control and appropriate oral 
anticoagulation,227 has proved highly effective in this regard.140,141 Furthermore, the 
ongoing role of weight and risk factor management has proven pivotal in the reduction of 
AF symptoms in longer term follow up,142 although the impact of this intervention on 
other outcomes such as healthcare resource utilisation, is not yet known. Our findings 
concerning a greater use of AF ablation in males compared to females is consistent with 
other published data.22,233 This trend is in line with gender differences in treatment in 
other cardiovascular conditions234-236, and is worthy of further investigation. As AF 
ablation is currently a treatment recommended for symptomatic management of AF, it is 
possible that differences in symptom presentation account for this difference. It is also 
possible that females are less likely to be offered this procedure, although reasons for this 
are unclear and require further investigation. 
 
2.4.5 Costs of AF hospitalisations 
Finally, direct costs of hospitalisations due to AF have grown significantly and at a greater 
rate than that of MI and HF. Whilst costs of hospitalisations across all three conditions 
have similarly increased over time, the increase in the number of AF hospitalisations 
appears to be mostly responsible for the significantly greater increase in total costs for 
this condition compared to MI and HF. Whilst total direct costs associated with AF 
hospitalisations remain the lowest of all three conditions studied, this is likely to change 







Our data have several limitations. Firstly, whilst our data suggest a progressive increase 
in AF hospitalisation over a 21-year period, it is likely to be an underestimation of the 
true burden of the condition. Complications due to AF, such as stroke and HF, are likely 
to account for a significant component of AF-related hospitalisations and are not 
accounted for in our data. Therefore, the true burden of AF is likely to be significantly 
greater than that represented by the present analyses. Our data are also unable to 
discriminate between repeat hospitalisations and procedures as discussed above. 
Therefore, whilst total rates of AF hospitalisations have increased significantly, we 
cannot determine from our data what proportion of this is due to greater rates of incident 
hospitalisations or recurrent admissions for highly symptomatic individuals. Finally, 
national trends in cardioversion data were only available through the Medicare database 
maintained by the Department of Health, although it is unlikely that the use of 
cardioversion has contributed significantly to overall increases in AF hospitalisations 
given the relatively small increase observed in the Medicare Benefits Schedule database.  
 
2.6 CONCLUSIONS 
The burden of AF continues to rise at a rapid rate, with hospitalisations for AF now 
outnumbering other common chronic cardiovascular conditions. Moreover, the increase 
in number and economic cost of AF hospitalisations in Australia appears to be exceeding 
that of other comparable countries. Further strategies to mitigate these trends, such as new 
models of care delivery and cardiovascular risk factor management, should be widely 





Table 1: Number of hospitalisations, average length of stay and total bed days from 1993-2013 in Australia 
(AF – atrial fibrillation, MI – myocardial infarction, HF – heart failure) 
 


















































1993 15,555 31,194 38,700 8.8 17.7 21.9 4.0 8.0 10.0 62,220 249,552 387,000 
1994 17,996 31,624 39,617 10.1 17.7 22.2 4.0 7.0 10.0 71,984 221,368 396,170 
1995 19,601 32,997 40,543 10.8 18.3 22.4 4.0 7.0 9.0 78,404 230,979 364,887 
1996 22,056 32,807 40,851 12.0 17.9 22.3 4.0 7.0 9.0 88,224 229,649 367,659 
1997 25,096 33,258 41,660 13.6 18.0 22.5 3.0 7.0 8.0 75,288 232,806 333,280 
1998 27,245 33,548 41,825 14.6 17.9 22.4 3.0 7.0 8.0 81,735 234,836 334,600 
1999 31,110 35,417 41,624 16.4 18.7 22.0 3.0 6.0 8.0 93,330 212,502 332,992 
2000 33,249 37,670 41,049 17.4 19.7 21.4 3.0 6.0 8.0 99,747 226,020 328,392 
2001 36,157 40,331 41,824 18.6 20.8 21.5 3.0 6.0 8.0 108,471 241,986 334,592 
2002 36,656 43,764 41,007 18.7 22.3 20.9 3.0 6.0 8.0 109,968 262,584 328,056 
2003 36,191 46,883 41,355 18.2 23.6 20.8 3.0 6.0 8.0 108,573 281,298 330,840 
2004 38,296 47,629 41,263 19.0 23.7 20.5 3.0 6.0 8.0 114,888 285,774 330,104 
2005 41,510 49,533 42,005 20.4 24.3 20.6 3.0 6.0 8.0 124,530 297,198 336,040 






















































2007 47,164 55,676 45,128 22.4 26.5 21.5 3.0 5.0 8.0 141,492 278,380 361,024 
2008 48,869 55,233 45,197 22.6 25.7 21.0 3.0 5.0 7.0 146,607 276,165 316,379 
2009 51,381 55,003 45,004 23.2 25.2 20.6 3.0 5.0 7.0 154,143 275,015 315,028 
2010 55,984 56,545 50,089 25.2 25.5 22.6 2.9 4.9 7.2 162,354 277,071 360,641 
2011 59,148 56,172 50,983 26.3 24.9 22.6 2.8 4.8 7.2 165,614 269,626 367,078 
2012 59,781 54,068 52,041 26.1 23.6 22.7 2.8 4.8 7 167,387 259,526 364,287 
2013 61,424 54,116 53,643 26.3 23.2 23.0 2.6 4.7 6.9 159,702 254,345 370,137 
Change 
(%) 





Figure 1: Hospitalisations for AF, MI and HF for the time period 1993-2013  


































































































Figure 2: AF hospitalisations as a percentage of total hospitalisations from 1993-2013 

































































































Figure 3: Absolute numbers of AF hospitalisations by age group from 1993-2013 
























































































































































Figure 4: Costs associated with AF, MI and HF hospitalisations from 1993-2013 in AUD  

























































































Atrial fibrillation (AF) poses a significant personal and healthcare burden and is poised 
to become one of the greatest healthcare challenges of this century. It is associated with 
significant morbidity and mortality,224 and has demonstrated globally increasing 
incidence and prevalence rates.2 Much of the burden related to this condition is due to 
healthcare resource utilisation with AF related hospitalisations and associated 
complications demonstrating a rapid global rise.7,237 New ways of both preventing and 
treating this condition have become urgent healthcare needs.  
 
3.1.2 Alcohol and health outcomes 
The association between alcohol and health outcomes is complex with reports of both 
benefit and harm. Recent data has suggested that whilst alcohol may be associated with 
some cardiovascular benefits, this may be offset by an increase in mortality, alcohol-
related cancers and injury, raising questions about the overall net benefit of alcohol 
consumption.238  In this study of 114 970 individuals in 12 countries, high levels of 
alcohol intake were associated with an increase in all-cause mortality with no impact of 
high levels of alcohol intake on any other outcomes including cancer, stroke, 
cardiovascular disease and myocardial infarction.238 At the moderate intake level, a 




disease was evident.238 This was also evident in a case control study of 27,778 individuals 
across 52 countries, low to moderate alcohol consumption was associated with a 
reduction in risk of incident MI.239 A meta-analysis of 84 studies examining the risk of 
varying levels of alcohol intake on incident coronary heart disease events, incident stroke, 
cardiovascular mortality, coronary heart disease mortality and stroke mortality 
demonstrated that low alcohol intake of ≤1 SD per day was associated with a reduction 
in all of the outcomes of interest.240 Specifically, any alcohol consumption was associated 
with a 29% reduction in incident coronary heart disease events (OR 0.71, 95% CI 0.66-
0.77; p<0.001) and a 25% reduction in coronary heart disease mortality (OR 0.75, 95% 
CI 0.68-0.81; p<0.001).240  
 
3.1.3 Alcohol and AF 
The association between alcohol and AF has been extensively described with the term 
‘holiday heart’ first coined nearly 40 years ago with the observation that atrial arrhythmia-
related hospitalisations occurred more frequently following holiday periods and 
weekends.241 Since then, alcohol has been identified as a modifiable risk factor for the 
development of AF with numerous cohort studies describing various degrees of 
association.  Furthermore, two recent meta-analyses have described a graded dose 
response with increasing consumption of alcohol demonstrating a greater risk of incident 
AF.100,101 However, it is unclear if there is a ‘safe’ level of alcohol intake that can be 
recommended to prevent the onset of AF. Furthermore, considerable uncertainty exists 
concerning appropriate recommendations for alcohol consumption in those with 
established AF. The aim of this study is to update the evidence for the strength of the 




if a ‘safe’ threshold exists, and to summarise the evidence concerning alcohol and 
prognosis in those with established AF.  
 
3.2 METHODS 
3.2.1 Literature search 
This systematic review was performed in accordance with the Meta-Analysis of 
Observational Studies in Epidemiology guidelines.242 Electronic literature searches were 
undertaken using PubMed and Embase databases with no date restriction up to 1 
February, 2016 to identify studies examining the impact of alcohol on the risk of incident 
AF and prognosis in those with established AF. Keywords used include atrial fibrillation, 
alcohol drinking OR alcohol OR binge drink OR ethanol OR risk OR incidence OR 
prevalence, dose-response relationship, drug OR dose OR drinking behavior.  Reference 
lists of selected articles were manually searched to ensure all relevant papers had been 
identified. The full search strategy is outlined in Table 1. 
 
3.3 STUDY SELECTION 
3.3.1 Inclusion and exclusion criteria 
The primary outcome for this study was the development of incident AF or a combination 
of AF and atrial flutter. Inclusion criteria for this study were: 1) prospective design; 2) 
reported at least three categories of alcohol intake; 3) published in English; 4) included 
only participants who were free of AF of AF/flutter at baseline; 5) reported AF or a 




retrospective or case control design; 2) described less than three levels of alcohol intake 
which would not allow ascertainment of a dose response and 3) reported alcohol intake 
in a dichotomous fashion, i.e. yes or no response or alcohol abusers compared to non-
abusers.   
 
3.3.2 Study selection and data extraction 
Two investigators independently reviewed all relevant articles to identify studies meeting 
criteria for inclusion. Any discrepancies were discussed, and a consensus decision 
reached. Data extracted from relevant publications included: first author, years of data 
collection, year of publication, number of participants, gender balance, mean age, follow 
up period, reported alcohol categories including reference group used, number and gender 
in each reported alcohol category, ascertainment of AF diagnosis and covariates adjusted 
for.  Risk of bias in each study was assessed utilising the Quality in Prognosis Studies 
tool (QUIPS) tool and classified as low, moderate or high.243 See Table 2 for an 
assessment of risk of bias for included studies. 
 
3.3.3 Statistical analysis 
The hazard ratio (HR) for the development of the outcome was extracted from each study 
according to each category of alcohol intake. The most adjusted model in each study was 
utilised. Risk estimates reported separately by sex were pooled separately. Heterogeneity 
across studies was assessed using the I2 statistic. The presence of publication bias was 
visually assessed using funnel plots of effect size against standard error. A 2-tailed value 




a random effects model in Review Manager (RevMan) Version 5.3, Copenhagen: The 
Nordic Cochrane Centre, The Cochrane Collaboration, 2014). 
 
3.4 RESULTS 
3.4.1 Characteristics of included studies 
A total of 1,877 articles were identified from the electronic literature search examining 
the impact of alcohol consumption on incident AF. 1,771 were excluded based on title 
and abstract review leaving 106 articles retrieved for full text review. 97 articles were 
excluded for reasons outlined in Figure 1 with a total of 9 studies, incorporating 249,496 
participants, meeting criteria for inclusion in the meta-analysis.  
Reported mean age was 60.4±10.4 years and 56.6% of the overall study 
population were female. Seven studies reported incident AF as their primary outcomes 
measure with two studies including both incident AF and atrial flutter as a primary 
outcome.101,244 Most studies were undertaken in either the USA or Europe with one study 
undertaken in Japan99 and another study incorporating Asian countries in their 
population.245 Mean study follow up ranged from 4 to 17.6 years. Eight of the nine 
included studies had a low risk of bias. One study, published in abstract form only, had a 
moderate risk of bias.246 Attempts to contact the authors of this study to obtain further 
details were unsuccessful. Each analysis was conducted with both the inclusion and 
exclusion of this study to ensure it did not significantly impact on results obtained. There 





3.4.2 Estimation of alcohol consumption 
Alcohol intake was assessed by questionnaire in six studies, interview in two studies and 
was not reported in another study. Confirmation of AF diagnosis was mixed with studies 
utilising ECG criteria, hospital codes or international classification of disease (ICD) 
codes. Reference groups varied with five studies reporting no alcohol intake and the 
remaining four using low alcohol intake which was generally classified as less than one 
standard drink (SD) per week. Remaining categories of alcohol intake varied with two 
studies reporting gender differences in alcohol classification at the moderate and high 
levels of intake.98,247 Three studies reported on a total of 32,684 males separately97-99 and 
four studies reported on alcohol intake in 73,587 females.97-99,248 Characteristics of the 
included studies are outlined in Table 3. 
 
3.4.3 High alcohol intake 
The highest alcohol category in each study compared to the reference group (Table 3) 
was associated with a significant increase in risk of AF development (HR 1.34; 95% CI 
1.20-1.49; p<0.001) without evidence of statistically significant heterogeneity between 
studies (I2 statistic = 22%, p=0.23; Figure 2). Sensitivity analysis excluding studies whose 
highest alcohol intake was less than three standard drinks (SD) per day did not materially 
alter this result (HR 1.40; 95% CI 1.19-1.64; p<0.001). Exclusion of one study, which 
has only been published in abstract form,246 and another study who reported a large 
variation in their highest alcohol intake group (13-161 grams of ethanol per day)249 also 
did not significantly alter this result. High alcohol intake was significantly associated with 
incident AF in males and females (HR 1.68; 95% CI 1.18-2.41; p=0.004 and HR 1.29; 




heterogeneity between studies reporting gender differences (I2= 53%; p=0.12 and I2 = 
0%; p=0.45 respectively).  
 
3.4.4 Moderate alcohol intake 
Moderate alcohol intake, reported by most studies as 1-2 SD per day, was associated with 
a small but significantly increased risk of incident AF (HR 1.11; 95% CI 1.05-1.18; 
p=0.0002) without evidence of statistical heterogeneity between studies (I2 = 0%; p=0.66; 
Figure 3). Exclusion of one study published in abstract form only did not impact on this 
result.246 Exclusion of two studies, which classified moderate alcohol intake as up to 3 to 
4 SD per day for men, did not impact on this result.96,249 Whilst moderate alcohol intake 
in males was also significantly associated with AF development, this was not the case for 
females (HR 1.26; 95% CI 1.04-1.54; p=0.02 and HR 1.03; 95% CI 0.86-1.25; p=0.74; 
respectively) with no evidence of statistical heterogeneity (I2=0% for both analyses, 
p=0.61 and p=0.86, respectively; Figures 4 and 5).  
 
3.4.5 Low alcohol intake 
Consumption of low alcohol compared to the reference group in each study was not 
associated with risk of AF (HR 1.03; 95% CI 0.97-1.09; p=0.30) with no evidence of 
significant heterogeneity (I2=0%; p=0.88). There was no evidence of gender variation 
with non-significant results reported for low alcohol intake in both males and females 
(HR 1.01; 95% CI 0.82-1.24; p=0.93 and HR 0.93; 95% CI 0.82-1.05; p=0.25; 
respectively). Sensitivity analyses excluding studies who did not utilise ‘no alcohol 




on the impact of up to 6-7 SD per week, compared to no alcohol as a reference group, did 
not demonstrate a significant association with AF (HR 0.95; 95% CI 0.85-1.06; p=0.37; 
Figure 6).  
 
3.4.6 Alcohol consumption and established AF 
Eight studies were identified from the systematic review which included all relevant 
articles using the search criteria outlined above until 1 February 2016. The study 
population comprised 19,547 individuals (39% female, mean age 69.6±10.1 years) and 
examined outcomes including mortality, thromboembolism, maintenance of sinus rhythm 
post catheter ablation and progression from paroxysmal to permanent AF.  
 
3.4.7 Mortality 
Two studies have examined the impact of mortality in relation to alcohol consumption in 
those with established AF.250,251  Results are inconsistent with one finding an association 
with former alcohol consumption (HR 1.27; 95% CI 1.06-1.52) but not any other level of 
alcohol intake,250 and the other study reporting an association between men consuming > 




Five studies have examined the impact of alcohol consumption on risk of 
thromboembolism (TE).251-255 Two studies reported overall TE risk with one describing 




no association in men251 and another reporting a reduction in TE risk with any level of 
alcohol intake, reported in a dichotomous manner (OR 0.70; 95% CI 0.52-0.95; 
p=0.02).252 Two studies have examined the impact of alcohol consumption on risk of 
ischemic stroke (IS) with one finding no association253 and another describing a reduction 
in risk for those consuming > 14 SD per week (RR 0.4, p=0.04).254 In the final study 
examining this outcome, alcohol was not associated with the composite endpoint of 
cardiovascular death and IS or either of these components separately.255 
 
3.4.9 Progression from paroxysmal to chronic AF 
One study described an increase in the risk of progression from paroxysmal to chronic 
AF in those consuming moderate to high levels of alcohol (greater than 21 SD per week; 
OR 3.0; 95% CI 1.1-8.0).256 
 
3.4.10 Catheter ablation 
The role of alcohol consumption on the outcome of catheter ablation has been examined 
in one study of 122 patients with paroxysmal AF.257 Multivariate analysis in this study 
showed that any level of alcohol intake was associated with an increased risk of AF 
recurrence after 21 months of follow up (HR 1.58; 95% CI 1.09-2.30; p=0.017).257 
Furthermore, increasing levels of alcohol intake were associated with a reduced 
likelihood of success post catheter ablation with alcohol abstainers demonstrating a 
higher success rate compared to both moderate and heavy alcohol consumers.257  
Whilst not specifically examining the impact of alcohol on outcomes in the AF 




(approximately 2.5-3 SD) or less per week as part of a physician led cardiovascular risk 
factor management program, was associated with a reduction in AF burden and severity 
and favorable structural remodeling in those with established AF.140-142 In this program 
there was an almost fivefold increase in arrhythmia free survival in overweight 
individuals who had been referred for ablation of symptomatic AF participating in the 
aggressive risk factor management program compared to the control group.141 
 
3.5 DISCUSSION 
Alcohol use has been linked to the development of AF. However, the nature of this 
association and the resultant prognosis remains poorly characterised. As such, the 
development of treatment guidelines has been limited. The current systematic review and 
meta-analysis demonstrates the following new information:  
• Low levels of alcohol intake are not associated with incident AF with up to 
6-7 SD per week not conferring an increase in risk;  
• Moderate levels of alcohol consumption are associated with an increase in 
AF risk in males but not females;  
• High alcohol intake is associated with an increased risk of incident AF 
across both genders;  
• Recommendations in those with established AF are yet to be definitively 
established, but observational data would suggest that reducing alcohol to 





3.5.1 Gender differences in risk of incident AF with alcohol intake 
Our findings concerning high and moderate levels of alcohol consumption are consistent 
with previously published research examining the impact of alcohol on AF development 
but provide new insight in to the association between low alcohol intake and AF with up 
to one SD daily not demonstrating an impact on incident AF. Gender differences were 
apparent in our study and this has previously been described in the literature. The Malmo 
Diet and Cancer Study failed to find an association between any level of alcohol intake 
in women and incident AF, but did report an association in men at high levels of alcohol 
intake.258 A case control study of the Framingham cohort demonstrated that increasing 
levels of alcohol intake was significantly associated with incident AF in men but not 
women,95 and two studies included in this current study, describing gender subgroup 
analyses, found an association in males, but not females, at the highest level of alcohol 
intake.98,244  In each of these studies, no association between any level of alcohol intake 
and incident AF was demonstrated for women whilst for men the highest level of alcohol 
intake significantly increased risk. However, it should be noted that levels of alcohol 
intake in two of the four studies reporting gender subgroup analyses reported a lower 
level of alcohol intake in the highest category group in females compared to males which 
could possibly account for some of the reported differences. Each study is also somewhat 
limited by smaller numbers of women in the highest alcohol category, perhaps reflecting 
generally different trends in drinking patterns between males and females.  As the 
majority of studies have not provided gender subgroup analyses, it is possible that 
moderate alcohol intake is an AF risk factor for men but not women, but further 





3.5.2 Low alcohol intake and incident AF 
Our findings concerning low alcohol intake are somewhat in contrast with two previously 
published meta-analyses which describe a small but significant increase in AF risk with 
each 1 SD per day consumed of approximately 8%.101,259 In our study we restricted the 
inclusion criteria to that of prospective studies only, whilst the two previously published 
meta analyses also used studies of a retrospective and/or case control design, perhaps 
accounting for some of this difference. Furthermore, our meta-analysis included two 
recent studies from Japan and Italy which have not been included in previous reviews and 
provide an increasingly global perspective on the role of alcohol in incident AF. One of 
the previously published meta-analyses describes significant heterogeneity between 
studies utilised which we did not find in our analysis.259 It  also reported larger risk 
estimates for incident AF when incorporating studies of a case control design, which we 
excluded in our study, and may have possibly accounted for an overestimation of risk. 
 
3.5.3 Mechanisms linking alcohol intake to AF 
Mechanisms by which alcohol may impact on AF development are yet to be clearly 
elucidated. Proposed mechanisms include conduction slowing, with the original ‘holiday 
heart’ study demonstrating a prolongation of PR, QRS and QTc intervals thereby raising 
speculation that this may facilitate re-entry and enhance the likelihood of AF.260 Other 
proposed mechanisms include a shortening of the effective refractory period,261 increased 
sympathetic activity as a result of catecholamine release and a rise in plasma free fatty 
acids which are thought to be arrhythmogenic in nature. 260 More recently, the role of 
vagal activation has also featured with one study suggesting that individuals reporting 




thereby giving rise to the theory that alcohol may stimulate a vagal response and greater 
propensity for AF episodes.262 It is unclear if the association between alcohol and incident 
AF is mediated only through its cardio-metabolic effects including weight gain and 
hypertension which are independent risk factors for AF. A graded association has been 
demonstrated linking alcohol consumption and  hypertension.263 
 
3.5.4 Alcohol intake in established AF 
There is little data concerning prognosis in individuals with AF in relation to alcohol 
consumption. The few studies that have published in this area have demonstrated 
conflicting results, making recommendations in this area difficult. However recent 
observational data, whilst not specifically examining the impact of alcohol consumption 
on outcomes in the AF population, has demonstrated that reduction in alcohol intake to 
30 grams per week or less is associated with enhanced patient outcomes. 141,142 Further 
research in this field is warranted to address the gap in the literature concerning 
appropriate recommendations for alcohol consumption in the AF population. 
 
3.6  LIMITATIONS 
Whilst the data is limited by the alcohol categories stipulated in each study, the impact of 
up to one SD per day does not appear to demonstrate an association. However, at exactly 
what threshold this may become significant remains unknown. This is due to the 
limitation of not knowing, within each category of alcohol intake, exactly what each 
individual is consuming. In the low alcohol category for many studies, this could range 




threshold at which this increases incident AF risk would be difficult to elicit without very 
detailed data collection from study participants. Furthermore, little is known about 
patterns of drinking habits and its impact on AF – whilst the data may suggest that up to 
6-7 SD per week is not associated with AF, it is unclear if this risk is the same in an 
individual who consumes 7 SD in one day or 1 SD over seven days, and the majority of 
studies to date have not addressed this issue. The risk associated with former drinking is 
also not clearly elucidated, although this is clearly less amenable to intervention. The 
impact on type of alcohol consumed and risk of AF is also not clear and further research 
in this area is warranted. One study reported no association between type of alcohol 
consumed and AF risk,250 whilst another study describes an increase with consumption 
of spirits or wine of more than 14 SD per week (but not beer),101 and another reporting 
beer and spirits at more than 21 SD per week in males increased AF risk, with no 




Low alcohol intake, of up to one SD per day, does not appear to confer an increase in risk 
of incident AF. Whilst both moderate and high levels of alcohol intake are associated with 
incrementally increasing levels of AF risk, gender differences are apparent. High alcohol 
consumption heightened AF risk across both genders, whereas moderate levels of alcohol 
intake conferred an increase in AF risk in males but not females. Recommendations in 
those with established AF remain elusive due to conflicting findings in studies but should 




situation. Recent data would suggest that limiting alcohol intake to 30 grams per week in 

































(Atrial fibrillation [all]) AND (alcohol drinking [MH] OR alcohol*[all] OR binge 
drink*[all] OR ethanol[all]) AND (risk[all] OR incidence [all] OR prevalence [all]) 






(‘Atrial fibrillation’) AND (‘Drinking behavior’/syn OR alcohol* OR binge next/1 



















Table 2 – Assessment of risk of bias in studies included in meta-analysis 
 
 



















Liang et al Moderate Low Low Low Low Low Low 
Sano et al Low Low Low Low Low Low Low 
Frost and 
Vestergaard 
Low Low Low Low Moderate Low Low 
Mukamal et al 
(CHS) 
Low Low Moderate Low Low Low Low 
Conen et al Low Low Low Moderate Low Low Low 
Shen et al Low Low Low Low Moderate Low Low 
Mukamal et al 
(Copenhagen) 
Low Low Low Low Moderate Low Low 
Di Castelnuovo 
et al 
Low Low Moderate Moderate Low Moderate Moderate 


















Liang et al96  2012 29.8 66.4 
Multiple regions – 
40 countries from 
Europe, US, 
Australia, Asia 
>55 years of age 
plus history of CVD 
(CAD, PAD or 
CVD) or diabetes 
mellitus with end 
organ damage 
30433 Questionnaire 






2004 53 56 Denmark 
Population based 
study – the Danish 
Diet, Cancer and 
Health Study 
47949 Questionnaire 
Mukamal et al98  2005 54 51 Denmark 
Population based 




Conen et al264 2008 100 53.5 US 
Population based 








(CVD – cardiovascular disease; CAD – coronary artery disease; PAD – peripheral arterial disease; NR – not recorded; BMI – body mass 
index; g – grams; BP – blood pressure; FEV1 – forced expiratory volume; CHF – congestive heart failure; ICD – international 
















Shen et al249  2011 56 62 US 
Population based 





2007 56 73.1 US 
Population based 


































Covariates adjusted for 
Liang et al96 
Low <1 drink per week 
Moderate 1-14 drinks for 
women and 1-21 drinks 
for men 
High < 2 drinks per day 
for women and > 3 drinks 
per day for men 
Binge drinkers more than 
5 drinks per day 
Low alcohol 




Incident AF ECG 
Age, sex, BMI, region, past 
medical history of CAD, stroke 
or TIA, hypertension, diabetes, 
chronic renal disease, sleep 
apnea, smoking status, 
education, physical activity, 
stress, use of statin, trial 
allocation (Ramipril, 
telmisartan, both vs placebo) 
Sano et al99  
                 Never 
Past 
Light (<23g/day ethanol) 
Light to moderate (23-45 
g/day ethanol) 
Moderate (46-69 g/day 
ethanol) 






ECG verified by 
physician with 
minority (2%) from 
hospital reporting of 
embolic stroke due 
to AF 
Age, sex, smoking status, BMI, 
hypertension, hyperglycaemia, 
hyperlipidaemia, major ST-T 
abnormalities, previous MI 
Frost and 
Vestergaard97  
Quintile 1 4.1±2.6g/day 















Age, height, BMI, smoking, 
systolic BP, treatment for 
hypertension, total serum 















Covariates adjusted for 
Mukamal et al98  
Weekly number of 
drinks: 
Females: <1, 1-6, 7-13, 
14-20, >21 
Males: <1, 1-6, 7-13, 14-
20, 21-27, 28-34 and >35 






Small number by 
study ECG. 
Age, smoking, education, 
cohabitation, family history of 
CVD, diabetes, income, 
physical activity, BMI, FEV1, 
height, use of BP medication, 
systolic BP, incident diagnoses 
of CHD or CHF 
Conen et al264 
None, <1 drink per day, 
1-2 drinks per day, >2 





ECG or medical 
report noting AF in 
past medical history 
verified by a 
physician 
Age, systolic blood pressure, 
history of hypertension, BMI, 
race/ethnicity, smoking, history 
of diabetes, history of 
hypercholesterolaemia, 
exercise, education and 
randomised treatment 
assignment 
Shen et al249  
None, 1-3 g/day, 3-13 
g/day, 13-161 g/day 
None 4 years Incident AF ECG 
Age, sex, BMI, systolic BP, 
hypertension treatment, ECG, 
PR interval, significant heart 














Covariates adjusted for 
Mukamal et al250  
None, former drinkers, 
<1 drink per week, 1-6 
drinks per week, 7-13 
drinks per week and 
greater than 14 drinks per 
week 
None 9.1 years Incident AF 




Age, sex, race, income, height, 
waist circumference, physical 
activity, psychoactive 
medication, diabetes, 
hypertension, CHD, congestive 
heart failure and total 
cholesterol 
 
Di Castelnuouvo et 
al246  
Never, former drinkers, 
occasional drinkers, 1-12 
g/day, 13-24 g/day, 24-48 







Age, sex, smoking, education, 
income, physical activity,  
BMI, total calorie intake, 
history of CVD, hypertension 
or diabetes 
Larsson et al101  
Never, past, <1 drink per 
week, 1-6 drinks per 
week, 7-14 drinks per 
week, 15-21 drinks per 
week, >21 drinks per 
week 





Age, sex, education, smoking 
status, BMI, family history of 
MI before the age of 60, history 
of CHD or heart failure, history 
of diabetes and history of 
hypertension 
(BMI – body mass index, CAD – coronary artery disease, TIA – transient ischaemic attack, FEV – forced expiratory volume, CHD – coronary 












1877 Records identified 




1771 Records excluded as 
they did not meet 
inclusion criteria 
106 Full text articles 
assessed for 
eligibility 
97 Full-text articles excluded::
6 Dichotomous alcohol intake 
3 Duplicate studies 
10 Editorial, letter 
29 Review articles 
4 Not published in English 
14 Alcohol not presented as a continuous or categorical variable 
25 Incident AF/flutter not primary outcome 
6 Retrospective or case control 





















































Chapter 4: Integrated Care for Atrial 
Fibrillation 
4.1 INTRODUCTION 
Atrial fibrillation (AF) is an emerging global epidemic. In 2010, it was estimated that 33.5 
million individuals were living with AF globally, with this figure expected to rise 
significantly over the coming decades.2 In stark contrast to other chronic cardiovascular 
conditions which have seen associated declines in mortality, recent data has demonstrated 
an almost doubling of age adjusted mortality rates related to AF over the last two 
decades.2 Furthermore, significant resultant costs are associated with AF, with 
hospitalisations as the main driver, due to both the condition itself, and related 
complications including stroke and heart failure.8 Indeed, this rapid increase in 
hospitalisations has been described as a ‘rising tide’ showing no sign of abating with data 
suggesting that hospitalisations for AF have now surpassed those related to heart 
failure.7,265 Both hospitalisation and complications related to AF may be preventable with 
appropriate guideline adherent care delivery to enhance outcomes in this population. 
Indeed, current registry data suggests that AF is often sub-optimally managed with poor 
guideline adherence to appropriate anticoagulation for stroke prevention.266 It is clear that 






4.1.1 The Chronic Care Model 
The integrated care approach has its origins in the chronic care model developed by 
Wagner and colleagues,267 with the recognition that chronic condition management calls 
for a different approach to more traditional models of care delivery. Central to this model 
is the patient as the primary focus, with other essential elements including a 
multidisciplinary team and community support structures.  This model is in stark contrast 
to more traditional paternalistic models of care in which the patient played a passive role 
in decisions concerning their care. Enhancing patient outcomes with the use of chronic 
condition management is achieved through redesigning daily practice to ensure care is 
delivered tailored to the patient’s needs and values and based on best available evidence. 
This is often supported with the use of electronic clinical support systems.  
Numerous studies have demonstrated the efficacy of this approach in chronic 
condition management. In a small cluster randomised controlled trial in diabetes care, 
implementation of a chronic condition management (CCM) program which demonstrated 
strong fidelity to the original chronic care model, resulted in a significant reduction in 
HbA1c in those attending these practices compared to an education only arm or usual 
care.268 There was also significant reductions in non HDL cholesterol although no impact 
on blood pressure was observed in this intervention. The frequency of self-monitoring of 
blood glucose also improved in the CCM group compared to others although no 
statistically significant between group differences was observed in relation to diabetes 
knowledge.268  
In another observational study of CCM practice sites compared to traditional 
models of care in the UK, the use of CCM was associated with a statistically significant 




(UKPDS) risk score after one year follow up of 1170 participants across 13 health care 
organisations.269 This model also demonstrated strong fidelity to the original chronic care 
model and implemented all of the critical components of this model. A greater magnitude 
in risk reduction was observed in those at higher risk of cardiovascular events as per the 
UKPDS score.269 
One of the largest studies to date based on the chronic care model was an 
observational study of 102 primary care practices in Utah, USA. In this study, practices 
that participated in team based approach care based on the chronic care model were 
compared to those who undertook traditional practice management.208 Over long term 
follow up of approximately four years, team based approach care was associated with 
improvements in quality related outcomes including screening for depression and 
adherence to components of diabetes care, although there was no improvement in the use 
of advanced care directives and a lesser likelihood of controlled hypertension in those 
attending team based care practices. Measures of acute health care resource utilisation 
were also reduced in the team care approach including a reduction in emergency 
department visits and hospitalisations, in addition to a reduction in primary care physician 
visits.208 
  
4.1.2 Models of care delivery for chronic cardiovascular conditions 
Whilst a multitude of evidence exists for the use of co-ordinated systems of care in other 
chronic cardiovascular conditions including heart failure270 and acute coronary 
syndromes,186 there is comparatively less in the AF field. Recently, several studies have 
been undertaken examining the use of integrated care in the AF population 209,271 but to 






This systematic review and meta-analysis was conducted in accordance with the PRISMA 
guidelines.272 The aim of our study was to examine the impact of the integrated care 
approach in the AF population, compared to usual care, on outcomes including mortality, 
hospitalisations, emergency department presentations, cerebrovascular outcomes and 
patient reported outcomes including quality of life, anxiety and depression. 
 
4.2.1 Literature search 
PubMed, Embase and CINAHL databases were searched from inception to February 2016 
with keywords including ‘atrial fibrillation’, ‘integrated health care’, ‘multidisciplinary’, 
‘ambulatory care’, ‘ambulatory monitoring’, ‘outpatient’, ‘interdisciplinary 
communications’, ‘outcome’, ‘treatment failures’, ‘death’, ‘mortality’, ‘fatal’, 
‘hospitalisation’, ‘hospital admissions’, ‘quality of life’ and ‘symptom burden’.  See 
Table 1 for an outline of the full search strategy in PubMed.  
 
4.2.2 Inclusion and exclusion criteria 
Inclusion criteria were the use of an integrated care approach, focus on holistic and 
comprehensive AF management, presence of a control group and a minimum six month 
follow up period. Randomised and non-randomised studies were eligible for inclusion. 
Exclusion criteria were studies that focussed on one area of AF management (e.g. 
anticoagulation), were not published in English or had less than 50 participants. A 




provision of multidisciplinary care at different stages of the care process in different 
institutional areas’.273 
4.2.3 Data extraction 
Two investigators independently reviewed all relevant articles to identify studies meeting 
criteria for inclusion. Any discrepancies were discussed, and a consensus decision 
reached. Data extracted from relevant publications included: first author, years of data 
collection, year of publication, number of participants, gender balance, mean age, follow 
up period, outcomes reported, and covariates adjusted for.  Risk of bias in each study was 
assessed using the Cochrane tool.274 See Table 2 for assessment of risk of bias for 
included studies. The authors of one study were contacted and provided information 
concerning all-cause mortality to facilitate report of this as an outcome measure.209 
 
4.2.4 Statistical analysis 
The risk estimate for the development of the outcome was extracted from each study. The 
most adjusted model in each study was utilised. Heterogeneity across studies was 
assessed using the I2 statistic. The presence of publication bias was visually assessed using 
funnel plots of effect size against standard error. A 2-tailed value of p<0.05 was 
considered statistically significant and all analyses were performed using a random 
effects model in RevMan Version 5.3, Copenhagen: The Nordic Cochrane Centre, The 






The search yielded a total of 1219 articles that were assessed by title and abstract.  Of 
those, 1180 were excluded as they did not meet the inclusion criteria. The remaining 39 
articles were retrieved for full text assessment with three meeting criteria for inclusion in 
our meta-analysis.209,211,212  A study flow chart is depicted in Figure 1. Risk of bias was 
assessed as low in two of the included studies and moderate in one study. The total study 
population was 1383 participants of which 43% were female. Mean age was 66.9±15.4 
years. Characteristics of the three studies included in the meta-analysis are outlined in 
Table 3. Outcomes that were able to be extracted from two or more of the included studies 
included all-cause mortality, cardiovascular hospitalisations, AF related hospitalisations 
and cerebrovascular events. A meta-analysis of results regarding AF related ED 
presentations was not performed as this data was not available in the included studies or 
quality of life due to heterogeneity in assessment tools used for this outcome. Similarly, 
there was a lack of original data on other patient reported outcomes including anxiety, 
depression and symptom burden. Visual assessment of funnel plots did not reveal any 
evidence of publication bias. 
 
4.3.1 All-cause mortality 
Based on two studies reporting on this outcome, an integrated care approach resulted in 
a significant 49% reduction in all-cause mortality (OR 0.51, 95% CI 0.32-0.80, p=0.003; 
see Figure 2). There was no evidence of significant heterogeneity (I2=0%, p=0.51). The 
absolute event rate for the intervention group was 3.0 per 100-person years (95% CI 1.37-





4.3.2 Cardiovascular related hospitalisations 
Integrated care was associated with a significant 42% reduction in cardiovascular 
hospitalisations (OR 0.58, 95% CI 0.44-0.77, p=0.0002; see Figure 3) based on three 
studies, without any evidence of significant heterogeneity (I2=6%, p=0.35).  The absolute 
event rate was 8.0 per 100-person years in the integrated care arm (95% CI 2.56-25.02) 
compared to 11.87 in the control group (95% CI 4.59-30.71). Analysis of this outcome 
with the exclusion of one study212 ,due to a higher risk of bias, did not significantly alter 
the outcome (OR 0.58, 95% CI 0.38-0.89, p=0.01). 
 
4.3.3 AF related hospitalisations 
The integrated care approach did not have a statistically significant impact on AF related 
hospitalisations (OR 0.82, 95% CI 0.56-1.19, p=0.29; Figure 4) based on two studies 
reporting on this outcome, without any evidence of significant heterogeneity (I2=0%, 
p=0.38). An absolute event rate of 5.5 per 100-person years was demonstrated in the 
intervention arm (95% CI 1.02-29.59) compared to 7.0 per 100-person years in the control 
group (95% CI 1.87-26.23). 
 
4.3.4 Cerebrovascular events 
Similarly, there was no evidence of any benefit of an integrated care approach on 
cerebrovascular events based on three studies reporting on this outcome (OR 1.00, 95% 
CI 0.48-2.09, p=1.00; Figure 5). There was no evidence of significant heterogeneity 
(I2=0%, p=0.68). There were comparable absolute event rates in both arms of the study 




and 0.66-1.82 for the control group). Exclusion of one study from this analysis 212, due to 
a higher risk of bias, did not significantly alter this result (OR 1.00, 95% CI 0.42-2.38, 
p=1.00). 
 
4.3.5 Patient reported outcomes 
A meta-analysis of results related to quality of life or anxiety and depression was not 
possible due to heterogeneity of assessment tools utilised across studies. Two studies 
reporting on quality of life outcomes did not report any statistically significant between 
group differences at final follow up and, similarly, no impact of an integrated care 
approach on either anxiety and/or depression was demonstrated.147,211 None of the 
included studies reported on effect of the intervention on symptom burden. 
 
4.3.6 Number needed to treat (NNT)  
Statistically significant outcomes were further analysed to determine a NNT compared to 
published data for heart failure clinics 275. For all-cause mortality, a NNT of 19 in an AF 
program was demonstrated to prevent one death, compared to 17 in heart failure clinics. 
With respect to hospitalisations, a NNT of 18 in AF care programs to prevent one 
cardiovascular related hospitalisation, compared to 11 in a heart failure clinic to prevent 






The integrated care approach has demonstrated enhanced patient outcomes in several 
chronic conditions. This meta-analysis of studies evaluating the role of an integrated care 
approach in atrial fibrillation demonstrates that integrated care is associated with: 
• Enhanced patient outcomes including reduction in all-cause mortality and 
cardiovascular hospitalisations; 
• No significant impact on AF related hospitalisations and cerebrovascular events; 
• Insufficient original data to report on a synthesis of data related to patient reported 
outcomes; 
• A highly efficacious NNT, which compares favourably to other approaches 
including co-ordinated heart failure care programs, for outcomes including all-
cause mortality and hospitalisations.  
 
These findings have significant implications regarding care delivery in the AF 
population and support the use of integrated care as an effective and efficacious 
intervention. However, many questions remain unanswered and further research is 
required to address the way in which delivery of this approach is optimally implemented.  
 
4.4.1 Integrated care management for AF 
Whilst each study included in this meta-analysis utilised an integrated care approach, 
there are significant differences in populations recruited and methodology employed for 
care delivery. The first study by Hendriks and colleagues was a single centre study 
undertaken in the Netherlands.209  This study recruited participants who had been referred 




nurse led, cardiologist supervised clinic. The program incorporated protocoled diagnostic 
testing, patient education and recommendations for AF management based on current 
guidelines at the time. The study also employed a software decision support system to 
facilitate guideline adherence, guide treatment recommendations and support decision 
making. After a mean follow up of 22 months, there was a significant 35% reduction in 
the composite endpoint of cardiovascular mortality and hospitalisations (HR 0.65; 95% 
confidence interval (CI) 0.45–0.93; p=0.017).209 
The Standard versus Atrial Fibrillation specific strategy (SAFETY) study was a 
multicentre Australian based study in which participants who were admitted to hospital 
primarily due to AF, were eligible for inclusion in the study.271 The intervention was 
diverse and included a home visit undertaken by a specialised cardiac nurse 7-14 days 
post discharge, an education package, referral to other healthcare professionals including 
physician referral for those requiring urgent review at the home visit and 
recommendations to the medical team concerning optimal AF treatment. After a mean 
follow up of two and a half years there was proportionately more event free days in the 
intervention group (defined as days alive and out of hospital) but no significant difference 
in the co-primary composite outcome of all-cause mortality and hospitalisations (HR 
0.97, 95% CI 0.76–1.23; p=0.851).211 
The final study was a ‘before and after’ study undertaken in Canada with eligible 
participants having presented to the emergency department primarily due to symptoms 
arising from AF.212 In the intervention phase, participants received a brief educational 
telephone call by a cardiac nurse following discharge, were invited to attend a group 
education session and undertook one clinic visit in a nurse led, cardiologist supervised 




cardiovascular hospitalisations and AF related ED visits was statistically significant (OR 
0.71; 95% CI 0.59-1.0; p=0.049).212 
 
4.4.2 Impact of the integrated care approach in AF 
Despite differences employed in each study, we did not find any evidence of statistically 
significant heterogeneity in any of our outcomes, strengthening the conclusions drawn 
from our results. However, it is of interest to further explore each of these studies to 
explore clinical applicability and direct areas for future research. Although none of the 
studies were appropriately powered for all-cause mortality as an outcome measure, it is 
encouraging that co-ordinating care through an integrated approach had a clear and 
consistent effect in the two studies reporting on this. Similarly, the positive impact on 
cardiovascular hospitalisations is also consistent although reasons for the impact on this 
outcome but not AF hospitalisations is of interest. Firstly, how much of the reduction in 
cardiovascular related hospitalisation is due to enhanced clinical surveillance and 
improvements in cardiovascular risk factor status is not well defined. Two of the three 
studies did not report on changes in cardiovascular risk factor status, whilst the SAFETY 
study did not find any significant difference in any cardiovascular risk factor measures 
between groups at final follow up. Recently, the role of intense management of 
cardiovascular risk factors in the AF population has gained significant momentum with 
the recognition that this approach is associated with reduced symptom burden and an 
enhanced likelihood of sinus rhythm post catheter ablation.141,276,277 It is also possible that 
participants having access to specialist care when required could have prevented 
cardiovascular related hospital admissions. The lack of impact on AF related 




with co-morbidities accounting for the need for hospitalisation. It is also possible that this 
reflects a type 2 error due to a small sample size and a significant impact may be observed 
in a larger population.  
Similarly, cerebrovascular events were not significantly reduced with the use of 
this approach. This perhaps belies the complex issue of anticoagulation, with numerous 
issues, including the informed decision of the patient, to take in to consideration. It may 
also reflect the need for enhanced surveillance and management of cardiovascular risk 
factors with increased recognition that both AF and stroke share common risk factors, 
and this may play a significant role in the pathogenesis of cerebrovascular ischaemic 
events in AF. Encouragingly, recent data has suggested a significant increase in 
appropriate use of anticoagulation based on CHA2DS2-VASc score, with the clinical 
adoption of novel oral anticoagulant therapy (NOAC),278 which were not in widespread  
use at the time two of the three studies were undertaken. The importance of reassessment 
of stroke risk scores over time has also been highlighted with recent large registry data 
from Taiwan demonstrating that in almost 90% of individuals who experienced an 
ischaemic stroke, the CHA2DS2-VASc score had increased over time due to the 
development of comorbidity.130 In this study 4103 individuals of a total cohort of 31 039 
individuals with AF experienced an ischaemic stroke, many of which may be potentially 
preventable if appropriate oral anticoagulant therapy had been instituted in response to 
changing circumstances.130 
 
4.4.3 Integrated care and appropriate anticoagulation use   
Two of the studies reported on appropriate prescription of anticoagulation based on 
CHADS/CHA2DS2-VASc score 




Hendriks et al warranting further exploration. Whilst it is clear from the baseline 
demographics that the SAFETY study had a generally sicker and co-morbid population, 
the method by which anticoagulation was addressed may also be relevant. As a clinic-
based study, Hendriks and colleagues were able to initiate anticoagulation and discuss 
any relevant issues at subsequent visits, whilst the SAFETY study made 
recommendations to treating clinicians without being able to start appropriate 
antithrombotic therapy if it was indicated. This should be a consideration for future 
studies as it is a phenomenon other studies have also found with appropriate therapy often 
not initiated unless it is undertaken by the specialist clinic.279 The importance of both 
integrated care in AF and cardiovascular risk factor management in this population has 
recently been highlighted with current guidelines recommending these approaches as part 
of standard care delivery.115,128  
 
4.4.4 Integrated care and patient reported outcome measures 
There was insufficient original data to undertake a meta-analysis on patient reported 
outcomes due to either lack of report on these outcomes or heterogeneity in assessment 
tool utilised. This is a point worthy of consideration in the design of future studies in this 
field. The use of standardised clinical and patient reported outcomes measures in AF, 
such as those recommended by the International Consortium for Health Outcomes 
Measurement (ICHOM) for coronary heart disease280 and heart failure, 281 would be of 
significant benefit in both future research in this field and in design of optimal care 






The results of this meta-analysis point to integrated care as a highly effective method of 
care delivery, which is further strengthened by examining outcomes in studies which have 
a control group undertaking usual care, to provide the highest level of evidence in support 
of this approach. However, several limitations need to be considered with regards to the 
current study. Firstly, whilst it is clear that the integrated care approach is associated with 
enhanced patient outcomes, it is difficult to know which components of this approach, 
and to which AF subpopulations, it would be of most benefit. Secondly, the setting and 
personnel required varied between studies and may need to be individualised with the 
recognition of AF as a heterogeneous condition with patients often having complex and 
competing needs, making appropriate recommendations in this area difficult. A schematic 
of how the integrated care approach may be applied in the AF population has previously 
been described and is outlined in Figure 6.282 This highlights the importance of the 
multidisciplinary team approach with the patient at the core, and decision support systems 
to facilitate delivery of best practice, guideline adherent care. The possibility that an 
impact of the integrated care approach on both AF related hospitalisations and 
cerebrovascular events may be observed in a larger sample size also needs to be taken in 
to consideration due to a type 2 error in the current study. Finally, the need for clearly 
described methodology to allow for replication of studies is difficult due to the nature of 
such interventions but would be of benefit to the clinical and research community in 






This meta-analysis of current evidence demonstrates integrated care as a highly effective 
intervention when applied to the AF population with associated reductions in all-cause 
mortality and cardiovascular related hospitalisations. The integrated care approach, now 
recommended by international AF guidelines, has a crucial role in improving outcomes 
in this rapidly increasing population and should be widely implemented in the clinical 
setting. However, further work is needed to refine the optimal settings, methods and 
components of care delivery in such approaches, with strong consideration given to 
























Delivery of Health Care, Integrated 
[mh:noexp] OR 
“integrated health care” OR  
 multidisciplinary OR  
“ambulatory care” OR  









“treatment failure” OR 
“treatment failures” OR 
((cardiac OR 
cardiovascular OR heart) 
AND (death* OR 
mortalit*)) OR 
Fatal* OR 
Hospitalisation [mh] OR 
“hospital admission” OR 
“hospital admissions” OR 
“quality of life” OR 
HRQL OR “life quality” 
OR 
“quality adjusted life year” 
OR qaly OR “quality 
adjusted life years” OR 
“short form 12” OR SF-12 
OR SF12 OR 
“short form 20” OR SF-20 
OR SF20 OR 
“short form 36” OR SF-36 
OR SF36 OR 
“short form 8” OR SF-8 
OR SF8 OR 
“symptom burden” OR 













Table 2: Risk of bias in studies included in meta-analysis 
 








bias - Blinding 
of participant 
and personnel 










Hendriks et al209 Low N/A N/A Low Low Low 
Stewart et al211 Low N/A N/A Low Low Low 











Table 3: Characteristics of studies included in the meta-analysis 
 
 t aHendriks et al209 Stewart et al211 Carter et al212 
Mean age 66.5±13 71.5±12 62.8±15.4 
Total participants 712 335 336 
% female 41 48 39 
Study type RCT RCT Before and after 
Year of publication 2012 2015 2016 








Referred to outpatient clinic  
with AF 
Hospital admission  
with AF 
Presented to ED  
with AF 
Duration of follow up (years) 1.83 2.51 2.06 
Primary outcome measure CV hospitalisation and death 
All-cause mortality and/or 
unplanned readmission, 
proportion of event free days 
Death, CV hospitalisation, AF ED 
visit 
 














1219 studies assessed by title 
and abstract
1180 did not meet inclusion 
criteria
39 studies retrieved for 
full text assessment
36 excluded:
25 Not holistic AF clinic
4 No control group
3 Duplicate studies
4 Not published in English













































































Chapter 5: A Review of the Inpatient and 
Emergency Department 
Management of Atrial Fibrillation 
– the REVIEW AF Study 
5.1 INTRODUCTION 
Atrial fibrillation is an emerging global epidemic associated with significant morbidity 
and mortality. Numerous opportunities exist to improve outcomes in the AF population, 
including appropriate use of OAC to manage stroke risk, which remains suboptimal, and 
strategies to reduce associated mortality and other poor outcomes with this condition. 
Furthermore, health care resource utilisation due to AF has risen exponentially in recent 
decades. The main driver of AF costs are hospitalisations related to the condition itself, 
and its associated complications including stroke and heart failure.24  Whilst increasing 
rates of AF related hospitalisations have been demonstrated globally, modifiable factors 
associated with these rising rates have not been well characterised. Although rising 
incidence and prevalence rates associated with AF and the ageing population are likely to 
be significant contributors, it is not known if other potentially modifiable factors are 
associated with increased health care resource utilisation in this condition.  
 
5.1.1 The use of OAC for stroke risk in AF 
The advent of DOAC therapy has led to improved rates of this therapy to manage stroke 
risk in AF.131 The GARFIELD registry has demonstrated improved use of OAC in those 
at highest risk of stroke (CHA2DS2-VASc score of ≥2) from 2010 to 2015 with more than 




Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) has also 
demonstrated high rates of OAC use in those with a CHA2DS2-VASc score of ≥2, with 
82.2% of individuals in this category appropriately treated.283 Despite these 
improvements, Australian data has suggested that use of this therapy in individuals at 
high risk of stroke remains underutilised. In a single centre study of 19,613 individuals 
with AF from 1999-2012, 76.3% and 71.3% of Indigenous and non-Indigenous 
Australians with a CHA2DS2-VASc score of ≥2 were not prescribed anticoagulation.
132 
Overuse of this therapy was also evident with 24% and 16.7% of those with a CHA2DS2-
VASc score of 0 prescribed anticoagulation. More recently, a study of 609 individuals in 
rural Western Australia reported that approximately one third of all individuals with AF 
and a CHA2DS2-VASc score of ≥1 were not prescribed anticoagulation.
284 
 
5.1.2 Health care resource utilisation in AF 
Hospitalisations remain the costliest component of AF care. Characterisation of ED re-
presentations and hospitalisation readmissions in individuals with AF have demonstrated 
significant heterogeneity across studies. A retrospective sample of 6439 individuals with 
non-valvular AF in the USA demonstrated an 18% readmission rate at 30 days.153 
Readmissions were associated with significant health care burden with a mean length of 
stay of 7.4±8.0 days and occurred a mean of 9.7±9.0 days after admission with AF. In 
this cohort, AF remained the most common reason for re-presentation accounting for 
10.2% of all readmissions. This was followed by congestive heart failure at 6.7% and 
coronary atherosclerosis at 3.1%.153 In higher risk populations (individuals with AF ≥75 
years of age or ≥70 years with one additional risk factor) re-hospitalisations are a 




reason over a 12 month follow up period. Of those that were hospitalised, 35% (1223 
individuals) of the cohort were hospitalised for cardiovascular reasons of which AF or 
atrial flutter was the most common reason (47.5%). This was followed by congestive 
heart failure (9.9%), coronary artery disease (7.4%) and stroke/TIA (6.2%) related 
admissions.154 
 
5.1.3 Predictors of rehospitalisation in AF 
Prior studies have identified varying factors as predictors of AF related hospitalisations. 
Whilst numerous studies have described advanced age as a predictor of repeat 
hospitalisations154,157, other potentially modifiable comorbid conditions have also been 
described. Both the CHADS2 and CHA2DS2-VASc score were predictive of first 
cardiovascular hospitalisation in a large US based cohort.159 Other factors associated with 
hospitalisations in a cohort of 9484 community dwelling individuals with AF included 
coronary artery disease, hypertension, cerebrovascular disease and peripheral vascular 
disease.158 In this study, a higher symptom burden as determined by the EHRA score, was 
also predictive of hospitalisation. A high comorbid burden as characterised by the 
Charlson Comorbidity Index (CCI) score, a longer length of stay and admission to 
hospital through the emergency department was predictive of repeat all cause 
hospitalisations at 30 days in a US based cohort of 6439 individuals with AF listed as 
either a primary or secondary diagnosis.153 Interestingly, in this cohort individuals with 
AF listed as a secondary diagnosis had a significantly higher rate of readmission than 
individuals with a primary diagnosis of AF. In the 1161 individuals who were readmitted 
to hospital within 30 days, 82.5% had AF listed as a secondary diagnosis at their index 




Other predictors of rehospitalisation in individuals with AF from another retrospective 
cohort include hypertension, peripheral vascular disease, coronary artery disease, valvular 
heart disease and female gender.154 The cost of repeat admissions for AF in this study was 
also significantly greater than initial presentations ($3589 [SD $4194] vs $4418 [SD 
$6294] for index and repeat hospitalisations for AF respectively).154 
 
5.1.4 Mortality in AF 
Mortality associated with AF has increased globally in recent decades and has 
demonstrated a 2-fold and 1.9-fold increase for males and females respectively between 
1990 and 2010.2 A study of 71,683 individuals from four large studies of the use of 
anticoagulation in AF demonstrated a mortality rate of 4.72% per year.285 The most 
common causes of death were cardiac related including sudden cardiac death, heart failure 
and myocardial infarction.  Significant differences in characteristics of individuals who 
died over follow up compared to those alive at final follow up were evident with higher 
rates of heart failure, diabetes, permanent/persistent AF, older age and a greater likelihood 
of death in males.285 Similar results were also found in a study of 8,962 individuals with 
AF from four hospitals in France between 2000-2010.286 Over a mean follow up of 929 ± 
1082 days, 14% of individuals died with an annual mortality rate of 5.5% per year. Heart 
failure was the most common cause of death in this cohort with significant differences in 
clinical characteristics evident in those who died compared to those alive at final follow 
up. Individuals who died were more likely to be older, more likely to have permanent AF, 
and to higher rates of most cardiovascular risk factors including hypertension, diabetes, 
dyslipidaemia and current smoking.286 A higher cardiovascular comorbidity burden was 




Given the growing health care burden and poor patient outcomes associated with 
AF contemporary factors associated with ongoing hospitalisations are of paramount 
importance. Furthermore, modifiable factors are of interest due to the possibility to 
structure interventions that may reduce subsequent health care resource utilisation. 
However, the nature of re-hospitalisations in individuals with AF in Australia have not 
been characterised. Additionally, factors associated with AF related hospitalisations have 
not been examined. The aim of this study is to characterise reasons for readmission in a 
contemporary cohort of individuals with AF, in addition to identifying factors associated 
with readmission to hospital. Guideline adherence to appropriate use of OAC according 
to stroke risk will also be examined. Mortality rates, and associated patient characteristics, 
will also be determined. 
 
5.2 METHODS 
5.2.1 Study design 
This was a retrospective study of consecutive individuals presenting to the ED of three 
hospitals in Adelaide, South Australia over a 12-month period from 22 March 2013 to 22 
March 2014, primarily due to AF. The study was undertaken by electronic health record 
review. The follow up period was three to four years. This study was registered with the 
Australian and New Zealand Clinical Trial Registry (ACTRN12618001890224). Ethical 
approval was obtained from the Royal Adelaide Hospital Human Research Ethics 





5.2.2 Patient selection 
Participants were recruited from an electronic database of individuals who had presented 
to the emergency department of three metropolitan hospitals in Adelaide, South Australia 
due to AF. A principal diagnosis of AF, by ICD-9 or ICD-10 coding, was required for 
study eligibility. Participants were excluded if their index presentation was an elective 
admission, they were an overseas or interstate visitor, or they were <18 years of age. For 
follow up events, elective day case admissions due to non-cardiovascular causes were not 
collected (e.g. haemodialysis, chemotherapy). 
 
5.2.3 Study outcomes definitions 
Sociodemographic information was obtained from each presentation to hospital including 
patient age, postcode (as a surrogate marker of socioeconomic status), date and time of 
presentation and length of stay. All ED presentations and hospital admissions were further 
categorised in to three groups: AF related, cardiovascular related (excluding AF and atrial 
flutter) and all other causes based on a combination of ICD coding and review of the 
electronic health record attached to each event. Any event was categorised as AF related 
if it pertained to episode management, admission for AF related complications or 
monitoring or procedures undertaken due to AF. Any atrial flutter event was categorised 
as AF related whilst all other arrhythmias were categorised as ‘other cardiovascular’ 
events. Other cardiovascular events were categorised based on coding and electronic 
health record review and included any other type of cardiovascular event excluding those 
related to AF or atrial flutter. All other events were categorised as ‘all other causes. 
Further information was obtained from the ‘AF related’ group including the use of rate 




score, appropriate use of oral anticoagulation, type of oral anticoagulation used, referral 
on to a cardiologist for outpatient care and the provision of a personalised plan to manage 
future AF episodes. In addition to this, for each participant’s index presentation, a 
Charlson Comorbidity Index score was calculated based on listed comorbidities.287 
Deaths that occurred during the follow up period were obtained from two sources: the 
electronic health record (if death occurred in a metropolitan public hospital) or publicly 
available death notices published online. Cause of death was unable to be obtained from 
these records.  
 
5.2.4 Appropriate use of oral anticoagulation 
The appropriate use of oral anticoagulation to reduce stroke risk was assessed using the 
CHA2DS2-VASc score. As per the European Society of Cardiology 2012 AF management 
guidelines,288 which were current at this time in clinical practice, any use of OAC or 
antiplatelet therapy (without vascular disease) was considered inappropriate for a 
CHA2DS2-VASc score of 0 (except in the context of undertaking cardioversion or AF 
ablation). Any type of therapy (no therapy, aspirin or other antiplatelet therapy or OAC) 
was considered appropriate for individuals with a CHA2DS2-VASc score of 1 and OAC 
was considered necessary in all individuals with a CHA2DS2-VASc score of ≥2 unless 
there was a documented contraindication. Documented contraindications included: high 
falls risk, previous haemorrhagic stroke or major bleeding, uncontrolled hypertension, 





5.2.5 Primary and secondary outcomes 
The primary outcome measure was the number and type of hospital re-presentations in 
this cohort of individuals with an AF related index ED presentation. Secondary outcome 
measures include factors predictive of AF related ED re-presentation, factors predictive 
of AF re-hospitalisation, appropriate use of OAC according to stroke risk and differences 
in baseline characteristics for those who died during follow up, compared to those who 
were alive at final follow up date. Differences in length of stay for repeat hospital 
presentations for each type (AF related, other cardiovascular and all other causes) was 
also examined. 
 
5.2.6 Endpoint adjudication 
All data was collected by one investigator with independent adjudication of endpoints by 
two investigators. Any disagreements were resolved by consensus. 
 
5.2.7 Statistical analysis 
Baseline demographic and clinical variables were analysed using descriptive statistics 
(means and standard deviations for continuous variables and counts and percentages for 
categorical variables). The number of re-presentations and admissions to hospital that 
occurred over follow up were expressed as means and standard deviation.  
Re-admission status: Differences in baseline and index presentation characteristics 
between patient groups defined by AF-related re-admission/re-presentation status (never 
re-admitted vs ever re-admitted) were analysed using the Mann Whitney U test and Chi 




Factors associated with AF related re-admissions, and variables associated with 
admission to hospital for AF following an ED presentation were investigated using binary 
logistic regression modelling. Differences in characteristics between those who obtained 
advice for management of future AF episodes was examined by Fisher’s exact test of 
association for categorical variables or Mann Whitney U Test for continuous variables.  
Covariates considered in the multivariate model included: age, gender, baseline 
comorbidities (hypertension, heart failure, diabetes, vascular disease), CHA2DS2-VASc 
score, HAS BLED score, Charlson Comorbidity Index, treatment at initial presentation 
(rate controlling medications, rhythm controlling medications or electrical cardioversion), 
rhythm on discharge from hospital (sinus rhythm or not), provision of non standardised 
advice to manage future AF episodes and referral to a Cardiologist for follow up. 
Multivariable cox proportional hazards regression modelling was used to estimate hazard 
ratios and corresponding 95% confidence intervals. If a clinical plan was described by a 
treating physician to guide the patient in the event of future AF episodes, this was noted 
as a non-standardised AF action plan. The proportional hazards assumption was assessed 
graphically using Kaplan-Meier plots, and using a test based on Schoenfeld residuals.  
Time to first repeat AF hospitalisation: Cox regression modelling was used to examine 
the crude and adjusted effects of selected variables on the time to first repeat AF 
hospitalisation. 
Length of stay for repeat hospital presentations: A negative binomial regression model 
was used to estimate differences in length of stay (in hours) between AF-related 




Rate of AF-related re-presentations: Negative binomial regression modelling was used 
to examine factors associated with the number (count) of repeat AF related presentations 
per patient that occurred during follow-up. 
Mortality status: Differences in baseline and index presentation characteristics between 
patients who died during follow-up and those who were alive at the end of follow-up were 
assessed using Mann Whitney U tests and Chi-square tests for continuous and categorical 
predictors, respectively.   
All statistical analyses were performed using Stata (version 15, StataCorp, College 
Station, Texas, USA). The level of statistical significance was set at 0.05. 
 
5.3 RESULTS 
The cohort comprised 437 individuals who had all presented to hospital with an index 
presentation that was primarily due to AF. See Figure 1 for the study flow chart. Mean 
follow up time, defined as time from index presentation, was 3.7±0.4 years. Males 
comprised 49.9% of the cohort (218 participants). Mean age was 68.7±14.5 years. See 
Tables 1 and 2 for other baseline characteristics. There were a total of 2741 events 






5.4 APPROPRIATE USE OF OAC FOR STROKE RISK 
5.4.1 First AF presentations and OAC prescription 
Of the 437 individuals from this study cohort, 193 (44.2%) presented with a first diagnosis 
of AF. A CHA2DS2-VASc score of 0 was recorded in 30 individuals with prescription of 
OAC occurring in 2 (6.7%) cases (Figure 2). A CHA2DS2-VASc score of 1 was recorded 
in 34 (17.6%) individuals with a first AF presentation. In 7 (20.6%) individuals OAC was 
prescribed, whilst this did not occur in 26 (76.4%) individuals. Use of OAC was not 
documented in one (2.9%) case. 
In 129 (66.8%) of these cases a CHA2DS2-VASc score of ≥2 was recorded and in 
119 (61.7%) individuals there were no documented contraindications to the use of OAC. 
In 74 (62.2%) of these presentations OAC was not commenced, whilst in 45 (37.8%) 
individuals OAC was prescribed (Figure 2). Of the 74 presentations in which OAC was 
not commenced, 54 (73%) presentations involved prior or new prescription of Aspirin, 
Clopidogrel or a combination of both therapies. In 11 individuals, commencement of 
OAC was recommended to the treating general practitioner without being initiated in the 
hospital setting.  
 
5.4.2 Use of oral anticoagulation in established AF 
There were 609 unplanned AF presentations over the entire study duration which 
occurred in individuals with a prior diagnosis of the condition. A CHA2DS2-VASc score 
of 0 was recorded in 56 (9.2%) presentations of which 3 (5.4%) were prescribed OAC 
during hospital presentation (Figure 2). A CHA2DS2-VASc score of 1 occurred in 79 




(6.3%) cases. There were 16 presentations in which an individual was already 
anticoagulated (20.3%). This was unknown due to lack of documentation in 5 cases. 
The majority of these presentations (474 presentations - 77.8%) recorded a 
CHA2DS2-VASc score of ≥2. A total of 39 (8.2%) of these presentations had a 
documented contraindication to the use of OAC. In 248 (57.0%) of these presentations, 
OAC had previously been prescribed. Of the 190 presentations where OAC was not 
prescribed and there was no documented contraindication, prescription of OAC occurred 
in 34 cases (17.9%). In 143 (75.3%) presentations with no documented contraindications, 
OAC had not previously been prescribed and was not prescribed during hospital 
presentation (Figure 2). In the 143 cases where no OAC had been prescribed prior to ED 
presentation or during the ED visit and/or hospital admission, 73 (51.0%) presentations 
involved individuals taking either Aspirin alone, Clopidogrel alone or combination 
therapy. Commencement of OAC therapy was recommended, but not commenced, in 10 
(5.3%) of these presentations.  
  
5.5 HOSPITAL RE-PRESENTATIONS 
5.5.1 Hospital re-presentation characteristics 
There were a total of 2304 repeat hospital presentations that occurred in the cohort of 437 
patients over follow up. The number of repeat presentations recorded per patient ranged 
from 0 (81 participants; 18.5%) to 101 (1 participant). Approximately 50% of the cohort 
had at least two re-presentations during follow up. Mean number of follow up events 
across the cohort was 5.3±9.1. The most common reasons for a follow up presentation 
(ED presentation or hospital admission) were those relating to causes other than AF or 




related presentations (mean 1.2±2.2) and then cardiovascular related reasons (mean 
0.8±1.9). Limiting the analysis to the cohort who re-presented on at least one occasion 
did not materially alter this result. Most individuals were admitted to hospital at their AF 
related index presentation (72.3%). See Figure 3 for the distribution of repeat hospital re-
presentations.  
 
5.5.2 First hospital re-presentation 
AF presentations accounted for 37.6% of first hospital re-presentations. Other 
cardiovascular causes was attributable to 14.9% of first re-presentations whilst all other 
causes accounted for 47.2% of first re-presentations. 
 
5.5.3 AF related re-presentations 
Of the 356 individuals who had at least one hospital re-presentation, 202 (56.8%) had at 
least one event that was AF related over the follow up period. Most of this cohort (50.3%) 
had between 1 and 4 AF re-presentations in total during follow-up (Figure 4). In the first 
12 months following the index presentation, AF accounted for 39% of all repeat hospital 
admissions and 30% of all repeat ED presentations. During the remaining follow up 
period AF accounted for 11-33% of all hospital readmissions and 16-25% of all ED 
presentations (Table 3). 
 
5.5.4 Cardiovascular related re-presentations 
Of those patients who re-presented to hospital, 148/356 (41.6%) experienced an 




related. Of those who had at least one cardiovascular related re-presentation, 91.2% had 
between 1-4 follow up re-presentations (Figure 5). Annual rates of readmission for other 
cardiovascular causes ranged from 15-18%, with ED presentations accounting for 10 -
24% of all re-presentations annually (Table 3). 
 
5.5.5 Re-presentations related to other causes 
Re-presentation due to other causes occurred in 278 patients, representing 78.1% of the 
cohort who had at least one event during follow up. Most of this cohort (64.3%) had 
between 1-4 follow up presentations (Figure 6). This category accounted for 45-73% of 
all annual readmissions, and 50-75% of all repeat ED presentations per annum (Table 3). 
 
5.5.6 Length of stay for re-presentations 
The mean length of stay for ED re-presentations was 4.5±4.4 hours. There were no 
significant differences between length of stay for AF re-presentations compared to those 
for other cardiovascular reasons (IRR 1.05, 95% CI 0.89-1.24; p=0.19); nor for AF re-
presentations compared to those for other causes (IRR 0.92, 95% CI 0.82-1.04; p=0.19).  
For hospital admissions, no difference was observed between length of stay for 
admissions due to AF reasons and admissions for other cardiovascular reasons (IRR 1.34, 
95% CI 0.96-1.87; p=0.09). Hospital admissions relating to other causes were 





5.6 FACTORS PREDICTIVE OF AF RE-PRESENTATIONS 
5.6.1 Impact of age and gender 
Increasing age was associated with a decrease in the likelihood of an AF re-presentation 
(AF related ED presentation or hospital admission). Each one-year increase in age was 
associated with a 2% reduction in risk of AF related re-presentations (OR 0.98, 95% CI 
0.98-0.99; p<0.0001). For each 5-year age increase, the associated risk of AF re-
presentation decreased by 7% (OR 0.93, 95% CI 0.89-0.97; p<0.0001).  
Males had a greater likelihood of re-presentation for AF over follow up. In the age 
and gender adjusted model, males were approximately 30% more likely to re-present 
during follow up compared to females (OR 1.29, 95% CI 1.03-1.60; p=0.025). 
 
5.6.2 Factors associated with AF related ED re-presentations 
Of 437 individuals, 82 (18.8%) presented to ED over the follow up period at least once 
for an AF related reason, whilst 355 did not. The group who re-presented to ED were less 
likely to have heart failure (6.1% vs 16.1%, p=0.020), were less likely to have been 
admitted to hospital at their index presentation (50.0% vs 77.5%, p<0.0001) and had a 
shorter length of stay at index presentation (23.5±30.2 hours vs 59.5±107.4 hours for 
repeat vs non-repeat ED presenters respectively). The repeat ED presenters were less 
likely to be in sinus rhythm on discharge from hospital at their index presentation (Table 
4).  
Univariate analysis demonstrated that heart failure was associated with a 
significant reduction in the risk of repeat ED presentation. Admission to hospital at index 




index length of stay (OR 0.98, 95% CI 0.98-0.99; p<0.0001) were both associated with a 
reduction in the risk of ED re-presentation in the univariate model. Documented evidence 
of an ad hoc non-standardised AF action plan for management of future AF episodes was 
associated with a significant increase in the risk of repeat ED re-presentations (OR 6.91, 
95% CI 2.90-16.4; p<0.0001). In the multivariable model, the non-standardised AF action 
plan remained a significant predictor of repeat ED presentation (OR 6.66, 95% CI 2.4-
18.3; p<0.0001; see Table 5). Admission to hospital at index presentation was associated 
with a significant reduction in risk of ED re-presentation for AF (OR 0.39, 95% CI 0.19-
0.80; p=0.01). 
Predictors of the total number of AF related ED presentations over follow up were 
also examined (Table 6). In the univariate model, heart failure was predictive of the total 
number of repeat ED presentations for AF (IRR 0.12, 95% CI 0.02-0.91; p=0.04), but was 
not significant in the multivariate model. Hypertension was of borderline significance in 
the univariate model and remained predictive in the multivariate model (IRR 10.2, 95% 
CI 1.61-64.4; p=0.014). In the univariate and multivariate model, each one hour increase 
in the index presentation length of stay was predictive of the number of AF related ED 
presentations over follow up (IRR 0.97, 95% CI 0.96-0.99; p<0.0001 and IRR 0.98, 95% 
CI 0.96-0.99, p=0.037 for univariate and multivariate respectively; Table 6). 
 
5.6.3 Factors associated with AF related hospitalisations 
In the cohort of 437 individuals, 125 (28.6%) were readmitted for an AF related cause 
whilst 312 did not experience a readmission for AF. The cohort who were readmitted 
were more likely to have hypertension (63.2% vs 43.9%, p<0.0001) and had a higher 




1.5±1.1, p<0.00001) at their index presentation (see Table 7). Factors predictive of 
readmission for AF in a univariate model included hypertension (OR 2.19, 95% CI 1.43-
3.36; p<0.0001) and each one unit increase in the CHA2DS2-VASc and HAS-BLED 
scores (OR 1.18, 95% CI 1.06-1.32; p=0.003 and OR 1.58, 95% CI 1.29-1.94; p<0.0001 
for CHA2DS2-VASc and HAS-BLED scores respectively; Table 8). However, after 
adjustment for other variables in a multivariable model, the only factors significantly 
predictive of readmission was the non standardised AF action plan and each unit increase 
in the HAS-BLED score (OR 2.76, 95% CI 1.00-2.01; p=0.05 and OR 1.42, 95% CI 1.00-
7.63; p=0.05 respectively; Table 8).  
In univariate analysis, each one unit increase in the HAS-BLED score was 
predictive of the number of repeat AF hospitalisations over follow up (IRR 1.87, 95% CI 
1.17-2.98; p=0.009). Multivariate analysis demonstrated that the presence of heart failure 
was associated with a reduction in total number of repeat AF hospitalisations over follow 
up (IRR 0.14, 95% CI 0.02-0.98; p=0.018) Each one unit increase in the HAS-BLED 
score was associated with increasing numbers of AF hospitalisations over follow up (IRR 
2.24, 95% CI 1.01-4.98; p=0.05; Table 9).  
 
5.6.4 Time to first AF related ED presentation 
The Kaplan Meier curve for time to first AF related ED presentation following discharge 
from the index presentation demonstrates that the probability of AF related ED 
presentation rises steeply in the first year after discharge to approximately 10% and 





5.6.5 Time to first AF related hospitalisation 
Similar trends were demonstrated in the Kaplan Meier curve for time to first AF related 
hospital readmission. The probability of readmission rose most sharply in the first 12 
months after the index presentation to approximately 10% with a more gradual increase 
to approximately 30% after four years (Figure 8). Factors associated with time to first AF 
related hospital readmission were increasing age at index presentation, the presence of 
baseline hypertension and higher CHA2DS2-VASc and HAS-BLED scores at index 
presentation in a univariate model. However, in the multivariate model the only factor 
that remained predictive was the HAS-BLED score at index presentation (HR 1.41, 95% 
CI 1.05-1.89; p=0.02; Table 10). 
 
5.6.6 Factors predictive of admission to hospital for unplanned AF re-
presentations 
Over follow up, a total of 366 repeat unplanned AF re-presentations occurred in 164 
individuals. This resulted in admission to hospital in 62.8% of all AF related re-
presentations. In univariate analysis, heart failure (OR 3.34, 95% CI 1.26-8.83; p=0.015), 
admission at index presentation (OR 2.44, 95% CI 1.47-4.06; p=0.001), each one hour 
increase in the index presentation length of stay (OR 1.01, 95% CI 1.47-4.06; p=0.002) 
and the use of rate controlling medications at the index presentation (OR 2.07, 95% CI 
1.24-3.48; p=0.006) were all associated with an increased risk of admission to hospital 
for subsequent AF related ED re-presentations. In the multivariate model, only admission 
to hospital at the index presentation (OR 2.45, 95% CI 1.24-4.84; p=0.010) and the non-




hospital for unplanned AF re-presentations over follow up (OR 3.11, 95% CI 1.09-8.87; 
p=0.034; Table 11). 
 
5.6.7 Characteristics of individuals with a non-standardised AF action plan 
Notable differences in baseline characteristics were evident in those who obtained a non-
standardised AF action plan compared to individuals who did not receive this plan. Those 
who had a plan were younger (69.6±14.4 years vs 60.6±14.7 years; p=0.008), had a lower 
Charlson Comorbidity Index (4.1±2.0 vs 2.8±1.8; p=0.006), were less likely to be 
admitted to hospital at their index presentation (73.6% vs 40.0%; p=0.003), had a shorter 
length of stay at index presentation (55.7±101.5 hours vs 6.6±6.5 hours; p<0.0001, were 
more likely to receive electrical cardioversion at index presentation (13.8% vs 35%; 
p=0.052), were less likely to be treated with a rate control strategy at index presentation 
(60.6% vs 25.0%; p=0.006), were more likely to be referred to a Cardiologist (53.0% vs 
80.0%; p=0.045) and had lower CHA2DS2-VASc (2.9±1.9 vs 1.6±1.5; p=0.003) and 
HAS-BLED scores (1.7±1.1 vs 1.2±1.4; p=0.050; all non AF action plan vs action plan 
recipients respectively; Table 12). 
 
5.6.8 Mortality 
There were 71 deaths recorded out of the study population of 437 individuals (16.2%). 
Cause of death was unable to be ascertained in this study. Patients who died during follow 
up were older at index presentation (79.8±10.7 years vs 66.6±14.1 years; p<0.00001). 
They were also more likely to have heart failure (31.0% vs 10.9%) and had higher 
Charlson Comorbidity Scores at baseline (6.0±2.0 vs 3.6±1.8; p<0.001). Compared to 




admitted to hospital at index presentation (83.1% vs 70.2%) and a longer length of stay 
(76.0±161.4 hours vs 48.3±80.6 hours). Mortality during follow up was also associated 
with a decreased likelihood of sinus rhythm at discharge from index presentation, a 
reduced likelihood of referral to a Cardiologist and higher CHA2DS2-VASc and HAS-
BLED scores at index presentation (Table 13). The Kaplan Meier curve demonstrates a 
relatively constant increase in risk of death over the follow up period (Figure 9). Over 
follow up the average mortality rate was 3.78% per annum. This ranged from 2.28% to 
4.66% per year.  
 
5.7 DISCUSSION 
AF is associated with significant and growing health care burden with our study 
demonstrating numerous opportunities for improvement. Factors associated with repeat 
hospitalisations in this population have been poorly characterised with resultant missed 
opportunities to reduce this burden. Furthermore, appropriate use of oral anticoagulation 
remains suboptimal with both under and overuse of this therapy. Our results demonstrate 
that AF is associated with: 
• Underuse of anticoagulation in 62% of those at high risk of stroke with a first AF 
presentation; 
• Ongoing underuse of anticoagulation with 75% of repeat AF presentations in 
individuals at high risk of stroke not prescribed OAC despite tertiary hospital 
review;  
• Significant ongoing rates of repeat hospitalisations, of which AF alone is 




• Admission to hospital for AF in more than 72% of cases at index presentation 
and more than 62% of occasions over follow up; 
• An increased risk of AF related hospitalisation in the first 12 months following 
an ED presentation, with this condition alone accounting for almost 40% of all 
hospital admissions; 
• A 7-fold increase in risk of repeat ED presentations, a 3-fold increase in risk of 
hospitalisations and a more than 3-fold increase in risk of admission to hospital 
following repeat ED presentations for AF in those given non-standardised advice 
for management of future AF episodes; 
• An average annual mortality rate of 3.78% per annum. 
These results demonstrate that AF is associated with significant ongoing health care 
burden and urgent action is required to stem the growing tide of hospitalisations 
associated with AF. Whilst most re-presentations are not AF related, this condition alone 
accounts for a significant proportion of ongoing health care resource utilisation. 
Furthermore, significant opportunity exists to improve the appropriate use of oral 
anticoagulation in this population. 
 
5.7.1 Appropriate use of oral anticoagulation 
OAC is an effective therapy for the mitigation of stroke risk. Recent data from the 
GARFIELD and ORBIT AF registries demonstrated that in those with a CHA2DS2-VASc 
score ≥2, rates of appropriate OAC use were 69% and 87% respectively,131 which is 
significantly better than rates observed in this study. However, data from earlier time 




demonstrated that in the fourteen-year period leading up to 2012, 76.3% and 71.3% of 
Indigenous and Non Indigenous Australians were not prescribed OAC despite elevated 
risk scores132. A single centre retrospective analysis in Australia of 2118 individuals with 
non valvular AF demonstrated that whilst the introduction of DOAC therapy improved 
rates of OAC from 52.5% in the pre DOAC era to 60.7% in the post OAC period, OAC 
therapy was still not prescribed in 37% of the cohort with a CHA2DS2-VASc score of 
≥2.289 In the American College of Cardiology National Cardiovascular Data Registry's 
Practice Innovation and Clinical Excellence (PINNACLE) Registry of 429,417 
outpatients with AF from 2008-2012, whilst increasing CHA2DS2-VASc scores were 
associated with an increased likelihood of prescription of OAC, this still remained poor 
overall.290 In those at considerable stroke risk (CHA2DS2-VASc score >4), less than 50% 
of eligible participants were prescribed anticoagulation.290 
 Despite tertiary hospital review, 62% of individuals with a first AF presentation 
were not prescribed OAC despite a CHA2DS2-VASc score of ≥2 in our study. This is 
comparable to other datasets in which more than 50% of eligible patients are not 
prescribed this therapy despite hospital review.291 Furthermore, our dataset has 
demonstrated that this effect continued over time where, although 57% of AF 
presentations were appropriately anticoagulated prior to presentation, only a minority of 
eligible presentations (17.9%) involved prescription of this therapy in hospital. In more 
than half of the cases in which OAC was not prescribed, this involved the use of other 
antithrombotic therapy including aspirin, clopidogrel or combination therapy. This may 
reflect physician uncertainty about appropriate therapy or concern about excess bleeding 
risk. In the GARFIELD registry, ‘physician choice’ was cited as the most common reason 
for withholding OAC therapy in those at high risk of stroke (48.3%) and may be reflective 




5.7.2 Rates of hospital admission for AF 
Notably our results demonstrate a rate of admission to hospital for AF that exceeds 
that of other published data. The index ED presentation for AF in our dataset resulted in 
hospital admission in more than 72% of cases. Over the follow up period, unplanned ED 
presentations with AF resulted in hospital admission in more than 62% of cases. 
Comparable datasets have demonstrated much lower rates of admission with a study 
examining hospitalisations in a large cohort of 33,699 individuals in Ontario, Canada 
resulting in admission to hospital in 48.3% of presentations.293 Wide practice variations 
were evident in this study with admission rates ranging from 3% to 91% across 
geographical locations. Propensity matched analysis in this study demonstrated that 
mortality and repeat all cause ED visits and hospitalisations were higher in the group 
admitted at index presentation whilst other adverse outcomes including any stroke or 
major or minor bleeding did not differ between groups at one year irrespective of initial 
admission status.293 From an earlier timepoint, US data over the 12 year period leading 
up to the end of 2004 demonstrated a significant increase in the population adjusted rate 
of ED presentation for AF, whilst the admission rate remained relatively constant over 
the study period at approximately 64%.294 These variations in rates of admission to 
hospital suggest that factors beyond clinical need may play a role in decisions to admit 
and may offer an opportunity to intervene to reduce the costliest component of AF care. 
Indeed, this was supported by our multivariate model which was unable to delineate any 
clinical factors associated with risk of admission to hospital for repeat ED presentations 





5.7.3 Readmission type in AF 
AF accounted for 22% of all hospital readmissions in our dataset. This is in line with 
other studies which have also demonstrated high rates of readmission in AF cohorts, with 
many of these events related to AF, even over shorter follow up duration. In a multi-centre 
study examining the impact of an antiarrhythmic medication (dronedarone) on 
cardiovascular hospitalisations in AF, rates of readmission at one year approached 40% 
for all causes, with AF and atrial flutter accounting for the majority of all cardiovascular 
hospitalisations at 47.5%.154 This is comparable to our dataset where, in the first year 
following an unplanned presentation to ED with AF, almost 40% of all hospital 
readmissions were due to AF. In another cohort of individuals with AF, readmission rates 
to hospital at 30 days were 18%.153 Of the cohort who were readmitted, the most common 
reasons were general and non-specific symptoms (12.8%) followed by AF at 10.2%.153  
Similarly, in a large US based study of 388,340 with a principal diagnosis of AF rates of 
readmission at 30 days, utilising the National Readmissions Database, was 15%. The 
most common reason for readmission were AF and heart failure.295 Together, these 
studies support our data suggesting an early higher risk of representation to hospital for 
AF related reasons, with our long term data reflecting an ongoing, although somewhat 
tempered, increase in risk. 
Whilst admissions related to AF were shorter than those related to other causes, 
there was no difference between those of AF or cardiovascular causes. As the burden of 
AF hospitalisations in Australia has exponentially risen in recent times, and at a 
significantly greater rate than that of other cardiovascular conditions including HF and 
MI, factors associated with this rise and strategies to address the growing burden of AF 





5.7.4 Predictors of AF related readmissions 
Our multivariate model was unable to delineate many factors associated with 
readmissions for AF. Whilst other studies have varied in this regard there have been few 
consistently identified predictors of readmission. In Australia higher rates of AF related 
hospitalisations have been observed in older age groups.156 In a US based study 
geographical variations in rates of admission to hospital following an ED presentation for 
AF were noted, with congestive heart failure the only significant clinical predictive factor 
(OR 6.44, 95% CI 2.49-16.63).294 Congestive heart failure has also been identified as a 
predictive factor for all cause hospitalisation in other studies in AF populations.10,160 
Other significant predictors of readmission have included a longer length of stay at index 
presentation and a higher Charlson comorbidity index score, reflective of a generally 
sicker population.153 Older age and greater comorbid burden in addition to female gender 
were associated with a higher risk of all cause 30 day readmissions in another study.295 
In an anticoagulated community based cohort in the Netherlands, factors associated with 
hospitalisation included older age, vascular disease and heart failure.157 Whilst other 
studies have demonstrated comorbidities predictive of admission to hospital in AF 
including hypertension, vascular disease and diabetes, we were unable to elicit any 
predictive clinical factors in our dataset. This may be due to a smaller sample size but 
potentially highlights that many AF related admissions are not necessarily based on 
clinical need and could be preventable with strategies including improved outpatient 
management of the condition. Our data demonstrates a higher risk of AF related 
presentations in males and younger patients with a steep rise in this risk in the first year 
following presentation. It is plausible that improved early outpatient management 
following discharge from hospital could significantly impact on rates of subsequent ED 




highlighted in a recently published study which demonstrated an early increased mortality 
rate, largely attributable to cardiovascular causes including heart failure, sudden cardiac 
death and acute coronary syndrome, in the one month following newly diagnosed AF in 
the hospital setting. Stroke and systemic embolism and major bleeding rates were also 
significantly elevated in the month following diagnosis with a reduction over the 
subsequent one-year period.296 Early outpatient follow up after hospital presentation 
could possibly prevent or allow for earlier identification of adverse events. 
 
5.7.5 Education and action plan 
This study is the first to examine the impact of non-standardised clinician advice for the 
management of future AF episodes on the impact of repeat ED presentations and 
hospitalisations for AF. Significant differences were noted between individuals who 
received this AF action plan compared to those who did not, and generally suggest that 
this plan was more likely to be utilised in a ‘lower risk’ population as was evident by 
younger age and lower comorbidity burden. However, this non-standardised AF action 
plan was the only factor predictive of both repeat ED presentations and hospitalisations 
for AF. Furthermore, the presence of this plan was also predictive of an increased risk of 
repeat admissions to hospital for unplanned AF presentations. Whilst this was a surprising 
and unexpected finding it can perhaps be explained by several possibilities. Whilst 
individuals are given an action plan they may neither understand nor recall details of this 
plan when required. We were unable to determine if action plans were written down or 
verbally conveyed which may also impact on an individual’s ability to implement their 




to be assessed in detail and may include provision to go to hospital if symptoms did not 
improve and could contribute to increasing ED presentations.  
The impact of personalised plans as part of chronic condition management was 
explored in a recent Cochrane systematic review examining their use in asthma. Due to 
significant heterogeneity across the 15 studies identified in relation to both interventions 
and study outcomes, there was no definitive evidence to support either benefit or harm 
with the use of action plans in asthma.297 Although action plans are also widely used in 
heart failure, similarly there is no definitive evidence to support their role in improving 
patient outcomes or reducing hospitalisations.298 In a sicker population with chronic 
respiratory diseases (predominantly chronic obstructive pulmonary disease – 78.7%) 
requiring long term oxygen therapy the use of an action plan, as part of a structured 
educational visiting approach for both patients and carers, was associated with increased 
mortality. After 12 months of follow up mortality was 31% in the intervention group 
compared to 11% in controls (p=0.0008).299 
Health literacy may also play a significant part in an individual’s ability to 
comprehend an action plan. A recently published study which examined the impact of 
improving the readability and reducing the level of difficulty in patient discharge 
instructions following trauma surgery resulted in a 50% reduction in the monthly 
readmission rate.300 Rates of patient phone calls were also significantly reduced following 
implementation.300 This study highlights the importance of ensuring that individuals have 
a written copy of their action plan and can adequately comprehend and implement the 
instructions it conveys. 
However, written and electronic material, in the context of ongoing support and 
monitoring from health care professionals, has demonstrated benefit in other studies as 




hypertensive population where significant improvements in home and office blood 
pressure readings, improvements in diet, physical activity levels and weight reduction 
were observed in 149 individuals with the use of smartphone apps and a web based patient 
portal.301 Based on home BP readings a nurse or pharmacist was able to adjust each 
individuals medication regime. Each study participant set two to three lifestyle goals with 
progress monitored through the patient applications and web-based portal. In AF, a nurse 
led integrated care approach which included the provision of educational counselling 
sessions by a nurse and standardised written material, protocol driven diagnostic testing 
and an electronic decision support decision for the health care provider resulted in a 
significant reduction in cardiovascular hospitalisations and mortality in a single centre 
study of 712 participants in the Netherlands.209 Based on these and other chronic 
condition studies undertaken to date it is likely that a combination of factors contributes 
to improved outcomes including written/electronic instructions, re-enforcement of these 
instructions at subsequent appointments and intensive and comprehensive follow up by a 
multidisciplinary team. The ability to access urgent support in between scheduled 
appointment times is also likely to be an important factor. 
 
5.7.6 Strategies to reduce AF admissions 
Other strategies to reduce hospital admissions due to AF have been examined including 
the use of ED management protocols to standardise AF treatment. In a recently published 
US study, the use of such a protocol, in addition to next day follow up at an AF clinic, 
resulted in a 24% reduction in the rate of admission to hospital for individuals presenting 
with AF.164 Similarly, the use of an ED protocol in another study also resulted in a 64% 




to ED with AF.165 Individuals who were admitted to hospital also experienced a shorter 
length of stay, although the time spent in ED was significantly greater with the use of the 
ED protocol compared to the control period.165 Despite the observed improvements with 
ED management protocols, their use in clinical practice is limited and has never been 
tested in an Australian health care setting. 
 
5.7.7 Mortality 
AF has an established association with increased all cause and cardiovascular mortality 
with a recent meta-analysis demonstrating a 46% increase in all-cause mortality risk (RR 
1.46, 95% CI 1.39-1.54) and a more than 2 fold increased risk of cardiovascular mortality 
(RR 2.03, 95% CI 1.79-2.30).302 Although we were unable to ascertain the causes of death 
in our cohort, the overall mortality rate at more than 16% over follow up is significant 
and highlights the poor outcomes associated with the condition. The baseline 
characteristics of those who died differed from the rest of the cohort and are reflective of 
a generally sicker population with a higher comorbid burden. This is similar to results of 
other studies,285,286 and highlights the need for management of other comorbid risk factors 
and conditions as a potential avenue for improving outcomes in AF. The impact of 
improved care of other conditions in the AF population such as heart failure, hypertension 
and vascular diseases on risk of mortality is however, not known.    
 
5.8 LIMITATIONS 
Our study has several limitations worthy of discussion. Firstly, this is likely to be an 




occurring in the public health system. It is possible that factors may not have been 
recorded in the electronic health record and therefore not accurately recorded in the 
database e.g. an individual could have had a personalised AF action plan, but this was not 
identified as it was not recorded in the electronic health record. As our study population 
is based on individuals presenting to hospital primarily due to AF, the results may not be 
reflective of other AF populations. Finally, there were several important factors that we 
were unable to identify from the electronic health record including depression, anxiety 
and symptom burden (e.g. EHRA class) as these were not routinely screened for and 
recorded in the electronic health record. It is possible that these and other demographic 
and clinical factors that we were unable to collect could be associated with repeat ED 
presentations and hospitalisations for AF. 
 
5.9 CONCLUSIONS 
AF is associated with significant health burden. Hospitalisations are the main driver of 
AF related cost and occur frequently in this population. AF related ED presentations and 
hospitalisations are more likely to occur in males and younger individuals and attention 
should be directed at these populations to prevent growing health care burden. Admission 
to hospital frequently occurs in the setting of unplanned ED presentations for AF and may 
often be inappropriate with our study suggesting that this is largely driven by factors 
beyond that of clinical need. The use of a non-standardised AF action plan is associated 
with an increased risk of both repeat ED presentations and hospitalisations with further 
research needed to understand this unexpected finding. Strategies to reduce the 
burgeoning numbers of the AF population and subsequent increase in associated health 




of the condition. These may also contribute to improved appropriate use of OAC which 
remains suboptimal in our cohort. Given the heterogenous nature of AF and of repeat 
hospitalisations, the need for a new paradigm in care delivery through a comprehensive, 








































 Table 1: Baseline characteristics 
 
 
 Postcodes were matched to Index of Relative Socio-Economic Advantage and Disadvantage (IRSAD) ranks. IRSAD quintiles were 
generated based on IRSAD rankings within Australia using Socio-Economic Indexes for Areas (SEIFA) for 2016 from the 
Australian Bureau of Statistics (http://www.abs.gov.au/ausstats/abs@.nsf/mf/2033.0.55.001) 
                                                 
 
(SES – socioeconomic status, TIA – transient ischaemic attack, TE –thromboembolism) 
Patient characteristics  
 Sex: male, n (%) 218 (49.9) 
 Age at initial presentation (years), mean±SD 68.7 ± 14.5 
 SES: IRSAD1 quintile, n (%)  
  1 (lowest) 69 (15.9) 
  2 62 (14.3) 
  3 74 (17.0) 
  4 111 (25.5) 
  5 (highest) 119 (27.4) 
Index presentation details  
 Admitted: yes, n(%) 316 (72.3) 
 Length of stay (hours), mean±SD 52.8 ± 98.6 
Treatment at initial presentation: yes, n (%)  
Electrical cardioversion 64 (14.7) 
Rate control medication administered 255 (58.5) 
Rhythm control medication administered 97 (22.3) 
Reverted to SR on discharge 246 (56.4) 
AF action plan 20 (4.6) 
Cardiologist referral 275 (62.9) 
Risk Assessments  
 CHA2DS2-VASc score documented: yes, n (%) 52 (11.9) 
 CHA2DS2-VASc score, mean±SD 2.83 ± 1.88 
 HAS-BLED score documented: yes, n (%) 0 (0) 
 HAS-BLED score, mean±SD 1.66 ± 1.08 
Comorbidities: yes, n (%)  
 Heart failure 62 (14.2) 
 Hypertension 216 (49.4) 
 Diabetes 75 (17.2) 
 Prior stroke/TIA/TE 48 (11.0) 
 Vascular disease 101 (23.1) 
 Renal disease 13 (3.0) 
 Liver disease 7 (1.6) 



























Charlson Comorbidity Index n (%) 
  0 21 (4.8) 
  1 16 (3.7) 
  2 53 (12.1) 
  3 84 (19.2) 
  4 111 (25.4) 
  5 67 (15.3) 
  6 36 (8.2) 
  7 21 (4.8) 
  8 10 (2.3) 
  ≥ 9 13 (3.0) 








(ED – emergency department, CV – cardiovascular) 
 




















104(38.8) 44(16.4) 120(44.8) 54(30.3) 26(14.6) 95(53.4) 
March 2014-
March 2015 
82(22.1) 69(18.6) 220(59.3) 64(20.9) 30(9.8) 207(67.7) 
March 2015-
March 2016 
52(16.0) 59(18.2) 213(65.5) 31(16.06) 23(11.9) 134(69.4) 
March 2016-
March 2017 
30(11.3) 42(15.8) 194(72.9) 40(25.6) 18(11.5) 98(62.8) 
March 2017-
March 2018 
19(14.2) 23(17.2) 92(68.7) 20(22.7) 21(23.9) 44(50.0) 
March 2018-
July 2018 
5(33.3) 0(0.0) 10(66.7) 1(25.0) 0(0.0) 3(75.0) 
Total follow 
up duration 




Table 4: Characteristics of individuals who re-presented to ED for AF compared to non-re-presenters 
 Repeat ED presentation group 
(n=82) 















Age at index presentation (years), mean±SD               68.6±11.9                69.1±15.0 0.378 
Baseline comorbidities      
Heart failure: n (%) 5 (6.1) 57 (16.1) 0.02 
Hypertension, n (%) 48 (58.5) 168 (47.3) 0.067 
Diabetes, n (%) 15 (18.3) 60 (16.9) 0.763 
Prior stroke/TIA/TE: n (%)  5 (1.2) 43 (12.1) 0.270 
Charlson Comorbidity Index score (mean±SD)              3.75±1.72                4.05±2.12 0.187 
INDEX PRESENTATION CHARACTERISTICS      
Admitted, n (%) 41 (50.0) 275 (77.5) <.001 
Length of stay (hours), mean±SD              23.5±30.2               59.5 ± 107.4 <.001 
Treatment      
Electrical cardioversion: n (%) 14 (17.1) 50 (14.1) 0.722 
Rate control, n (%) 45 (54.9) 210 (59.1) 0.374 
Rhythm control, n (%) 81 (98.8) 343 (96.6) 0.299 
Sinus rhythm on discharge, n (%) 44 (53.7) 191 (53.8) 0.001 
AF action plan, n (%) 13 (15.9) 10 (2.8) <.001 
Cardiologist referral, n (%) 52 (63.4) 221 (62.3) 0.001 
CHA2DS2-VASc score, mean±SD               2.66±1.69                2.86±1.92 0.462 
HAS-BLED score, mean±SD               1.74±1.04                1.64±1.09 0.415 
 
^ P-value for chi-square test of association for categorical predictors, or Mann-Whitney U test for continuous predictors 
 








Table 5: Predictors of AF related ED re-presentations  
Predictor Univariable   Multivariablea 
Odds Ratio (95% CI)     P-value  Odds Ratio (95% CI) P-value 








Age at index presentation, per year increase 0.998 (0.98-1.01) 0.785 1.04 (0.995-1.089) 0.079 
Heart Failure 0.34 (0.13-0.88) 0.025 1.11 (0.31-3.98) 0.868 
Hypertension 1.57 (0.97-2.56) 0.068 2.15 (0.82-5.62) 0.120 
Diabetes 1.10 (0.59-2.06) 0.763 1.86 (0.70-4.94) 0.211 
Prior stroke/TIA/TE 0.74 (0.18-1.24) 0.128 1.33 (0.29-6.03) 0.710 
Charlson Comorbidity Index, per unit 
increase 
0.93 (0.82-1.05) 0.238 0.96 (0.75-1.22) 0.735 
Admitted at index presentation 0.29 (0.18-0.48) <.0001 0.39 (0.19-0.80) 0.011 
Index presentation LOS, per hour increase 0.986 (0.979-0.994) <.0001 0.992 (0.983-1.002) 0.108 
Electrical cardioversion 1.26 (0.66-2.40) 0.491 1.03 (0.42-2.49) 0.953 
Rate control medication 0.79 (0.49-1.29) 0.349 1.69 (0.86-3.31) 0.126 
Rhythm control medication 2.83 (0.36-22.1) 0.320  b  
Sinus rhythm at discharge 1.18 (0.69-2.01) 0.546 1.30 (0.68-2.48) 0.431 
AF action plan 6.91 (2.90-16.4) <.0001 6.67 (2.42-18.3) <.001 
Cardiologist referral 1.32 (0.77-2.26) 0.311 1.36 (0.72-2.60) 0.345 
CHA2DS2-VASc score, per unit increase 0.94 (0.83-1.07) 0.371 0.66 (0.39-1.11) 0.116 
HAS-BLED score, per unit increase 1.09 (0.87-1.36) 0.444 1.30 (0.83-2.03) 0.249 
 
a ORs are adjusted for all other variables in the table 
b Variable omitted from multivariable model due to collinearity 
 




Table 6: Predictors of the number of AF related ED re-presentations 
Predictor Univariable   Multivariablea 
   IRR      (95% CI) P-value IRR     (95% CI) P-value 








Age at index presentation, per year 
increase 
0.98 (0.93-1.04) 0.578 0.99 (0.90-1.08) 0.810 
Heart failure 0.12 (0.02-0.91) 0.040 2.26 (0.21-23.8) 0.497 
Hypertension 3.30 (0.96-11.3) 0.058 10.2 (1.61-64.4) 0.014 
Diabetes 0.44 (0.11-1.76) 0.244 0.48 (0.08-2.85) 0.418 
Prior stroke/TIA/TE 0.32 (0.02-5.33) 0.425 0.45 (0.02-10.5) 0.617 
Charlson Comorbidity Index, per 
unit increase 
0.72 (0.51-1.02) 0.064 1.32 (0.79-2.20) 0.291 
Admitted at index presentation 0.18 (0.05-0.62) 0.007 0.16 (0.03-0.77) 0.022 
Index presentation LOS, per hour 
increase 
0.97 (0.96-0.99) <0.0001 0.98 (0.961-0.999) 0.037 
Electrical cardioversion 1.09 (0.26-4.56) 0.901 1.39 (0.26-7.34) 0.698 
Rate control medication 0.56 (0.17-1.84) 0.341 3.11 (0.70-13.8) 0.136 
Rhythm control medication 1.20 (0.07-19.9) 0.899  b  
Sinus rhythm at discharge 2.31 (0.70-7.57) 0.167 2.39 (0.58-9.91) 0.228 
AF action plan 4.63 (0.49-44.0) 0.182 4.72 (0.65-34.5) 0.120 
Cardiologist referral 2.09 (0.63-6.93) 0.226 1.51 (0.44-5.17) 0.511 
CHA2DS2-VASc score, per unit 
increase 
1.02 (0.73-1.43) 0.918 0.53 (0.19-1.49) 0.232 
HAS-BLED score, per unit 
increase 
1.02 (0.56-1.86) 0.946 1.28 (0.60-2.73) 0.516 
 
a ORs are adjusted for all other variables in the table 
b Variable omitted from multivariable model due to collinearity 
 


















        64(51.2) 




Age at index presentation (years), mean±SD      70.6±12.6 68.0±15.1 0.165 
Heart failure 15 (12.0) 47 (15.1) 0.407 
Hypertension 79 (63.2) 137 (43.9) <.001 
Diabetes, n (%) 28 (22.4) 47 (15.1) 0.066 
Prior stroke, TIA, TE: n (%) 17 (13.6) 31 (9.9) 0.554 
Charlson Comorbidity Index score (mean±SD)         4.3±1.9 3.9±2.1 0.078 
Admitted 91  (72.8) 225  (72.1) 0.885 
Length of stay (hours), mean±SD       54.8±89.2    52.0±102.3 0.573 
Electrical cardioversion 16  (12.8) 48  (15.4) 0.760 
Rate control medication: n (%) 81  (64.8) 174  (55.8) 0.223 
Rhythm control medication: n (%) 122  (97.6) 302  (96.8) 0.654 
Sinus rhythm on discharge: n (%) 76  (60.8) 170  (54.5) 0.622 
AF action plan: n (%) 9  (7.2) 11  (3.5) 0.233 
Cardiologist referral: n (%) 83  (66.4) 192  (61.5) 0.609 
CHA2DS2-Vasc score, mean±SD         3.2±1.8 2.7±1.9 0.0023 
HAS-BLED score, mean±SD         2.0±1.0 1.5±1.1 <.001 
^ P-value for chi-square test of association for categorical predictors, or Mann-Whitney U test for continuous predictors 
 






Table 8: Predictors of AF related readmissions 
Predictor  Univariable   Multivariablea  
Odds Ratio (95% CI) P-value  Odds Ratio (95% CI) P-value 
 Female (ref) 
 Male 
1.00 
0.94 (0.62-1.43) 0.774 
 1.00 
1.24 (0.66-2.30) 0.503 
Age at index presentation, per year increase 1.01 (0.997-1.028) 0.102  1.00 (0.96-1.03) 0.900 
Heart Failure 0.77 (0.41-1.43) 0.408  0.72 (0.30-1.72) 0.466 
Hypertension 2.19 (1.43-3.36) <.0001  1.35 (0.63-2.86) 0.439 
Diabetes 1.63 (0.97-2.74) 0.068  1.10 (0.52-2.34) 0.797 
Prior stroke/TIA/TE 1.43 (0.76-2.69) 0.268  0.86 (0.29-2.50) 0.776 
Charlson Comorbidity Index score, per unit increase 1.09 (0.99-1.21) 0.083  1.01 (0.84-1.21) 0.952 
Admitted at index presentation 1.03 (0.65-1.65) 0.885  0.90 (0.50-1.62) 0.721 
Index presentation length of stay, per hour increase 1.00 (0.998-1.002) 0.785  1.00 (0.997-1.002) 0.879 
Electrical cardioversion 0.81 (0.44-1.48) 0.490  0.94 (0.46-1.91) 0.863 
Rate controlling medication 1.45 (0.94-2.26) 0.096  1.44 (0.83-2.52) 0.195 
Rhythm control medication 1.35 (0.36-4.98) 0.655  b 
Sinus rhythm at discharge 1.29 (0.82-2.02) 0.274  1.56 (0.92-2.64) 0.097 
AF action plan 2.11 (0.85-5.23) 0.106  2.76 (1.00-7.63) 0.051 
Cardiologist referral 1.22 (0.79-1.90) 0.369  1.36 (0.82-2.27) 0.231 
Index presentation CHA2DS2-VASc score, per unit increase 1.18 (1.06-1.32) 0.003  1.11 (0.74-1.66) 0.603 
Index presentation HAS-BLED score, per unit increase 1.58 (1.29-1.94) <.0001  1.42 (1.00-2.01) 0.051 
 
a ORs are adjusted for all other variables in the table 
b Variable omitted from multivariable model due to collinearity 
 
 





Table 9: Predictors of the number of AF related readmissions 
Predictor Univariable Multivariablea 
IRR 95% CI P-value IRR 95% CI P-value 
Female (ref) 
Male 
        1.00 
0.80 
(0.31-2.03) 0.631 
        1.00 
0.57 
(0.14-2.38) 0.440 
Age at index presentation, per year 
increase 
0.99 (0.95-1.03) 0.601 0.93 (0.86-1.02) 0.130 
Heart failure 0.35 (0.10-1.23) 0.101 0.14 (0.02-0.98) 0.018 
Hypertension 3.50 (1.32-9.28) 0.012 2.65 (0.42-16.7) 0.918 
Diabetes 1.24 (0.37-4.11) 0.729 0.72 (0.10-5.10) 0.869 
Prior stroke/TIA/TE 1.17 (0.29-4.81) 0.823 0.89 (0.05-16.9) 0.511 
Charlson Comorbidity Index, per 
unit increase 
0.88 (0.69-1.12) 0.295 1.16 (0.69-1.97) 0.486 
Admitted to hospital 0.79 (0.29-2.14) 0.638 1.40 (0.36-5.49) 0.633 









Electrical cardioversion 0.67 (0.18-2.43) 0.540 0.78 (0.12-4.88) 0.790 
Rate control medication 2.03 (0.77-5.39) 0.153 1.89 (0.48-7.36) 0.361 
Rhythm control medication 0.63 (0.06-6.47) 0.695  b  
AF action plan 0.86 (0.13-5.75) 0.870 3.87 (0.33-45.3) 0.280 
Cardiologist referral 0.89 (0.33-2.42) 0.820 0.62 (0.18-2.12) 0.447 
CHA2DS2-VASc score, per unit 
increase 
1.12 (0.87-1.44) 0.394 1.32 (0.51-3.46) 0.566 
HAS-BLED score, per unit increase 1.87 (1.17-2.98) 0.009 2.24 (1.01-4.98) 0.047 
 
a ORs are adjusted for all other variables in the table 
b Variable omitted from multivariable model due to collinearity 
 




Table 10: Predictors of the time to first AF hospitalisation 
Predictor Univariable   Multivariablea 









Age at index presentation, per year 
increase 
1.01 (1.001-1.027) 0.031 1.001 (0.971-1.032) 0.954 
Heart failure 0.80 (0.46-1.37) 0.408 0.80 (0.37-1.74) 0.568 
Hypertension 1.93 (1.34-2.77) <.0001 1.25 (0.65-2.41) 0.504 
Diabetes 1.50 (0.98-2.28) 0.059 1.19 (0.64-2.21) 0.590 
Prior stroke/TIA/TE 1.34 (0.80-2.24) 0.260 0.89 (0.35-2.26) 0.802 
Charlson Comorbidity Index, per 
unit increase 
1.08 (0.99-1.17) 0.077 0.98 (0.84-1.14) 0.814 
Admitted to hospital 0.99 (0.67-1.47) 0.966 0.88 (0.52-1.48) 0.628 
Index presentation LOS, per hour 
increase 
1.00 (0.999-1.002) 0.652 1.00 (0.999-1.003) 0.368 
Electrical cardioversion 0.79 (0.46-1.33) 0.366 0.90 (0.48-1.67) 0.736 
Rate control medication 1.36 (0.93-1.98) 0.109 1.26 (0.79-2.01) 0.330 
Rhythm control medication 1.25 (0.40-3.92)        0.706 b 
Sinus rhythm at discharge 1.14 (0.77-1.70) 0.507 1.33 (0.86-2.01) 0.206 
Cardiologist referral 1.02 (0.70-1.49) 0.899 1.41 (0.89-2.23) 0.146 
CHA2DS2-VASc score, per unit 
increase 
1.14 (1.05-1.25) 0.004 1.05 (0.74-1.48) 0.792 
HAS-BLED score, per unit increase 1.49 (1.26-1.76) <.0001 1.40 (1.04-1.89) 0.027 
 
a HRs are adjusted for all other variables in the table 
b Variable omitted from multivariable model due to collinearity 
 






Table 11: Predictive factors for admission to hospital for unplanned AF re-presentations 
 
Predictor Univariable   Multivariablea  










Age at index presentation, per year increase 1.00 (0.98-1.03) 0.670  0.99 (0.95-1.03) 0.566 
Heart Failure 3.34 (1.26-8.83) 0.015  1.00 (0.29-3.45) 0.997 
Hypertension 0.96 (0.58-1.58) 0.859  0.62 (0.26-1.49) 0.284 
Diabetes 1.06 (0.51-2.23) 0.868  1.27 (0.46-3.49) 0.647 
Prior stroke/TIA/TE 2.42 (0.85-6.85) 0.097  1.24 (0.25-6.04) 0.26 
Charlson Comorbidity Index score, per unit increase 1.08 (0.02-1.25) 0.346  0.88 (0.65-1.19) 0.416 
Admitted at index presentation 2.44 (1.47-4.06) 0.001  2.45 (1.24-4.84) 0.010 
Index presentation length of stay, per hour increase 1.01 (1.00-1.02) 0.002     
Electrical cardioversion 0.79 (0.42-1.46) 0.450  1.03 (0.50-2.14) 0.935 
Rate control medication 2.07 (1.24-3.48) 0.006  1.44 (0.79-2.61) 0.229 
Rhythm control medication 0.94 (0.40-2.21) 0.882   b  
AF action plan 0.98 (0.44-2.18) 0.969  3.11 (1.09-8.87) 0.034 
Cardiologist referral  0.93 (0.58-1.49) 0.752  1.02 (0.60-1.75) 0.937 
Index presentation CHA2DS2-VASc score, per unit 
increase 
1.08 (0.92-1.26) 0.348 
 
1.29 (0.82-2.03) 0.262 
 Index presentation HAS-BLED score, per unit increase 1.13 (0.90-1.41) 0.280  1.19 (0.82-1.73) 0.360 
 
a ORs are adjusted for all other variables in the table 
b Variable omitted from multivariable model due to collinearity 
 





Table 12: Baseline characteristics for those with and without a non-standardised AF action plan 
Variable No AF action plan 
(n=406) 
AF action plan 
(n=20) 
P-value^ 











Age at index presentation (years), mean±SD    69.6±14.4                 60.6±14.7 0.008 
Heart failure: n (%) 60 (14.8) 0 (0.0) 0.092 
Hypertension: n (%) 203 (50.0) 7 (35.0) 0.253 
Diabetes: n (%) 72 (17.7) 1 (5.0) 0.222 
Prior stroke/TIA/TE: n (%) 48 (11.8) 0 (0.0) 0.263 
Charlson Comorbidity Index score (mean±SD)   4.1±2.0                    2.8±1.8 0.006 
Admitted: n (%) 299 (73.6) 8 (40.0) 0.003 
Length of stay (hours), mean±SD     55.7±101.5                   6.6±6.5 <.001 
Treatment      
Electrical cardioversion: n (%) 56 (13.8) 7 (35.0) 0.052 
Rate control medication administered: n (%) 246 (60.6) 5 (25.0) 0.006 
Rhythm control medication administered: n (%) 88 (21.7) 7 (35.0) 0.383 
Reverted to SR on discharge: n (%) 220 (54.2) 15 (75.0) 0.156 
Cardiologist referral: n (%) 215 (53.0) 16 (80.0) 0.045 
CHA2DS2-Vasc score, mean±SD   2.9±1.9                   1.6±1.5 0.003 
HAS-BLED score, mean±SD   1.7±1.1                   1.2±1.4 0.050 
 
^
P-value for Fisher’s exact test of association for categorical predictors, or Mann-Whitney U test for continuous predictors 
 





Table 13: Baseline characteristics according to mortality status at end of study 
Variable Died during follow-up 
(n=71) 
Alive at the end of follow-up 
(n=366) 
P-value^ 












Age at index presentation (years), mean±SD         79.79±10.71                66.63±14.15 <.001 
Heart failure: n (%) 22  (31.0) 40  (10.9) <.001 
Hypertension: n (%) 34  (47.9) 182  (49.7) 0.777 
Diabetes: n (%) 17  (23.9) 58  (15.8) 0.098 
Prior stroke/TIA/TE: n (%)  12  (16.9) 36  (9.8) 0.172 
Charlson Comorbidity Index score (mean±SD)          6.04±2.01                   3.60±1.81 <.001 
Presentation details      
Admitted: n (%) 59  (83.1) 257  (70.2) 0.026 
Length of stay (hours), mean±SD          76.0±161.4                   48.3±80.6 0.003 
Electrical cardioversion: n (%) 2  (2.8) 62  (16.9) 0.003 
Rate control medication: n (%) 49  (69.0) 206  (56.3) 0.074 
Rhythm control medication: n (%) 68  (95.8) 356  (97.3) 0.498 
Sinus rhythm at discharge 26  (36.6) 220  (60.1) <.001 
AF action plan: n (%) 1  (1.4) 19  (5.2) 0.370 
Cardiologist referral: n (%)  29  (40.8) 246  (67.2) <.001 
CHA2DS2-VASc score, mean±SD           3.92±1.88                   2.61±1.81 <.001 
HAS-BLED score, mean±SD           2.08±0.95                   1.58±1.09 <.001 
 
^ P-value for chi-square test of association for categorical predictors, or Mann-Whitney U test for continuous predictor 
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Chapter 6: Nurse Led Atrial Fibrillation 
Management – the NEAT study 
6.1 INTRODUCTION 
6.1.1 Background 
AF has emerged as one of the greatest healthcare challenges of this century. Incidence 
and prevalence rates have exponentially risen over recent decades and show no sign of 
abate.2 Age adjusted mortality rates associated with the condition have increased 
approximately two fold for both males and females.2 Health care resource utilisation 
associated with AF is significant with hospitalisations the main driver of this.24 
Furthermore, impairment to health-related quality of life (HRQoL) in individuals with 
AF is considerably worse than the general population and those with other chronic 
cardiovascular conditions including post MI or percutaneous coronary intervention.25 The 
degree of impairment to HRQoL in AF is akin to the heart failure population.25 In large 
registry data from the USA lower quality of life, as assessed by the AFEQT in 10 132 
individuals with AF, was associated with a higher risk of all cause hospitalisation (HR 
1.49; 95% CI 1.2-1.84, p≤0.001).31 In the older population (≥65 years of age), HRQoL 
was significantly lower across numerous studies in individuals with AF compared to 
control groups.303 The use of both rate and rhythm control strategies was comparable in 
relation to improvement of quality of life measures. Factors predictive of poorer quality 
of life were examined across numerous studies and included being female, elderly, an 





6.1.2 The role of education in AF 
Patient education and engagement is a key component of the chronic condition model.202  
Few studies have examined the impact of education on outcomes in the AF population. 
An RCT of a brief nurse delivered education program in 240 individuals presenting to 
ED primarily due to AF demonstrated a significant reduction in the primary composite 
endpoint of any AF related complication including stroke, heart failure and any 
bradycardia requiring treatment, in addition to other non-specific outcomes including 
ventricular tachycardia, any arrhythmia causing haemodynamic instability, any 
haemorrhage in anticoagulated individuals and all-cause mortality.221 At 12 months, there 
were significantly less cumulative adverse events in the intervention group (31.9% vs 
48.4%; p=0.005). There were no statistically significant differences for ED presentations 
or hospitalisations between the groups.221 
The role of nurse delivered education in a post ablation cohort has been examined 
in a small single centre RCT of 41 individuals.222 In this study, education about an 
individual’s condition and their procedure was delivered both pre and post ablation during 
the hospital admission and by three telephone calls over a three month period post 
procedure. After a six month follow up period, significant improvements in 
symptomatology were evident in the intervention group compared to controls, in addition 
to improvements in some domains of the SF-36 including physical functioning and 





6.1.3 Risk factor management in AF 
Numerous studies have examined the impact of cardiovascular risk factor management in 
AF with varying results. Single centre physician led models have demonstrated the most 
significant outcomes to date. In a series of studies the use of an intensive model which 
simultaneously targets numerous cardiovascular risk factors including overweight and 
obesity, hypertension, dyslipidaemia, diabetes, obstructive sleep apnoea, smoking and 
alcohol intake in a dedicated clinic has demonstrated a reduction in both subjective and 
objective AF burden at both short and long term follow up.140-142 
Other studies have examined the impact of exercise based cardiac rehabilitation 
programs on outcomes in the AF population. The Routine vs. Aggressive risk factor 
driven upstream rhythm Control for prevention of Early atrial fibrillation in heart failure 
(RACE 3) RCT enrolled 250 individuals with persistent AF and early heart failure who 
were scheduled to undertake electrical cardioversion.148 The intervention arm of this 
study received four additional therapies which included: mineralocorticoid receptor 
antagonists, statins, ACE inhibitors or ARBs and cardiac rehabilitation. Cardiac 
rehabilitation consisted of 2-3 supervised exercise training sessions per week. In addition 
to this, participants attended a specialised clinic delivered by a nurse which included 
education and self-management strategies for both conditions. After 12 months of follow 
up, there was a greater likelihood of sinus rhythm in the intervention group compared to 
control as objectified by Holter monitoring. The intervention also resulted in a significant 
reduction in systolic and diastolic blood pressure, BMI, weight, total and LDL 
cholesterol. No impact on AF symptoms were observed.148 
An RCT examining the impact of an exercise program in participants who had 




of follow up, although no impact on quality of life as assessed by the SF-36 was 
evident.146 
A pilot study of a telephone-based intervention in 19 individuals with AF did not 
demonstrate any improvement in health related quality of life as assessed by the SF-12.304 
In this study, individuals attended an extensive baseline assessment with a nurse which 
also involved goal setting to improve overall cardiovascular risk factor status. However, 
after three months of follow up, this observational study did not demonstrate any 
differences in cardiovascular risk factor status in participants at baseline compared to 
follow up.304 
The aim of this study was to determine if a brief nurse led clinic, facilitated by a 
guideline based electronic decision support tool to ensure appropriate oral anticoagulation 
to reduce stroke risk, can improve health related quality of life and cardiovascular risk 
factor status in individuals with AF.  
 
6.2 METHODS 
6.2.1 Study design 
The Nurse Led Atrial Fibrillation Management (NEAT) study was a RCT undertaken 
collaboratively by the University of Sydney and the University of Adelaide. The study 
was registered with the Australian and New Zealand Clinical Trials Registry 
(ACTRN12615000928516). Ethics approval was received from the Sydney Local Health 
District Human Resources Ethics Committee with reciprocal agreement from the 






Eligible participants were referred for participation in the study by cardiologists at the 
Royal Prince Alfred Hospital and Concord Repatriation Hospital in Sydney, and the 
Centre for Heart Rhythm Disorders at the University of Adelaide, Australia. Inclusion 
criteria was AF documented on electrocardiogram and ≥18 years of age. Both inpatient 
and outpatients were eligible for participation. Exclusion criteria were non-English 
speaking individuals or an inability to provide informed consent. Participants were 
allocated to the intervention group or usual care by a computer generated 1:1 
randomisation schedule. The study conformed with the Declaration of Helsinki and 
informed consent was obtained from all participants. 
 
6.2.3 Baseline visit and follow up assessment 
All patients visited a nurse specialist for baseline assessment. This baseline visit included 
baseline socio-demographic and clinical data recorded in an electronic case record form. 
Information collected included demographic data such as age, gender and education level. 
Health related quality of life was assessed using the Short-form 12 questionnaire (SF-12). 
Cardiovascular risk factors recorded included smoking status, blood pressure 
measurement, alcohol consumption and physical activity level. Medication adherence 
was assessed with the Morisky Medication Adherence Scale and physical activity using 
the General Physical Activity Questionnaire (GPAC). 
All participants attended a final assessment on exit from the study after three 
months of follow up. This was undertaken by a researcher blinded to group allocation. 




Scale, the GPAC and cardiovascular risk factors including weight, waist, BMI, blood 
pressure, smoking status and alcohol intake. A current medication list was also recorded. 
 
6.2.4 Intervention 
Participants in the intervention arm of this study attended a brief nurse led educational 
and risk factor management program. The following components were incorporated in to 
the intervention: 
1. An electronic decision support tool designed to ensure appropriate use of 
OAC based on stroke risk score and current AF guidelines; 
2. Clinical profiling including medication adherence and cardiovascular risk 
factor status; 
3. Health counselling and goal setting 
 
At the baseline visit education was provided concerning basic AF pathophysiology, 
causes, potential complications, treatment options, appropriate stroke prevention 
therapies based on individual risk score and self-management of episodes. This session 
was facilitated by written educational material (Living with Atrial Fibrillation).305 
Following this, and using the principles of motivational interviewing, participants 
were encouraged to set 3-4 realistic risk factor or behavioural goals in line with their 
priorities and motivation. Goals were set by participants according to what was deemed 
most important to them. The health care professional assisted in ensuring that these goals 
were realistic and achievable over the follow up time frame and identified ways in which 




them. This also contained written information about each individual’s stroke risk score 
and if the current antithrombotic regime was appropriate according to this score. Follow 
up consisted of telephone only support. Each participant received 3-4 telephone calls over 
the three month follow up period to monitor their progress and re-assess goals if 
necessary. The control group attended standard follow up with their cardiologist and/or 
GP. The frequency of this follow up and care provided was left to the discretion of the 
treating physician. 
 
6.2.5 Outcomes measures 
The primary outcome measure was health related quality of life as assessed by the SF-12. 
Secondary outcome measures included cardiovascular risk factors such as blood pressure, 
BMI, self-reported smoking status and physical activity as assessed by the GPAC. Blood 
pressure was taken via automated measurement (Omron healthcare, Lake Forest, IL). This 
was recorded with the participant in a seated position after at least five minutes resting. 
The first blood pressure measurement was utilised. Height and weight were recorded in 
light clothing with shoes removed and utilising the same tape measure and scales for each 
individual’s baseline and follow up measurements. Medication adherence was assessed 
by the Morisky Medication Adherence Scale. 
 
6.2.6 Power analysis 
Based on the CHOICE-AF study, in which patients were encouraged to set individual 
goals to manage their risk factors, and international data for HR-QoL, the sample size for 




12 physical function domain (effect size of 0.75) and alpha of 0.8 and critical level of 
0.05 a minimal total sample size of 60 or 30 participants per group.304,306 Allowing for 
20% loss to follow up, 72 participants were recruited (36 per group).  
 
6.2.7 Statistical analyses 
Primary analyses were conducted using SPSS for Windows (Version 23.0).  Continuous 
variables will be reported as mean±standard deviation (SD), and categorical variables as 
numbers and percentages.  Within subject differences between baseline and follow-up 
was analysed using Wilcoxon signed ranks tests for non-parametric variables (two-tailed 
p<0.05 considered significant).  Between group comparisons was analysed using Students 
t-test, the Mann-Whitney U test (for non-normally distributed continuous data), and the 
χ² test.  SF-12 data will be analysed using software licensed and provided by Optum 
Insight.  Analysis will be limited to complete cases to avoid artificially increasing 
precision around the estimates by imputing values or carrying baseline values forward. 
 
6.3 RESULTS 
A total of 72 participants were randomised. Mean age of the study cohort was 65±11 
years and 43.7% were female. See Table 1 for baseline characteristics. One participant in 
the control group did not meet the inclusion criteria and was excluded from analysis. A 
total of 33 participants in each arm completed the three-month final follow up. See Figure 





6.3.1 Goal setting  
Participants in the intervention arm set a mean of 3 goals. The most commonly set goal 
related to improving physical activity levels (32%). Other frequently used goals set 
included self-monitoring and management of blood pressure (24%), closely followed by 
weight loss (22%). Less commonly set goals related to self-monitoring of cardiovascular 
risk factors (e.g. lipids, glucose monitoring) at 6% and pulse self-monitoring to facilitate 
recognition of AF episodes (4%). See Table 2 for a summary of goals set by participants. 
 
6.3.2 Telephone follow up 
Participants in the intervention arm received a mean of 3.4±1.1 phone calls over the 
follow up period. Mean duration of follow up phone calls was 8.8±4.9 minutes. 
 
6.3.3 Health related quality of life 
Significant differences were evident in baseline SF-12 scores between groups with the 
control group demonstrating a lower mean physical component summary score, physical 
functioning and role physical scores (Table 3). There was a significant improvement in 
the mental component summary (MCS) score in the control group from baseline to follow 
up (Table 2). No within group differences were evident from baseline to follow up with 
the physical component summary (PCS) score. An improvement in the bodily pain 
subscale of the SF-12 occurred for the intervention group over time. The control group 
demonstrated an improvement in the general health, social function and role emotional 




up for the PCS score, MCS score or any of the SF-12 subscales (Table 3 and Figures 2 
and 3). 
 
6.3.4 Cardiovascular risk factors 
Blood pressure 
At baseline, no significant differences in systolic or diastolic blood pressure were 
observed (128±21mmHg vs 130±21mmHg for systolic BP. p=0.65 and 71±11mmHg vs 
73±11mmHg for diastolic BP. p=0.30 for intervention vs control respectively). There was 
no significant between group differences for systolic or diastolic blood pressure 
(125±21mmHg vs 124±15mmHg for systolic BP, p=0.80 and 71±11mmHg vs 
73±11mmHg for diastolic BP, p=0.39 for intervention vs control respectively; Table 4 
and Figures 4a and b) at final follow up. 
 
Body mass index and waist circumference 
BMI did not demonstrate any significant between group differences at baseline (30.3±6.9 
kg/m2 vs 30.1±5.8 kg/m2, p=0.87 for intervention vs control respectively). At final follow 
up no significant between group differences were observed for BMI (30.0±6.7kg/m2 vs 
30.2±5.9kg/m2, p=0.90 for intervention vs control respectively) or waist circumference 
(104±13cms vs 104±16cms, p=0.97 for intervention vs control respectively; Table 4 and 






Smoking status did not differ between groups at final follow up (6.1% vs 3.0% current 
smokers for intervention vs control respectively and 93.9% vs 97.0% for non-smokers, 
p=1.0 for intervention vs control respectively; Table 4). 
 
Medication adherence 
There were no significant between group differences for medication adherence as 
assessed by the Morisky Medication Adherence Scale at baseline or final follow up 
(p=0.81 for interaction; Table 4). 
 
Physical activity 
Physical activity levels, as assessed by the General Physical Activity Questionnaire score, 
did not differ between groups at final follow up (8.5±1.1 vs 8.4±1.2, p=0.60 for 
intervention vs control respectively; Table 4). 
 
6.4 DISCUSSION 
Education and empowering individuals to achieve self-care are important elements of 
chronic disease management. This prospective randomised study in patients with AF, 
demonstrates that a nurse-led education program did not significantly impact on quality 
of life or cardiovascular risk factor status in a cohort of individuals with AF. Furthermore, 
behavioural modification, including medication adherence and physical activity levels, 




complexity and need for evaluation of interventions of service delivery to ensure optimal 
design of care models. 
 
6.4.1 Impact of prior interventions for AF on quality of life 
Several studies have examined the impact of various interventions on quality of life in 
AF populations. In a single centre RCT undertaken in the Netherlands of 712 newly 
diagnosed AF participants, an integrated care approach in a nurse led, cardiologist 
supported clinic, did not significantly impact on quality of life as assessed by the SF-36 
at final follow up.147 This occurred despite a significant reduction in the primary endpoint: 
a composite of cardiovascular mortality and hospitalisations.209 In both the NEAT 
intervention and the RCT undertaken in the Netherlands, high baseline levels of quality 
of life were observed and may account for the lack of observed effect. A nurse delivered 
home based intervention for individuals who had been admitted to hospital due to AF 
which included education, clinical profiling, referral on to other members of the 
multidisciplinary team as required and recommendations to treating physicians about gold 
standard care delivery according to current AF guidelines, also did not significantly 
impact on quality of life as assessed by the SF-12.211 An RCT which examined an exercise 
based rehabilitation program for individuals who had undertaken an ablation for AF did 
not demonstrate any impact of quality of life in individuals at short term follow up, despite 






6.4.2 Cardiovascular risk factor management in AF 
Numerous studies have examined the impact of cardiovascular risk factor management 
on outcomes in AF populations. Several studies have utilised a single centre physician 
led model in dedicated risk factor clinics. The first of these studies assessed the impact of 
a comprehensive risk factor management strategy on AF symptom burden as assessed by 
the AF symptom severity questionnaire (AFSS) in a RCT of 150 symptomatic overweight 
and obese individuals with AF.140 After 15 months of follow up AF burden, symptoms 
and symptom severity significantly decreased in the intervention group compared to 
control.  
In the RACE 3 study, a different approach to cardiovascular risk factor management 
was undertaken with a combination of pre-defined pharmacological therapy and lifestyle 
measures.148 In this study of 245 individuals with persistent AF and early heart failure, 
the intervention consisted of three pharmacological therapies (MRAs, statins, ACE-I or 
ARBs) in addition to an exercise based cardiac rehabilitation program. Furthermore, 
participants in the intervention arm attended a specialist nurse led outpatient clinic at 6 
weekly intervals to assist with self-management of both conditions. This intervention 
demonstrated a significantly enhanced likelihood of sinus rhythm, as demonstrated by 
Holter monitoring, after 12 months of follow up in the intervention group compared to 
the control group.148 
 
6.4.3 Risk factor management post catheter ablation for AF 
In the post ablation cohort, aggressive cardiovascular risk factor management has 




intervention. These studies have largely been undertaken in single centre physician led 
models and have simultaneously targeted numerous cardiovascular risk factors in a 
dedicated clinic. The first of these studies allocated 149 individuals, who had been 
referred for catheter ablation for symptomatic AF, to an intervention or control arm based 
on their decision to participate or decline the risk factor management program.142 The risk 
factor management program in this study utilised a comprehensive approach including 
weight reduction, physical activity, dyslipidaemia, hypertension, OSA, diabetes, smoking 
cessation and alcohol reduction. The clinic is solely dedicated to management of these 
risk factors with medical management of the arrhythmia occurring outside of this clinic. 
Follow up occurred on a three-monthly basis, or more frequently if required, and 
participants were required to maintain a lifestyle journal outlining all food and drink 
consumption, exercise undertaken and blood pressure results which was reviewed at each 
clinic visit. This intervention resulted in a greater likelihood of arrhythmia freedom in the 
intervention group compared to control after a mean follow up of approximately 3.4 years 
(HR 4.8, 95% CI 2.04-11.04; p<0.001).141 The effectiveness of this intervention was 
confirmed at longer term follow up of approximately five years, with the same risk factor 
management program resulting in an almost six fold increase in the likelihood of freedom 
from AF in individuals who achieved the greatest degree of weight loss (≥10%) compared 
to those who lost the least amount or gained weight (HR 5.9; 95% CI 3.4-10.3; 
p<0.001).142 However, although this strategy has been proven to be cost effective144, the 
impact on clinical events including hospitalisations and mortality has not been examined, 
nor has the impact of this intervention on health related quality of life. Furthermore, there 






6.4.4 Impact of the NEAT intervention on HRQOL and risk factor status 
The NEAT intervention did not significantly impact on either quality of life or 
cardiovascular risk factor status in this cohort of individuals with AF. These results are 
largely consistent with numerous other studies in AF populations, delivered by nurses and 
allied health practitioners, which have not demonstrated any impact on QOL.146,147,211 To 
date few interventions have positively impacted on this outcomes. One study, examining 
the impact of nurse led education in a cohort undertaking AF ablation, demonstrated 
improvement in two subscales of the SF-36 questionnaire.222 Recently, the quality of life 
substudy of RACE 3 demonstrated a greater  improvement in the intervention arm for the 
physical functioning, physical role limitations and general health subscores of the SF-36 
at one year follow up compared to usual care.307 Despite the well-recognised importance 
of patient reported outcomes such as quality of life, inherent difficulties in choosing 
between general and disease specific questionnaires has also been acknowledged in 
addition to the large sample sizes often required to demonstrate statistically significant 
differences.308  
The lack of impact on cardiovascular risk factor status is speculated to be in part 
attributable to the lack of intensity of the risk factor management program in addition to 
the short follow up duration. In the NEAT intervention there was only one face to face 
visit with the rest of the intervention delivered by telephone follow up. This may lead to 
a lack of accountability for participants who were not required to maintain a lifestyle 
journal nor undertake any further in-clinic visits. Furthermore, there were no pre-
specified risk factor targets to work towards with participants instead encouraged to set 




factors simultaneously was not undertaken in this study, with individuals instead working 
on risk factor or behavioural goals of their choice. The Substrate Modification with 
Aggressive Blood Pressure Control in AF (SMAC-AF) study, highlighted the need for a 
comprehensive approach to cardiovascular risk factor management. In this study, 
targeting a single risk factor (blood pressure) did not significantly impact on the risk of 
atrial arrhythmia recurrence in individuals post catheter ablation for AF.149  
 Several other possibilities must be considered in light of the lack of observed 
effect in this study. The structure of this intervention, in which education and follow up 
was provided by a nurse without the construct of a multidisciplinary team, may have been 
a contributory factor. Whilst other studies have demonstrated improved cardiovascular 
risk factor status with the intervention undertaken by a single physician provider, this has 
been in the context of support from an electrophysiologist to re-enforce advice provided 
in this clinic.141,142 Furthermore, the impact on cardiovascular risk factor status was 
evident after longer term follow up of 3.5 and 5 years respectively in these studies.141,142 
It is possible that the short follow up duration in part accounted for the lack of 
improvement in cardiovascular risk factor status.  
 
6.4.5 Future directions 
This study has highlighted several areas for consideration in the design of future studies 
examining alternative models of care delivery in AF. Building on work undertaken to date 
several factors are likely to contribute to improved patient outcomes in this population. 
These include provision of multidisciplinary care with the involvement of a specialised 




multidisciplinary team is likely to further enhance outcomes although the optimal team 
compositions remains unknown and, given the heterogenous nature of the conditions, is 
likely to require an individualised approach. Indeed, the impact of a multidisciplinary 
approach in AF has not been fully explored, although the RACE 3 study involved the use 
of a specialist nurse, physiotherapist and dietician where required. This study did 
demonstrate an increased likelihood of sinus rhythm at final follow up, although little 
clinically significant difference in cardiovascular risk factor status. Interventions that 
have demonstrated marked improvements in cardiovascular risk factor status in AF have 
simultaneously addressed multiple factors in a single intervention within a dedicated 
clinic.141,142 The impact of a clinic combining AF care and risk factor management in a 
single intervention has not been tested to date. 
 
6.5 LIMITATIONS 
Whilst this study examined the impact of a brief nurse led education and risk factor 
management program on outcomes in a random sample of individuals with AF, several 
limitations exist. Firstly, our sample represents a well-treated cohort overall at baseline 
which is not generally comparable to other reported AF populations. For example, a 
global anticoagulation registry (GARFIELD) demonstrated the appropriate use of OAC 
in 63.1% of individuals whilst in our cohort this occurred in 97.2% and 97.1% of 
individuals for the intervention and control groups respectively.266 This represents a 
sample with limited opportunity for improvement and is reflective of the high level of 




Secondly, the short-term duration of follow up in this study allows little time to 
significantly impact on parameters such as cardiovascular risk factors which have only 
demonstrated improvement in studies with longer follow up duration. Furthermore, 
although this was a generally overweight and obese cohort, blood pressure was well 
controlled at baseline and therefore the impact on risk factor outcomes is likely to be 
minimal, as weight management generally requires longer and more intense follow up 
management. Health related quality of life has been difficult to impact on in prior studies 
related to AF interventions and highlights the difficulty associated with impacting on this 
outcome measure. Finally, as this was a feasibility study, the limitation of the small 
sample size needs to be acknowledged and could, in part, account for the lack of impact 
observed, particularly in relation to cardiovascular risk factor status as the study was not 
powered for this outcome. 
 
6.6 CONCLUSIONS 
A brief nurse delivered education and risk factor management program, limited to one 
single clinic visit and telephone follow up, did not significantly impact on health-related 
quality of life in individuals with AF after short term follow up. This intervention had no 
significant impact on cardiovascular risk factor outcomes including blood pressure, 
smoking status, alcohol consumption, physical activity levels or weight reduction. Future 
interventions should focus on evaluating the impact of a comprehensive approach to AF 
management including intense and targeted control of cardiovascular risk factors to 












Age, mean±SD 63±12 66±10 0.23 
Females, n (%) 16 (44.4) 16 (45.7) 1.0 
Heart failure, n (%) 5 (13.9) 4 (11.4) 1.0 
Hypertension, n (%) 23 (63.9) 26 (74.3) 0.44 
Diabetes, n (%) 6 (16.7) 6 (17.1) 1.0 
Stroke/TIA, n (%) 4 (11.1) 5 (14.3) 0.74 
Vascular disease, n (%) 4 (11.1) 3 (8.6) 1.0 
Systolic BP, mean±SD 128 ± 21 130 ± 21 0.65 
Diastolic BP, mean±SD 71 ± 11 73 ± 11 0.30 
BMI, mean±SD 30.3 ± 6.9 30.1 ± 5.8 0.87 
Waist, mean±SD 103 ± 15 105 ± 20 0.67 
Current smoker, n (%) 1 (2.8) 1 (2.9) 
0.75 
Non-smokers, n (%) 35 (97.2) 34 (97.1) 
Any alcohol intake, n (%) 29 (80.6) 25 (71.4) 0.42 
Alcohol bingers, n (%) 4 (11.1) 9 (25.7) 0.14 
CHA2DS2-VASc score, 
mean±SD 
2.4±1.4 2.5±1.4 0.78 
CHA2DS2-VASc 0, n (%) 3 (8.3) 2 (5.7) 
0.91 CHA2DS2-VASc 1, n (%) 7 (19.4) 7 (20.0) 
CHA2DS2-VASc ≥ 2, n (%) 26 (72.2) 26 (74.3) 
Appropriate OAC, n (%) 35 (97.2) 34 (97.1) 1.0 
OAC   
0.84 
   Warfarin, n (%) 5 (13.9) 4 (11.4) 
    DOAC, n (%) 21 (58.3) 24 (68.6) 
Other antithrombotic 3 (8.3) 2 (5.7) 
None, n (%) 7 (19.4) 5 (14.3) 
MMAS 
   Low, n (%) 
   Medium, n (%) 










GPAC, mean±SD 8.6±1 8.5±1 0.67 
 
(TIA – transient ischaemic attack, BP – blood pressure, OAC – oral anticoagulation, DOAC – 
direct oral anticoagulant, MMAS – Morisky Medication Adherence Scale, GPAC – General 







Table 2:   Participant goal setting by type 
 
 Goal 1 (%) Goal 2 (%) Goal 3 (%) Total (%) 
Physical activity 
34 50 12 32 
Weight loss 
46 6 12 22 
Dietary interventions 
not focussing on weight 
loss 
6 3 0 3 
Smoking cessation 
3 0 0 1 
Hypertension 
management 
6 24 42 24 
Improved self-
monitoring 
3 9 18 10 
Social interaction 
0 0 6 3 
Medication adherence 
0 3 6 3 
Other 





































groups at baseline 
 (p value) 
Difference between 
groups at follow up  
(p value) 
Difference between 
groups over time 
 (p value) 
Difference 
within groups 























































































































































































Table 4: Risk factors and medication adherence measures at baseline and follow up 










Systolic BP mmHg,  
mean±SD 
128 ± 21 130 ± 21 0.65 125±21 124±15 0.80 
Diastolic BP mmHg,  
mean±SD 
71 ± 11 73 ± 11 0.30 71±11 73±11 0.39 
BMI kg/m2, mean±SD 30.3 ± 6.9 30.1 ± 5.8 0.87 30.0±6.7 30.2±5.9 0.90 
Waist cms, mean±SD 103 ± 15 105 ± 20 0.67 104±13 104±16 0.97 
Current smoker, n (%) 1 (2.8) 1 (2.9) 
0.75 
2 (6.1) 1 (3.0) 
1.0 
Non-smokers, n (%) 35 (97.2) 34 (97.1) 31 (93.9) 32 (97.0) 
Any alcohol intake, n (%) 29 (80.6) 25 (71.4) 0.42 28 (84.8) 26 (78.8) 0.75 
Alcohol bingers, n (%) 4 (11.1) 9 (25.7) 0.14 6 (18.2) 6 (18.2) 1.0 
Appropriate OAC, n (%) 35 (97.2) 34 (97.1) 1.0 31 (93.9) 32 (97.0) 1.0 
OAC  
0.65 
   Warfarin, n (%) 5 (13.9) 4 (11.4) 
0.84 
4 (12.1) 3 (9.1) 
    DOAC, n (%) 21 (58.3) 24 (68.6) 18 (54.5) 23 (69.7) 
Other antithrombotic, n (%) 3 (8.3) 2 (5.7) 3 (9.1) 2 (6.1) 
None, n (%) 7 (19.4) 5 (14.3) 8 (24.2) 5 (15.2) 
MMAS 
   Low, n (%) 
   Medium, n (%) 



















GPAC, mean±SD 8.6±1 8.5±1 0.67 8.5±1.1 8.4±1.2 0.60 
 
(BMI – body mass index, OAC – oral anticoagulation, DOAC – direct oral anticoagulant, MMAS – Morisky Medication Adherence Scale, GPAC – 




















2 - withdrew due to development 
of serious medical conditions
1  - withdrew consent
Final follow up
33 participants:
1 - withdrew consent
1 - lost to follow up





Figure 2: SF-12 summary component scores at final follow up 
(PCS – Physical component summary score, MCS – mental component summary score.  









































Figure 3: SF-12 subscale outcomes at final follow up 


































































































Figures 4a and b: Systolic and diastolic blood pressure at final follow up 















































































Figures 5a and b: BMI and waist circumference at final follow up 















































































In many countries ageing populations and the rising numbers of concomitant 
cardiovascular risk factors are contributing to the increasing prevalence of AF and other 
chronic diseases.309,310  A Swedish registry study of 272,186 patients with incident AF 
reported that 69.5% of patients had at least one of seven other long term co-morbid 
conditions compared to 29.2% in matched controls.311 A United Kingdome (UK) Biobank 
study of 3651 patients aged 40-70 years with self-reported AF found the presence of at 
least one other self-reported long-term co-morbidity in 80.4% of participants, compared 
to 65.3% of 498,986 controls.312   
Pharmacotherapy is a cornerstone in the management for AF and many of the co-
morbidities common in AF patients, including hypertension, heart failure, coronary artery 
disease and diabetes. Disease specific treatment guidelines recommend the prescribing of 
medication for many patients, and combination therapy is common in those with 
moderate to severe disease.128,313-317 For patients with multi-morbidity the potential 
benefit of combining evidence-based therapies needs to be balanced with the risk of 
adverse health outcomes. Definitions of polypharmacy have varied in research studies, 
with the most common being the use of five or more medications,318 although there is 
evidence suggesting a continuum of risk.319 The challenge of adjusting for multi-
morbidity is well-recognised.320 Many studies have focused on adverse outcomes in older 




drug reactions and events,324,325 falls,178,321,326,327 increased hospitalisations,178,321,322,328,329 
lower quality of life,330,331 increased healthcare costs,332 and medication burden on 
patients and carers.333  
 
7.1.2 Polypharmacy and AF 
Comparatively little research has been done on the prevalence of polypharmacy in AF 
patients, whether this is clinically appropriate or inappropriate, and possible associated 
adverse health outcomes. Polypharmacy prevalence has ranged from 40% to 95% 
depending on the setting, study population, ascertainment criteria and methods334,335 . 
Some medications commonly used by AF patients, including antihypertensive agents and 
anticoagulation agents, are leading causes of adverse drug events in the elderly325. Many 
patients also take non-prescription or alternative medicines which carry their own 
potential for harm and may interact with prescribed medicines336. In a cross-sectional 
study of chronic disease clusters in elderly hospitalised patients, AF with co-morbid heart 
failure showed the third strongest association with polypharmacy 337. Post hoc analyses 
of two direct acting oral anticoagulant trials suggest that polypharmacy may be 
independently associated with adverse health outcomes181,182.  
As polypharmacy in AF may be an under-appreciated risk factor for harm 
irrespective of anticoagulation status, we performed a systematic review and meta-
analysis to summarise the best available evidence. In addition, we discuss opportunities 
to identify and minimise inappropriate polypharmacy in patients with AF and explore the 






7.2.1 Literature search 
This systematic review was registered with PROSPERO (Registration number 
CRD42018105298) and was undertaken in accordance with the PRISMA guidelines.338 
PubMed and Embase database were searched without date restriction until 31 July, 2018. 
Keywords used included ‘atrial fibrillation’, ‘polypharmacy’, ‘polypharmacology’, 
‘pharmacoepidemiology’, ‘cardiovascular outcomes’, 'health outcomes', 
'cerebrovascular accident’, 'bleeding', 'mortality’, ‘death’, ‘hospitalisation’, ‘hospital 
admission’, ‘quality of life’, ‘transient ischaemic attack’ and ‘falls’. See Table 1 for an 
outline of the full search strategy in PubMed.  
 
7.2.2 Inclusion and exclusion criteria 
Studies were eligible for inclusion if they were prospective randomised controlled trials 
or of observational design, had a minimum follow up of three months and were published 
in English. Outcomes eligible for inclusion included all-cause or cardiovascular mortality, 
all-cause or cardiovascular hospitalisations, stroke and systemic embolism, TIA, major 
bleeding (according to the International Society of Thrombosis and Haemostasis 
definition as bleeding associated with: reduction in haemoglobin of 20g/L over a 24 hour 
period, transfusion of two or more units of red blood cells, fatal bleeding or bleeding at a 
critical site e.g. retroperitoneal, pericardial339), non-major bleeding, intracranial bleeding, 
quality of life and falls. These outcomes were selected as they are either commonly 
studied in the AF population, or of significant clinical importance. Studies were excluded 




health outcomes, economic costs or outcomes which were not directly health-related, 
including drug interactions without clinical sequelae.  
 
7.2.3 Study selection and data extraction 
Two study investigators independently reviewed all articles retrieved by the electronic 
search to determine eligible studies. Any discrepancies were discussed and resolved by 
consensus decision. Data extracted from relevant studies included: first author, year of 
publication, total number of participants, gender of included participants, mean age, 
follow up period, AF ascertainment, polypharmacy definition, types of medicines 
collected from participants, endpoint adjudication and covariates adjusted for. The risk of 
bias in each of the included studies was assessed using the Quality in Prognosis Studies 
tool243, and subjectively characterised as low, moderate or high. 
 
7.2.4 Statistical analysis 
The risk estimate for each outcome was independently extracted by two study 
investigators according to two levels of polypharmacy (moderate and severe). The most 
adjusted model in each study was utilised. Heterogeneity across studies was assessed 
using the I2 statistic. Publication bias was assessed by visual inspection of funnel plots of 
effect size against standard error. A two-tailed p value of <0.05 was considered 
statistically significant. All analyses were performed using a random effects model in 







A total of 790 articles were identified from the electronic search, with 64 retrieved for 
full text review. Of these, 59 did not meet the inclusion criteria, with the remaining 5 
studies eligible. (Figure 1). The prevalence of polypharmacy ranged from 40.1% (≥5 
cardiovascular medicines) to 76.5% (≥5 medicines).334 Two of these studies reported on 
common outcomes, and were able to be utilised for a meta-analysis,181,182 with the other 
two studies each looking at unique outcomes including cardiovascular mortality334 and 
quality of life.340 Mean age of the two studies included in the meta-analysis was 71.5±9.63 
years with a mean follow up of 682±35.4 days. The total study population of the meta-
analysis was 32,825 individuals of which 37.4% were female. In the two studies included 
in the meta-analysis risk of bias was assessed as low in one study,182 and moderate in the 
other (see Table 2 for assessment of risk of bias).181 
 
7.3.1 Polypharmacy definition 
There was slight variation in the definition of polypharmacy used across the two studies 
included in the meta-analysis. For the purpose of this study we have classified moderate 
polypharmacy as the group of 5-9 medications in one study182 and 6-8 in the other,181 with 
severe polypharmacy classified as ≥10 and ≥9 medicines respectively. The reference 
group was 0-4 medicines and 0-5 medicines respectively. See Table 3 for an outline of 






7.3.2 All-cause mortality 
Both moderate and severe polypharmacy were associated with significant increases in all-
cause mortality (HR 1.33; 95% CI 1.18-1.49; p<0.01; HR 1.72; 95% CI 1.23-2.41; 
p=0.002 respectively; see Figure 1). There was no evidence of statistical heterogeneity 
with moderate polypharmacy (I2=33%; p=0.22), however, there was evidence of 
heterogeneity with severe polypharmacy (I2=86%; p=0.008).  
 
7.3.3 Stroke or systemic embolism 
Neither moderate nor severe polypharmacy was associated with stroke or systemic 
embolism (HR 1.15; 95% CI 0.98-1.36; p=0.09; HR 1.26; 95% CI 0.84-1.89; p=0.26 
respectively; Figure 2). Moderate polypharmacy did not demonstrate any evidence of 
statistical heterogeneity with this outcome (I2=27%; p=0.24), with heterogeneity evident 
at the severe polypharmacy level (I2=77%; p=0.04). 
 
7.3.4 Major bleeding 
Major bleeding was significantly increased with both moderate and severe polypharmacy 
(HR 1.34; 95% CI 1.15-1.58; p<0.01; HR 1.80; 95% CI 1.55-2.09; p<0.01 respectively; 
Figure 3). There was no evidence of statistical heterogeneity with either moderate or 
severe polypharmacy (I2=38%; p=0.02; I2=0%; p=0.50 respectively).  
 
7.3.5 Intracranial bleeding 
There was no impact of moderate or severe polypharmacy on intracranial bleeding (HR 




Figure 5). Whilst there was evidence of statistical heterogeneity at the moderate 
polypharmacy level (I2=77%; p=0.04), there was no heterogeneity noted with severe 
polypharmacy with this outcome (I2=51%; p=0.15). 
 
7.3.6 Clinically relevant non-major bleeding 
Both moderate and severe polypharmacy was associated with an increased risk of 
clinically relevant non-major bleeding (HR 1.12; 95% CI 1.03-1.22; p<0.01; HR 1.48; 
95% CI 1.33-1.64; p<0.01 respectively; see Figure 6). Neither moderate nor severe 
polypharmacy demonstrated any evidence of statistical heterogeneity for this outcome 
(I2=0%; p=0.49; I2=0%; p=0.39 respectively).  
 
7.3.7 Cardiovascular death 
Post hoc analysis of the Atrial Fibrillation Follow-Up Investigation of Rhythm 
Management (AFFIRM) study, which examined the impact of polypharmacy of 
cardiovascular medicines only (defined as >5 medicines), demonstrated an increase in the 
risk of cardiovascular death (unadjusted HR 1.47; 95% CI 1.18–1.82; p<0.001) and stroke 
(unadjusted HR 1.17; 95% CI 0.85–1.60; p=0.34).334 The adjusted relative risk for 
cardiovascular death was 1.30 (95 % CI 1.03–1.64; p=0.03). 
 
7.3.8 Quality of life 
Post hoc analysis of the Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) 
Study,  which examined quality of life in 1762 elderly individuals (>75 years) with AF, 




life as assessed by the EQ-5D (parameter estimate -0.06, p=0.03).340 There was no impact 
at other polypharmacy levels (1-3 or 4-6 medicines).  Both moderate and severe 
polypharmacy was associated with a reduction in the physical component summary score 
of the SF-12, but not the mental component summary score. 
 
7.4 DISCUSSION 
The increasing complex requirements for the management of patients with AF has 
involved the use of multiple proven pharmacotherapies. This is compounded further by 
the need to treat co-existent conditions which often have a determining role on the AF 
process. Polypharmacy is increasingly recognised to be associated with adverse outcomes 
in chronic disease. This systematic review and meta-analysis evaluates the impact of 
polypharmacy on outcomes in a population with AF. In patients with AF, it demonstrates 
the following: 
1. Moderate and severe polypharmacy is associated with a 33% and 72% increase in 
all-cause mortality respectively; 
2. The risk of major bleeding is increased by 34% and 80% for moderate and severe 
polypharmacy respectively and; 
3. Clinically relevant non-major bleeding increased by 12% and 48% respectively 
with moderate and severe polypharmacy; 
4. Polypharmacy is associated with an increased risk of cardiovascular death, 
reduced quality of life and poorer physical functioning. 
 
To date, there has been a paucity of studies examining the impact of polypharmacy 




studies with independent endpoint adjudication as in the present meta-analysis. Given the 
increasing prevalence of concomitant risk factors in patients with AF,309,311 it is likely 
that, similar to other chronic diseases, the use of multiple medicines is driven by comorbid 
conditions.341 342  Adjustment for co-morbidities is a challenge in polypharmacy research 
and although the studies in our meta-analysis varied in this regard, significant hazard 
ratios were found in both studies with the exception of stroke or systemic embolism and 
intracranial bleeding.  
 
7.4.1 Possible reasons for adverse outcomes with polypharmacy 
The mechanisms underlying the adverse outcomes associated with polypharmacy are 
likely to be multifactorial and may vary between outcomes. These could include (i) 
reduced adherence and persistence to prescribed regimes (ii) drug-drug and drug-disease 
interactions and (iii) adverse drug reactions.  
Adherence and persistence to prescribed regimes has been inversely correlated 
with number of medicines used.343 In the heart failure population the number of drug-
related negative outcomes, including inadequately treated health issues, inadequate doses 
or duration of treatment and non-adherence, has demonstrated a significant correlation 
with increasing number of medicines prescribed.344 In one of the studies included in our 
meta-analysis 42.4% of patients taking ≥10 medications discontinued their anticoagulant, 
compared to 35.4% taking 5-9 medications and 31.8% taking 0-4 medications. 
Polypharmacy may similarly have affected persistence with other medications. Non-
adherence to Dabigatran in patients with AF, defined as less than 20% adherence, has 
been shown to be associated with an increase in all-cause mortality and stroke in an 




Drug-drug and drug-disease interactions may be a contributing factor to 
polypharmacy associated harm. It is possible that the observed increase in bleeding risk 
may reflect an increased likelihood of combining certain high-risk medications with 
anticoagulants.346 Many commonly used agents have potential interactions with 
anticoagulants including non-steroidal anti-inflammatory agents (NSAIDs), antiplatelet 
agents, or others with antiplatelet effects including selective serotonin reuptake inhibitors. 
In the ARISTOTLE post hoc analysis, Aspirin, NSAIDs or Prednisone were used by 
13.8% in those taking 0-5 medications, 31.7% taking 6-8, and 49.7% taking ≥9 
medications. The risk of drug-drug interactions likely increases with growing numbers of 
medicines prescribed, with the risk identified to be as high as 82% in individuals 
prescribed seven or more medicines.347 Many of these interactions may be under-
recognised by clinicians and possibly result in further use of medicines to treat adverse 
drug reactions. Compounding this situation, current guidelines are often single disease 
focussed, with little insight for clinicians concerning management of the comorbid 
individual, and the potential for interactions with drug therapy for other conditions348. 
The use of over-the-counter medicines is also under-recognised, with the risk of 
potentially unknown adverse interactions. A study of 250 individuals attending an 
anticoagulation clinic in Denmark demonstrated that almost 50% of individuals were 
taking alternative medicines including fish oil, and some with potential for interactions 
with warfarin. More research is needed to investigate whether adverse bleeding outcomes 
in AF patients using polypharmacy are associated with certain drug-disease interactions 
or combinations of pharmacotherapy.   
Adverse drug reactions (ADRs) are associated with significant morbidity and 
mortality and in elderly patients may account for 1 in 10 hospitalisations.325 As more 




cardiovascular agents, commonly used in the AF population, are associated with bleeding 
and falls which may contribute to increased all-cause mortality either as a direct effect or 
secondary to discontinuation of therapy.   
 
7.4.2 Other possible polypharmacy related adverse health outcomes 
Our systematic review did not identify any prospective studies examining the relationship 
between polypharmacy and hospitalisation or falls. A longitudinal study has shown an 
increase in age, multi-morbidity and polypharmacy in heart failure patients over the years 
1998 to 2008.342 The question of whether a similar trend may be contributing to observed 
increased AF hospitalisations deserves further investigation.349,350 Many studies in older 
patient populations have found polypharmacy to be associated with falls, and an 
unadjusted association was found in a small retrospective study of AF patients 
(p=0.027).351 Multivariate analysis revealed three independent fall predictors; 
benzodiazepine use, paroxysmal AF and history of hypertension. Falls in older people are 
typically multifactorial in nature. In a retrospective study of 211 older patients presenting 
to an emergency department due to falls, AF, neurological disorders and age ≤81 years 
were found to be independent predictors of non-accidental falls, with a history of AF 
increasing the risk 2.5 fold.352  This was after multivariate adjustment for polypharmacy 
and other predictors of non-accidental falls. Other data has demonstrated an independent 
association between AF and hip fracture,353 and raises the possibility that polypharmacy 
may be a contributing factor to this observation. 8.8% of patients with severe 
polypharmacy in the ARISTOTLE study had a history of falls during the year prior to 
enrolment, compared to 2.3% in those taking 0-5 medications (p<0.001).181  A separate 
post hoc analysis of the ARISTOTLE study found that patients with a history of falls had 




three-fold increased risk of falling during the trial.354 Larger prospective studies are 
needed to determine the mechanisms contributing to falls in AF patients and the possible 
role of polypharmacy. 
Other outcomes from our systematic review were identified from single studies 
and warrant future research to confirm their findings. In the secondary analysis of the 
BAFTA study, gender, number of medications and disability were found to be 
independently associated with quality of life in elderly AF patients. Those taking >3 
medications reported poorer quality of life, which was observed more consistently in 
those taking >7 medications. Possible confounders in this study include disease severity 
and multi-morbidity, and further research is needed to confirm these findings. 
 
7.4.3 Opportunities to improve outcomes 
Strategies to reduce inappropriate use of pharmacotherapy might improve outcomes. De-
prescribing has been defined as ‘the process of withdrawal of an inappropriate 
medication, supervised by a health care professional with the goal of managing 
polypharmacy and improving outcomes.355 Various methods for identifying inappropriate 
medication use have been described including the Medication Appropriateness Index, the 
Beers criteria and STOPP/START criteria.356 Guidelines for safe dose reduction, tapering 
and cessation of various drug classes, including statins, antiplatelet agents, proton pump 
inhibitors, sulfonylureas and benzodiazepines are available.357,358 Clinical knowledge and 
judgement is needed when applying these in practice, with a consideration of the patient’s 
views, prognosis and treatment goals. Recently, de-prescribing has been shown to be safe 
in a small study examining the use of de-prescription of non-evidence based medicines 
in the heart failure population.359 A cluster randomised trial demonstrated that the de-




cardiovascular risk can be safely undertaken, provided that appropriate monitoring is 
instituted, without any significant increase in short term cardiovascular risk.360 Other 
studies in older adult populations have suggested that this strategy is associated with 
clinically significant benefit with minimal risk of harm.361,362  
 
7.4.4 Deprescribing in AF 
We are unaware of any studies of deprescribing outcomes specific to patients with AF. 
Current AF treatment guidelines recommend avoidance of certain medications depending 
on the clinical context, for example antiarrhythmic drugs for rate control in those with 
permanent AF and aspirin monotherapy for stroke prevention.363 The adoption of these 
evidence-based recommendations into practice may be improved by including a separate 
guideline discussion and summary of deprescribing advice. Recommendations for 
managing the pharmacotherapy of AF patients in the context of other common co-
morbidities including hypertension, heart failure and diabetes may also help to minimise 
adverse outcomes.364,365  In all healthcare settings regular reconciliation and review of a 
patient’s medicines is a pre-requisite for identifying inappropriate pharmacotherapy, non-
adherence and treatment discontinuation. New models of integrated primary healthcare 
including patient-centred health care homes and sharing of patient data through electronic 
health records may help to optimise medication use in patients with multi-morbidity.366 
Multidisciplinary integrated care provided in AF clinics also has the potential to improve 
outcomes by preventing, identifying and managing inappropriate polypharmacy, and 
improving communication with other prescribers.367 Intervention studies of 
comprehensive medication review and deprescription of inappropriate pharmacotherapy 
are needed to evaluate whether polypharmacy is a modifiable risk factor in AF patients 





Our study has several limitations worthy of consideration. Whilst one of the included 
studies in our meta-analysis adjusted for multiple confounders,182 the other only adjusted 
for age, sex and geographical location.181 Even extensive adjustment however may not 
account for all variables which influence prescribing and health outcomes, including 
frailty, falls history and other unmeasured health markers. Despite heterogeneity in 
adjustment, the magnitude of effect of polypharmacy on statistically significant outcomes 
was similar, lending strength to the conclusion of polypharmacy associated harm. 
Furthermore, the associated risk demonstrated a dose dependent increase, with more 
‘severe’ levels of polypharmacy resulting in incrementally greater risk of adverse events. 
Other unreported factors may also impact on adverse outcomes, including the number of 
prescribers caring for individuals. This has been shown to be an independent predictor of 
adverse drug events,324,368 with each additional specialist conferring a 19% increase in 
risk in a multi-centre observational study.324 The observed increase in all-cause mortality 
may also be due to underuse of potentially beneficial medications. An Australian 
observational study of 4260 community-dwelling older men reported that both potential 
under-utilisation of indicated cardiovascular medicines and polypharmacy were 
independent predictors of cardiovascular events178. 
Both studies included in our meta-analysis are based on polypharmacy at the time of study 
enrolment, and the duration of polypharmacy during the study is uncertain. However, 
patients with multiple chronic diseases usually have a long term need for 
pharmacotherapy and it is likely that polypharmacy was sustained during the studies. In 
the ARISTOTLE post hoc analysis use of aspirin, NSAIDs and prednisone increased 
significantly as polypharmacy increased. It is therefore possible that polypharmacy 




anticoagulants, rather than the total number of medications used. Neither study defined 
the eligibility of non-prescription medications in their profiling, formulations such as 
inhalers and topical preparations or medications used only when needed. However, a 
sensitivity analysis which omitted herbal supplements, topical and eye medications in the 
ROCKET AF post hoc study also showed a dose-response association between remaining 
polypharmacy and efficacy and safety outcomes. The completeness and reliability of 
medication data used in our meta-analysis is likely strengthened by industry sponsorship 
of the original trials, in which the risk of adverse sequelae from potential drug interactions 
with new Factor Xa inhibitors in comparison to warfarin was of major interest to the 
sponsors.   
Finally, although only two studies were available for meta-analysis, the total number of 
patients was 32 825 from two studies with independently adjudicated outcomes, which 
strengthens the evidence for polypharmacy associated harm. Our systematic review 
identified four studies examining this area, which demonstrates the need for future 
research to further confirm our findings, in addition to interventions designed to reduce 
the risk of polypharmacy related adverse events in AF. 
 
7.6 CONCLUSIONS 
The growing burden of AF has led to a pressing need to identify ways in which outcomes 
can be improved in this population. Polypharmacy is common amongst individuals with 
AF, and our results demonstrate that, in an anticoagulated population, it is associated with 
numerous adverse outcomes including increased all-cause mortality, major bleeding and 
clinically relevant non-major bleeding. Mechanisms underlying this risk are unclear and 




adherence or persistence to prescribed regimens, or poor communication between 
numerous prescribers. Further studies examining deprescription of inappropriate 
pharmacotherapy in patients with AF are warranted to evaluate whether polypharmacy is 


























Table 1 – Search strategy for PubMed 
“atrial fibrillation” 
 
Polypharmacy [mh] OR 
Pharmacoepidemiology OR 
prescribing pattern* [all] 
OR 
Prescription pattern* [all] 
OR Practice pattern, 
Physicians’ [mh] 
 
Stroke [all] OR 
Cerebrovascular accident 
OR 
Cerebro vascular accident 
OR 
CVA OR 
Hemorrhage [mh] OR 
Haemorrhag* [all] OR 
Haemorrhag* [all] OR 
Bleeding [all] OR  




cardiovascular OR heart) 
AND 
(outcome* OR event*)) 
OR 
Hospitalisation [mh] OR 
Hospitalisation [all] OR 
“hospital admission” OR 
“hospital admissions” OR 
Health status [mh] OR 
“quality of life” OR 
HRQL OR “life quality” 
OR 
“quality adjusted life year” 
OR qaly OR “quality 
adjusted life years” OR 
“short form 12” OR SF-12 
OR SF12 OR 
“short form 20” OR SF-20 
OR SF20 OR 
“short form 36” OR SF-36 
OR SF36 OR 
“short form 8” OR SF-8 
OR SF8 OR 
“symptom burden” OR 
“Cost of illness” OR 









Table 2 – Assessment of risk of bias in studies included in meta-analysis 
 







































Table 3: Characteristics of studies included in the meta-analysis  
 
(CNS – central nervous system, MI – myocardial infarction, BMI – body mass index, DM – diabetes mellitus, TIA – transient ischaemic attack, CHF 
– congestive heart failure, COPD – chronic obstructive pulmonary disease, PAF – paroxysmal AF, DBP – diastolic blood pressure) 
 
 
*Safety end points adjusted for age, sex, region, previous stroke/TIA, anaemia, previous GI bleed, COPD, DBP, creatinine clearance (Cockroft-Gault), 
platelets, albumin, previous Aspirin, Vitamin K antagonist, thienopyridine and randomised treatment. 
 
Study Year of 
publication 
Total no. of 
participants 









ROCKET - AF182 2016 14264 73 39.7 Reference group: 
0-4 medicines, 5-9 
medicines, ≥10 
medicines 
1.9 years All-cause mortality, 








Age, sex, BMI, 




PAF, DBP, creatinine 
clearance (Cockcroft-
Gault), heart rate, 
alcohol use, and 
randomised 
treatment*  
ARISTOTLE181 2016 18201 70 35.3 Reference group 0-
5 medicines, 6-8 
medicines, ≥9 
medicines 
























databases searched until  31 
July, 2018
790 citations:
296 citations – Embase
494 citations - PubMed
64 citations retrieved 
for full text review
59 excluded:
Retrospective analysis – 11
Not reporting on polypharmacy – 28
Not English – 1
Abstracts – 10
Duplicate study – 3
Outcomes not reported – 5
Incident AF - 1






















































































Chapter 8: Final Discussion 
There is a pressing need to stem the growing tide of AF related health care resource 
utilisation and to improve outcomes in this condition. This thesis has demonstrated that 
hospitalisations due to AF now outnumber those for both MI and HF in Australia and 
highlights the urgent need to develop strategies to curtail this growing epidemic. The 
rising tide of AF related hospitalisations, as discussed in Chapter 2, has occurred across 
all age groups and both genders and is not accounted for by the increasing use of AF 
related procedures such as catheter ablation. The costs associated with AF hospitalisations 
have grown such that the growth over the sixteen-year period leading up to 2013, was 
more than double that of both MI and HF. The current trajectory of AF in Australia is not 
sustainable and urgent steps must be taken to address this epidemic.  
Steps taken must address the spectrum of AF from prevention to optimal 
management and possible cure. Globally the incidence of AF continues to rise and 
therefore strategies to prevent the onset of the condition are of significant interest. 
Numerous cardiovascular risk factors have demonstrated consistent associations with 
incident AF, however this has been poorly defined in the case of alcohol consumption. 
Whilst high levels of alcohol intake are known to be associated with development of the 
condition, Chapter 3 demonstrated that low levels of alcohol intake, of up to one SD per 
day, does not heighten AF risk. Furthermore, gender differences were apparent with males 
exhibiting a higher risk at lower levels of intake. Much remains unknown in this field 





Enhanced outpatient management using an integrated care approach in AF 
represents another avenue to improve outcomes in this population. The systematic review 
and meta-analysis undertaken in Chapter 4, which is the first to systematically evaluate 
the evidence for integrated care in AF, demonstrates that whilst only a small number of 
studies have evaluated this approach in AF, it is associated with a significant reduction in 
all-cause mortality and cardiovascular hospitalisations. No impact on cerebrovascular 
events or AF hospitalisations were observed and further research in this field is warranted 
to explore optimal modes and components of care delivery. 
The REVIEW AF study in Chapter 5 highlighted the need for improved strategies 
to reduce AF hospitalisations. This local data, abstracted through both coding and 
individual patient electronic health record review for each event and encompassing 
almost four years of follow up, demonstrated that health care resource utilisation in the 
AF population is significant. Males and younger ages were associated with higher rates 
of AF re-presentations and identify target populations to direct future strategies towards. 
The only factor predictive of both AF related ED presentations and hospitalisations was 
the presence of an AF action plan for management of AF episodes. Whilst this was a 
surprising finding, it provides important insights in to the possible role of health literacy 
and ensuring patient understanding and involvement in their care management. 
Whilst cardiovascular risk factor management in AF and the use of 
comprehensive AF care have demonstrated enhanced patient outcomes, Chapter 6 
demonstrated that a brief educational intervention which incorporated the use of 
motivational interviewing techniques and goal setting, did not result in an improved 
quality of life or cardiovascular risk factor status at short term follow up. This further 
supports the need for more comprehensive and integrated approaches to AF management 




Finally, in Chapter 7, the results of the first systematic review and meta-analysis 
examining the impact of polypharmacy on health outcomes in AF demonstrated that both 
moderate and severe levels of polypharmacy were associated with increased risks of all-
cause mortality, major bleeding and clinically relevant non-major bleeding. Whilst the 
use of additional medications in many other cardiovascular conditions including HF and 
MI is generally thought to be an important component of improved prognosis, this study 
demonstrates that this may not be the case in AF. The need to assess the appropriateness 
of each individual’s medication regime as well as their adherence and persistence are 
strategies that could be immediately implemented and may provide an avenue for 
















Chapter 9: Future Directions 
Many unanswered questions remain in the field of AF related research. From prevention 
to cure there is much to be achieved in endeavours to improve patient outcomes and 
reduce health care burden in the burgeoning AF population. In the prevention sphere, the 
identification of new risk factors will assist in strategies to prevent disease onset. A 
greater understanding of how modification of existing risk factors may impact on disease 
development and appropriate targets for these in AF prevention would contribute to 
stemming the growing incidence of this condition. 
 Further down the disease trajectory, optimal ways of managing the condition 
need to be explored. The in-hospital management of AF and ways in which admissions 
related to the condition can be prevented are a research priority, as AF admissions 
continue to grow exponentially and remain the costliest component of AF care. Whilst 
alternative models of care delivery have shown early promise in improving patient 
outcomes, further research in to optimal methods and components of service delivery 
need to be elucidated to better understand and develop translatable models. The evidence 
to date suggests that comprehensive models of care, targeting all aspects of AF 
management are associated with better patient outcomes, with less intense or fragmented 
models not associated with the same magnitude of effect. This approach would benefit 
from large multi-centre RCTs, to examine appropriate and relevant outcomes, and to 
ensure the widespread applicability of such models. Multiple opportunities exist to 
improve AF outcomes and there has never been a more pressing need to stem the ever-
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